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Interstitial Lung Diseases (ILDs) and Pulmonary Hypertension (PH) are umbrella terms 
to describe two groups of chronic and debilitating lung diseases. ILD and PH patients 
often experience a high symptom burden and deteriorated health-related quality of life 
(HRQOL). The most commonly encountered symptoms are dyspnea, reduced exercise 
tolerance, fatigue, and side effects of medication. In ILDs, especially the patients with 
progressive fibrotic ILD are confronted with a poor prognosis. Although recently new 
treatment options have been developed that slow down disease progression, many 
ILDs and all forms of PH are still progressive and incurable. In a small proportion of the 
patients lung transplantation may be an option.
Traditionally, the effect of medication is assessed using physiologic outcome param-
eters. However, in both disease areas there is an increasing awareness of the importance 
to include patient-centered outcomes such as symptoms and quality of life (QOL), 
when assessing treatment effects. Patients can play a central role in collecting outcome 
measures, by using patient-reported outcome measures (PROMs) and patient-recorded 
outcome measures. The most used physiological outcomes and PROMs in the ILD and 
PH field are shown in Table 1.
There is a paucity of patient-centered outcome measures and interventions aimed at 
improving QOL, both for patients with ILD and PH. Most of the existing PROMs have 
been developed in the United Kingdom (UK) or United States of America (USA). The 
research described in this thesis is focused on translating and validating ILD and PH 
PROMs for Dutch patients (part 1), develop patient-recorded outcome measures (part 2) 
and interventions aimed at improving QOL for patients (part 3).
Interstitial Lung Diseases (ILDs)
ILDs comprise more than 200 different disorders, characterized by interstitial inflamma-
tion, cellular proliferation, fibrosis or a combination of these processes of the lungs.1-3 
Disease course and prognosis are highly variable between the different ILDs and even 
between patients with the same disease. Some ILDs are reversible where others show 
a progressive scarring of lung tissue with rapid decline of lung function and ultimately 
death.3 ILDs are categorized into four groups: with a known cause (e.g. drug induced, 
auto-immune diseases, asbestosis), with an unknown cause (idiopathic interstitial pneu-
monias-IIPs), granulomatous disorders (e.g. sarcoidosis) and rare ILDs.4 It is estimated 
that in the Netherlands around 20.000 people suffer from a form of ILD, with Idiopathic 
Pulmonary Fibrosis (IPF) and sarcoidosis being the most common ones.5,6 In this thesis, 
ILD research is predominantly focused on these two diseases.
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Table 1. The most commonly-used clinical outcomes in IPF, sarcoidosis and PAH
Physiologic outcomes IPF Sarcoidosis PAH
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IPF is a fatal lung disease of unknown etiology, characterized by an irreversible decline 
of lung volume and gas exchange, leading to severe breathlessness, cough and exer-
cise intolerance.7,8 The prevalence of IPF in the Netherlands is estimated at 20 per 100 
000 persons.5 IPF occurs more frequent in men than in woman and the median age at 
diagnosis is 65 years.9,10 Although the clinical course of IPF varies, overall prognosis is 
poor with a median survival of 2-4 year after diagnosis when not treated.9 The main 
symptoms that patients with IPF suffer from are breathlessness, chronic cough, fatigue, 
anxiety and depression, which often severely impair their QOL.9,11,12 At the moment there 
is no cure for IPF except for lung transplantation. Two antifibrotic drugs (nintedanib and 
pirfenidon) are currently the standard of care. Studies demonstrated these drugs slow 
down disease progression as measured by a reduced rate of decline of FVC over 1 year, 
improve survival and reduce excacerbations.7,13 However, no convincing beneficial ef-
fect of these drugs on patients’ QOL was found.7,13 Besides, many patients experience 
side-effects of these drugs. 14 To gain insight in the balance of treatment effect versus 
potential treatment disadvantages, patient perspectives should be included, in daily 
care as well as in in clinical trials.15,16 Adequate tools are needed to asses these aspects 
of care. Furthermore, in the absence of a cure, the aim of patient care should not only be 
to prolong life but also to improve QOL, preserve or at least slow down deterioration of 
QOL. There is growing evidence that non-pharmacological therapies such as pulmonary 
rehabilitation (PR) improve exercise capacity and QOL of life of IPF patients.17,18 However, 
PR is commonly offered in a hospital setting and the beneficial effect often weans out 
Table 1. The most commonly-used clinical outcomes in IPF, sarcoidosis and PAH (continued)
FVC, forced vital capacity; TLCO, transfer factor of the lung for carbon monoxide; 6MWD, 6-minute walk 
distance; V’O2, oxygen uptake; V’E/V’CO2, ventilatory response (minute ventilation/carbon dioxide pro-
duction); PAP, pulmonary arterial pressure; PVR, pulmonary vascular resistance; WHO, World Health Orga-
nization; FC, functional class; RVSP, right ventricular systolic pressure; NT-pro BNP, N-terminal pro b-type 
natriuretic peptide; SF-36, Short-form 36-item Questionnaire; EQ-5D, EuroQol Group 5-Dimension Self-Re-
port Questionnaire; CRS-SR, chronic respiratory disease questionnaire-self reported; WHOQOL-100, World 
Health Organization–Quality of Life 100; WHOQOL-BREF, short (brief ) version of the WHOQOL-100; NHP, 
Nottingham Health Profile; K-BILD, King’s Brief Interstitial Lung Disease; ATAQ-IPF, A Tool to Assess Quality 
of life in IPF; L-IPF, living with IPF; SGRQ, St George’s Respiratory Questionnaire; (-I), IPF; KSQ, Kings Sarcoid-
osis Questionnaire; SAT, Sarcoidosis Assessment Tool; SHQ, Sarcoidosis Health Questionnaire; CAMPHOR, 
Cambridge Pulmonary Hypertension Outcome Review; MLHFQ: Minnesota Living with Heart Failure Ques-
tionnaire; LPH: Living with Pulmonary Hypertension questionnaire; CHFQ: Chronic Heart Failure Question-
naire; PAH-SYMPACT, Pulmonary Arterial Hypertension-Symptoms and Impact questionnaire; emPHasis-10: 
10-question survey proposed by the Pulmonary Hypertension Association UK; HADS: Hospital Anxiety and 
Depression Scale; MRC, Medical Research Council; BDI, Mahler Baseline Dyspnoea Index; UCSD-SOBQ, 
The University of California, San Diego Shortness of Breath Questionnaire; FAS, Fatigue Assessment Scale; 
FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; PROMIS, Patient-Reported Outcomes 
Measurement Information System; MFI, Multidimensional Fatigue Inventory; CASA-Q, Cough and Sputum 
Assessment Questionnaire; VAS, visual analogue scale; ; LCQ, Leicester Cough Questionnaire; CQLQ, Cough 
Quality of Life Questionnaire.
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after the training is stopped.19-21 There is a need of practical homebased interventions to 
improve QOL for patients with IPF.
Sarcoidosis is a chronic systemic inflammatory disease of unknown cause, characterized 
by the formation of granulomas.22 Although sarcoidosis can affect any organ, particularly 
the lungs, eyes, skin, liver and lymphatic system are involved. The occurrence of sarcoid-
osis varies greatly depending on race and geographic location and is highest in Nordic 
countries and African Americans.23 The estimated prevalence in the Netherlands is 50 
per 100.000, with approximately 2000 new cases annually.5 Sarcoidosis predominantly 
occurs in patients aged 25-45 years but can affect people of any age.24 Symptoms vary 
widely depending on the degree of inflammation and organs involved and range from 
asymptomatic to severe.22,25 General symptoms comprise fatigue, muscle pain, weak-
ness, aching muscles, fever, lack of appetite.24,26,27 In 90% of patients with sarcoidosis, 
the lungs are affected, leading to dyspnea and cough.22 The majority of patients recov-
ers from sarcoidosis spontaneously, however, in a significant minority disease becomes 
chronic and progressive.22
Sarcoidosis may have a major impact on the lives of patients and relatives. Quality of life 
is not only influenced by symptoms due to organ impairment, but by many other factors 
including side effects of medication, fatigue and the anxiety and stress.22,28 With such a 
variety in disease courses, organs involved, symptoms and severity of disease, measur-
ing QOL in sarcoidosis is a challenge and sarcoidosis-specific instruments involving the 
most affected organs are needed.
The main aim of treatment is to limit or prevent organ damage and improve QOL.27 Cor-
ticosteroids are the first choice of treatment; however limited and outdated evidence 
exists on optimal dosage and timing of this medication.29,30 Furthermore, corticosteroid 
use is associated with side-effects such as weight gain, osteoporosis and reduced QOL.31 
More research is needed to optimize and personalize treatment for patients with sar-
coidosis, including careful evaluation of the risk-benefit balance and including patient 
preferences.
Pulmonary Hypertension (PH)
PH is a pathophysiological disorder, characterized by an elevated blood pressure in the 
pulmonary circulation that will lead to progressive right heart dysfunction and ultimately 
death.32,33 The worldwide prevalence of PH is estimated at 1% of the population and 10% 
of the individuals over 65 years old, mainly due to systolic or diastolic left heart failure 
(HFpEF).34 PH is categorized into five groups according to the World Health Organiza-






hemodynamic findings, and treatment strategy: (1) Pulmonary arterial hypertension 
(PAH), (2) PH due to left heart disease, (3) PH due to lung diseases and/or hypoxaemia, 
(4) Chronic ThromboEmbolic Pulmonary Hypertension (CTEPH) and other pulmonary 
artery obstructions and (5) PH with multifactorial or unclear cause.35 The research in this 
thesis focuses on PAH and CTEPH.
Pulmonary Arterial Hypertension (PAH) is a rare and incurable condition of the pulmo-
nary vasculature, characterized by endothelial dysfunction, muscularization of the small 
arteries and thickening of the adventitia, causing narrowing of the pulmonary arteries. 
This will lead to elevation of the pulmonary arterial pressures which will eventually 
cause progressive right ventricular failure.35 PAH can be associated with several underly-
ing diseases, e.g. collagen vascular disease, congenital heart disease, liver disease or HIV. 
In some cases, an underlying genetic mutation is demonstrated. However, if after careful 
analysis no underlying cause is found, the disease is called idiopathic. The diagnosis PAH 
has to be confirmed by means of a right heart catheterization (RHC)36; required is a mean 
pulmonary arterial pressure (mean PAP) ≥25 mmHg at rest, a normal wedge pressure ≤ 
15mmHg and a pulmonary vascular resistance (PVR) > 3 Wood units (WU).35
In CTEPH, the PVR and the mean PAP are elevated due to thromboembolic obstruction 
and arteriopathy.35 PAH affects more females than males. Data on the true prevalence 
of PAH and CTEPH are lacking due to under diagnosis, but in the Netherlands ap-
proximately 1400 patients with PAH or CTEPH are currently being treated (unpublished 
data).37 Symptoms initially occur mainly during exercise and include breathlessness and 
lack of energy.38 In more advanced disease, patients can experience chest pain with 
exercise, they will develop peripheral edema and they can experience syncope during 
exercise. These symptoms severely affect the daily life physical functioning of patients 
and restricts them from performing everyday tasks.32
In PAH the last 10-15 years advances have been made in the medical treatment due 
to a better understanding of the underlying pathways.35 Despite these improvements 
survival rates are still poor. Depending on the underlying cause, the 5-years survival 
is around 70%.39 However, in case of CTEPH about 60% of the patients can be treated 
with a pulmonary endarterectomy.40 In the majority of these patients this is a curative 
option. In some cases, patients suffer from rest PAH which can be treated with PAH 
specific medication. Recently a new treatment option has been developed, a balloon 
angioplasty (BPA).41,42 Lesions which are located too peripheral to be reached with pul-
monary endarterectomy, may be treated by means of BPA.
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Treatment of PAH and CTEPH focuses on achieving a low-risk status, so called “goal-
oriented” therapy.35 This condition is usually associated with good exercise capacity, 
preserved right ventricle function and a low mortality risk.35 The goal of treatment is 
to improve hemodynamics; to reduce pulmonary vascular resistance, herewith improve 
cardiac output and preserve right ventricle function.35 However, these last outcomes 
can only be measured during an invasive RHC. Therefore, alternatively less invasive 
outcomes measures have been developed which cannot directly determine the above 
mentioned measures, but provide information on the physical status of the patient. 
Currently, the most used physiological end-point in clinical trials is the distance walked 
in the 6-min walk test, to measure changes in exercise capacity.43 This is a relatively 
cheap and reproducible test. N-terminal pro B-type natriuretic peptide (NT-pro BNP) is a 
biomarker often used as marker of right ventricle function.44 Other important outcomes 
measures are shown in Table 1.
Despite the advancements in specific treatment in PAH and CTEPH, patients still have 
a poor prognosis and an impaired HRQOL due to physical, emotional and social prob-
lems.45 In 35% of the PH patients, stressors like delay until a correct diagnosis has been 
made, uncertainty about the prognosis and physical burden lead to depression, anxiety 
and panic attacks.46,47 Therefore, earlier detection of anxiety and depression by using 
well validated PROMs is needed to start psychological support in time.48 Only less than 
25% of the patients receive supportive treatment for their general wellbeing. Fortunately 
it has been increasingly acknowledged that the wellbeing of patients should also be 
evaluated in clinical care and research (6th world symposium on pulmonary hyperten-
sion).49 In clinical trials studying new treatment options, patient-reported outcomes 
are frequently included as secondary clinical endpoint.38 However, there is a lack of a 
PH-specific questionnaires in Dutch.
Generic questionnaires used may be less sensitive to measure HRQOL in PAH. We con-
cluded that a PAH-specific instrument is needed that is able to capture the burden of 
this specific disease. We therefore translated a PAH-specific questionnaire (CAMPHOR) 
for the Netherlands. Afterward a validation process was carried out to examine whether 
the Dutch version retained the measurement properties of the original CAMPHOR. This 
process and the results are described in part 1, chapter 4.
Apart from treatment with PAH specific drugs, PAH guidelines do recommend adding 
non-pharmacological therapies such as supervised pulmonary rehabilitation.35 Several 
studies demonstrated that beside hemodynamic impairment and ventilation-perfusion 
mismatches, respiratory and skeletal muscle dysfunction play an important role in 






PAH patients in daily life activities, it has a strong negative influence on QOL.52,54 Several 
studies demonstrated beneficial effects of PR programs in a clinical setting on exercise 
tolerance, muscle strength, functional status and QOL.55-57 However, little is known 
about the safety and effectiveness of a PR program in an outpatient setting. We there-
fore studied the effectiveness of a multidisciplinary PR program, including psychological 
intervention, education and contact with peers, in an entirely outpatient setting. The 
results of this study are described in part 3, chapter 9.
Outcomes
Outcomes can roughly be categorized into physiological outcomes and patient-reported 
outcomes (PROs). In diseases such as ILD and PH, the crucial clinical outcomes of treat-
ment are disease progression, mortality and QOL. However, use of survival as primary 
endpoint to evaluate treatment response is often not practicable, unless in end stage 
disease.43,58 Therefore, to evaluate treatment response faster and more direct, so called 
surrogate markers as substitute for clinically meaningful endpoints, are used.59
In IPF and sarcoidosis Forced Vital Capacity (FVC) is the most used primary endpoint.7,13,60,61 
FVC is easy to measure, reliable and able to capture changes in disease progression.9,62-64 
Compared to other physiologic markers, FVC best correlates with worsening of fibrosis. 
Furthermore, a 5-10% decline in FVC predicts worse prognosis.65 The 6-min walking 
distance (6MWD) and the transfer factor of the lung for carbon monoxide (TLCO), physi-
ologic markers for respectively functional status and gas exchange, are often used as 
secondary endpoints.
In PH, the 6MWD is the most used primary endpoint next to hemodynamic data.66-68 The 
6MWT is easy to measure, inexpensive and reproducible.43 Furthermore, 6MWT evalu-
ates the integrated responses to exercise of the pulmonary and cardiovascular systems, 
systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle 
metabolism.69 6MWD has prognostic value and is an estimate of daily life functional 
capacity.70 Next to 6MWT, NYHA functional class and soluble biomarkers e.g. NT-pro BNP 
levels are also used as secondary endpoint and as independent factors in risk stratifica-
tion for survival. 71,72
Although usually physiological outcomes are recorded in the hospital, technological ad-
vances have opened the way for homebased self-recording of physiological outcomes 
by the patients.
Prolongation of life (survival) as the main goal of new therapies is undoubtedly of ut-
most relevance to both physicians and patient. However, a reasonable treatment goal 
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should also be making the patient feel better. Therefore information on this aspect 
should at least be included as a secondary end-point in therapy trials.73 Physiological 
outcomes fail to capture aspects that are most relevant to the patient such as dyspnea 
(symptoms), level of independence, social functioning, psychological state and QOL. 
FVC and TLCO for example, poorly correlate with QOL and dyspnea.16,74,75 Patients, being 
experts on their disease, are the most reliable source to obtain information on how they 
feel and function in daily life, and what the effect is of treatment on their wellbeing. 
These aspects can be measured by tools called patient-reported outcome measures 
(PROMs). A Patient-Reported Outcome (PRO) is defined as “Any report coming directly 
from the patient without interpretation by a third party about how they feel or func-
tion in relation to a health condition and given intervention”.76 Patient perspectives on 
these aspects are always subjective, because a true value is never known. However, if 
validated well, PROMs are reliable tools to assess patient perspectives in a structured 
way, enabling quantification and interpretation.
PROMs can be questionnaires that measure single dimensions of a patient’s wellbeing 
such as symptoms (breathlessness) or specific domains as functioning, but may also 
measure broader and more complex concepts like QOL. QOL is defined as an individual’s 
perception of her/his position in life in the context of the culture and value systems in 
which she/he lives and in relation to her/his goals, expectations, standards and concerns. 
QOL is affected by the persons physical health, psychological state, personal beliefs, 
social relationships and their relationship to salient features of their environment.77 
When QOL, impacted by health or by treatment is studied, the term health-related 
QOL (HRQOL) is used in literature. HRQOL is restricted to the physical, psychological 
and social domains. Health status concerns the impact of a disease on health-related 
functioning. Two individuals with the same functional limitation (HS) can evaluate their 
QOL differently.78 Although the related concepts QOL, HRQOL and health status have a 
different meaning, in literature they are often used interchangeably.79
PROMs can be divided in generic and disease-specific questionnaires.80 Generic instru-
ments assess the wellbeing of persons regardless of their disease, giving the advantage 
to compare outcomes across diseases or to compare outcomes with those of the healthy 
population (higher generalizability). However, they may be insensitive to treatment effects, 
resulting in misleading estimates.81 Disease specific questionnaires are designed to assess 
the wellbeing of patients with a particular disease. They contain relevant items that were 
selected by patients with the targeted disease during the development process. This makes 
the questionnaire responsive and sensitive enough to capture small changes in health 
status that are important for these patients. Symptom or domain-specific questionnaires 






































































   























































































































































   
 











































































































































































































































































































































































































































































































































































































depression.82,83 Although in the last decades many generic and disease-specific PROMs 
have been developed, well validated ILD and PH questionnaires are still scarce. The most 
used physiological and patient-reported outcomes in ILD and in PH are shown in Table 1.
Like other clinical endpoints, a PROM must be reliable (producing consistent results), 
valid (has to measure what is intended to measure), and responsive to changes. To as-
sess its’ measurement properties, various standards has been suggested.76,84-89 The FDA 
has supplied extensive instructions what properties a PROM must have when used in 
clinical trials for label claims of new medication.76,90 The development of a PROM is a 
multistep and iterative procedure (Figure 1).
I. Preliminary instrument development (for whom and what?)
The first step is to determine the measurement aim and for whom the PROM is needed. 
This step is followed by making a clear framework of the relevant concepts that need to 
be measured e.g. symptoms, functional status, general health status or overall QOL. To 
construct a pool of items that reflect the area of interest, direct input of patients and ex-
perts is required (patient interviews, focus groups, expert opinions and literature search).
II. Optimization of instrument: assessment content and face validity (how?)
This step contains assessment of face and content validity. Through cognitive patients 
interviews and pilot testing, the items are assessed on:
- Clarity (is the questionnaire easy to read and clearly displayed? how do patients interpret 
the questions? )
- Relevance (do the patients recognize the relevance of the question?)
- Response range, including floor or ceiling effect, variance of responses (are the direc-
tions of the response scale clear? Is a yes/no answer sufficient? Or should this response 
scale cover a range of answering possibilities (e.g. frequency of dyspnea: never, seldom…..
to most of the time, all of the time?)
- Recall period (is this a realistic and relevant time interval to report on?)
- Item redundancy (are there overlapping questions, or non-relevant questions?)
- Relevancy of the items is analyzed using statistical techniques (e.g. impact factor 
analysis or Rasch analysis). If needed, redundant items are removed, followed by new 
pilot testing.
III. Cross-sectional assessment of psychometric properties (does it work well?):
The finalized PROM is tested in a substantial group of patients and examined on reliabil-
ity and validity. The PROM is reliable when the individual items in a (sub) scale correlate 
well (internal consistency), if it produces stable scores under identical conditions and if 






Altman plot with limits of agreement, intra class correlation). The PROM is valid when it 
correlates with related measures (convergent validity), with an earlier validated PROM 
that is assumed to be the gold standard (criterion validity) and if it captures differences 
in disease severities (known-groups validity).
IV. Longitudinal assessment of psychometric properties (does it capture changes over time?)
The responsiveness or the ability of the PROM to detect changes in disease status can 
be assessed over time. This is particularly important when assessing effectiveness of 
treatment in clinical trials.
For interpretation, an important aspect is to assess its’ minimal clinically important dif-
ference (MCID); the minimum change in score that is considered relevant for patients. 
Commonly, the MCID is estimated using anchor variables, linking changes in the PROM 
to changes in related patient-reported measures and clinically relevant indicators of 
which the MCID is known (anchor-based method). An alternative or supportive method 
is distribution-based MCID estimation, which uses statistical measures of variability.
V. Modification of the PROM (does it work in different settings?)
Every time a PROM is modified new testing from step I is recommended to demonstrate 
that the adapted PROM still is a reliable and valid instrument. In case of modifying the 
language, translation procedures must be followed in which the developers should be 
involved to assess whether the translated and adapted questionnaire will still measure 
what they intended to measure. More details on these translation procedures are shown 
in chapter 2 , 3 and 4.
In general, it is recommended to use an existing PROM, not only to avoid a lengthy and 
costly procedure to develop and validate a new one, but also to avoid an abundance 
of PROMs within one field. With too many PROMs in one field, experience and valida-
tion will dilute and comparison and pooling of data hampered. Inclusion of the same 
disease-specific PROM in clinical trials not only enables to compare outcomes between 
therapies but also enables to gain insight on the interpretation of scores and score 
changes and to establish the minimal important clinical differences. Validation is an 
ongoing process; the more evidence the more valid and applicable a PROM becomes.
Advances in physiological outcome measures
Patient-recorded outcome measures
In IPF, the FVC is currently the primary endpoint for clinical trials as it correlates best 
with fibrosis progression and is considered a surrogate end-point for mortality.91 Be-
sides, it is a reliable and valid measure, capable to capture changes and the test is easy 
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to perform. Reliability of FVC measurements in IPF patients has been demonstrated 
in large randomized trials that showed a stable FVC between screening and baseline 
visit.64 However with longer intervals, measurement variation is a potential problem and 
can vary between 5-9%, even in healthy persons with stable lung function.92,93 Possible 
failure to detect changes in FVC in clinical trials due to this variability noise complicates 
the development of new therapies.94 Another “problem” that arose with the registration 
of two drugs for IPF is that current trial design is add-on and not placebo-controlled 
anymore. This results in the need to detect smaller effect sizes. In IPF the yearly decline 
without treatment is estimated to be 200 ml. With the current anti-fibrotic treatment this 
decline is around 100 ml per year. This means that to study the effect of a new drug that 
is equally effective and halfs the decline in lungfunction, very large trials are needed. 
Johanssen et al.94 estimated that with the FVC traditionally recorded during hospital 
visits at baseline and after 24 weeks, 3840 participants are needed to demonstrate a 
difference of 50 ml FVC between the two arms with an effect size of 50%. An alternative 
could be to collect more data points, however, in practice it is not feasible to ask patients 
to visit the hospital weekly or even daily for a trial. A solution would be to ask patients 
to self-record lung function at home. Johanssen et al.94 calculated that with FVCs mea-
sured weekly for 24 weeks, the estimated group size can be reduced with 75% to 951 
participants, largely improving efficiency and reducing costs for clinical trials. However, 
data on feasibilty and reliability of homebased measurements of FVC are scarce and not 
using realtime data collection.94,95 We aimed to investigate if home monitoring and daily 
recording of FVC by IPF patients, using an e-health platform with realtime transmission, 
is feasible and reliable (part 2, chapter 6).
Home monitoring of FVC also is promising in pulmonary sarcoidosis. For the treatment 
of pulmonary sarcoidosis corticosteroids are first choice.96 Corticosteroids are associated 
with multiple side effects for patients such as weight-gain, diabetes, osteoporosis and 
mood disturbances.31 Until now treatment and tapering regiments are largely based on 
expert opinion and longterm treatment is recommended.22,97 In the study described in 
chapter 5 we evaluated the effect of prednison on lungfunction change, assessed by 
daily home-based spirometry. Better insights in response to therapy can help physicians 
to better tailor treatment, start earlier with tapering of the prednisolon, potentially 
resulting in less side effects and hence improving QOL.
TLCO
Another hurdle in the current trial landscape for IPF is the inclusion of patients. With 
many new compounds being studied in a rare disease, there is a need to adequately 
identify patients that are eligible for trials. The gain is twofold, all possible candidates 






are avoided. One of the important inclusion criteria is the TLCO. TLCO is a measure of 
pulmonary gas exchange function and is decreased in patients with IPF.10 Interpretation 
of the TLCO is usually based on comparisons of measured data with reference values 
based on healthy subjects.58 In IPF trials, screen failures are frequently based on a TLCO 
below lower limits, and are disappointing to patients. In 2017 the Global Lung function 
Initiative (GLI) group launched a new all-aged and globally derived reference value set 
for the TLCO.98 Although this GLI reference value set is currently the most accurate avail-
able, many lungfunction laboratories still use older reference value sets. This may not 
only lead to interlaboratory variability in treatment decisions but also in trial eligibility. 
In part 2 chapter 7 we assessed the impact of the new GLI TLCO reference equations on 
trial inclusion for IPF patients.
Interventions aimed at improving QOL
Despite advances that have been made in pharmacological treatment, IPF and PAH pa-
tients still suffer from severe exertional dyspnea, exercise intolerance, reduced QOL and 
decreased life expectancy. Dyspnea and impaired exercise tolerance lead to a down-
ward spiral of deconditioning, and decreased social participation, both affecting QOL. 
Guidelines on IPF and PAH care promote pulmonary rehabilitation as complemetary 
non-pharmocological treatments that improve QOL and exercise capacity, with exercise 
training being a component of pulmonary rehabilitation.9,35,55
For a long time PAH patients were recommended to avoid exercise because of risk of 
further deterioration of the right ventricular dysfunction and sudden cardiac death. 
However, in 2006 a study of Mereles demonstrated that highly supervised, individualised 
and low-intensity training is safe and feasible and beneficially effected symptoms, exer-
cise capacity and QOL.99 Since then many studies and meta-analysis have demonstrated 
that pulmonary rehabilitation positively effects symptoms, functional capacity, QOL and 
muscle strenght in PAH patients.50,56,100-102
Most of these PR studies in PAH patients are carried out or at least started in a hospital or 
inpatient setting.103 However, for most patients this is not feasible. Knowledge about the 
safety and about the effects of a multidisciplinary aproach in an exclusively outpatient 
setting is needed.38,104 In part 3, chapter 9, we evaluate the effectiveness of an entirely 
outpatient PR program with a multidisciplinary approach on exercise capacity, muscle 
strenght, soluble markers and QOL in PH patients.
In IPF, exercise capacity is known to be an important prognostic factor and positively 
correlated with the ease to perform daily physical activities.105,106 Randomized controlled 
trials showed that 8-12 weeks PR programs improved functional capacity, dyspnoea, 
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and QOL in IPF patients, though the longterm effects are still debated.17-21,107 Due to the 
relatively poor prognosis, IPF patients are often reluctant to follow inpatient pulmonary 
rehabilitation programs. Moreover, studies showed the benefical effects wean out after 
the program stopped, which may be explained by the rapid progression of IPF.19-21 There-
fore we aimed to develop a home-based training modality with the potency not only to 
improve exercise capacity and QOL of IPF patients but also to retain its’ positive effects. 
In part 3, chapter 8, we evaluate the effectiveness of a walk-bike on QOL and exercise 
capacity in IPF patients; a pilot study.
Outline of this thesis
The research described in this thesis is focused on validating PROMs for patients with 
ILD and PH (part 1), development of patient-recorded outcome measures (part 2) and 
interventions aimed at improving QOL for patients (part 3).
Part 1: Validating PROMs for patients with ILD and PH
In chapter 2 we describe the translation and validation proces of the originally English 
King’s Brief Interstitial Lung Disease (K-BILD) questionnaire into French, Italian, Swedish, 
and Dutch. In chapter 3 we demonstrate the validation of the English King’s Sarcoidosis 
Questionnaire (KSQ) in a Dutch sarcoidosis population. The translation and validation of 
the English Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the 
Netherlands is described in chapter 4.
Part 2: Development of patient-recorded outcome measures
In chapter 5 we show how we captured the early lung function response on steroid 
treatment in sarcoidosis patients by daily patient-recording of spirometry at home.
A pilot study on feasibility of daily home monitoring of FVC by IPF patients is described 
in chapter 6. In chapter 7 we assessed the impact of the new Global Lung Function 
Initiative TLCO reference values on trial inclusion for patients with Idiopathic Pulmonary 
Fibrosis.
Part 3: Interventions aimed at improving quality of life for patients
In chapter 8 we describe a crossover pilot study to the feasibility and efficacy of home-
based training with a walk-bike on QOL and exercise capacity in patients with idiopathic 
pulmonary fibrosis. We studied the effectiveness of a multidisciplinary PR program, in-
cluding psychological intervention, education and contact with peers, in an outpatient 
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ABSTRACT
No disease-specific instruments exist in Dutch, French, Italian, and Swedish to measure 
health status in idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases 
(ILDs). The King’s Brief Interstitial Lung Disease (K-BILD) is a 15-item validated question-
naire assessing health status in patients with ILD. The aim of this study was to translate 
and validate the K-BILD to French, Italian, Swedish, and Dutch versions. The K-BILD was 
translated following a forward–backward multistep procedure and tested in structured 
patient interviews. Subsequently, 195 outpatients with ILD were asked to complete 
K-BILD, St. George’s Respiratory Questionnaire (SGRQ), and Euroqol EQ-5D-5L (EQ5D), 
twice, 2 weeks apart. Internal consistency, concurrent validity, and repeatability were 
determined. No major difficulties occurred in the translation processes. The K-BILD was 
considered comprehensible and relevant by patients. One hundred seventy-six patients 
(108 IPF and 68 other ILDs) completed the translated K-BILD. Internal consistency was 
good for all K-BILD modules (Cronbach’s α 0.70–0.93). Concurrent validity of K-BILD was 
strong compared with SGRQ (r = -0.86) and EQ5D (r = 0.68), low with transfer capacity of 
the lung for carbon monoxide corrected for hemoglobin (r = 0.33) and with forced vital 
capacity (r = 0.35). The K-BILD and its domains were repeatable over 2 weeks; intraclass 
correlation coefficients were 0.86–0.93 (n = 159). Known groups validity showed K-BILD 
was able to discriminate between patients based on severity of disease. K-BILD’s validity 
and reliability for patients with IPF was similar to that of other ILDs. The French, Italian, 
Swedish, and Dutch translated K-BILD questionnaires were well-received by patients and 







Health related quality of life (HRQL) is impaired in the majority of patients with inter-
stitial lung disease (ILD) due to symptoms, such as dyspnoea and fatigue, limitations 
on physical activities, and social isolation.1–3 HRQL is quantified using disease-specific 
questionnaires on aspects of life that patients consider important. In clinical research, 
HRQL is an important endpoint to assess effectiveness of therapeutic interventions.
There are no disease-specific instruments to assess HRQL in idiopathic pulmonary 
fibrosis (IPF) and other ILD patients available in Dutch, French, Italian, and Swedish. 
Therefore, the St. George’s Respiratory Questionnaire (SGRQ), originally developed for 
chronic obstructive respiratory disease, is commonly used (50 items).4–7 In 2012, the 
King’s Brief Interstitial Lung Disease (K-BILD) health status questionnaire was made 
available.8,9 The K-BILD questionnaire contains 15 questions and is much shorter than 
the SGRQ and easy to administer. It is well validated and can be used to assess HRQL in 
a wide range of ILDs. K-BILD also showed a stronger concurrent validity than the SGRQ 
with pulmonary function in patients with IPF.8 The availability of the K-BILD in different 
languages could facilitate collaborative international research aiming to improve the 
quality of life in these rare diseases.
The aim of this study was to translate and validate the K-BILD to French, Italian, Swedish, 
and Dutch versions. The linguistic and psychometric validations of the Italian, French, 
Swedish, and Dutch K-BILD questionnaires are reported.
METHODS
Linguistic validation: translation, patient interviews, and adaptation
The K-BILD is a 15-item validated, self-completed questionnaire on disease-specific 
health status with a seven point response scale. It has three domains: breathlessness and 
activities, psychological and chest symptoms, and one question on financial problems. 
The domain and total score ranges are 0–100, with the higher scores corresponding with 
better HRQL.8
The translation and adaptation of the Dutch, French, Italian, and Swedish K-BILD ques-
tionnaires were conducted, respectively, at the pulmonary departments of Erasmus 
Medical Center in Rotterdam, the Netherlands, Louis Pradel Hospital, Lyon, France, the 






Permission to translate the K-BILD was asked from the copyright holders.10 The K-BILD 
questionnaire was translated into Dutch, French, Italian, and Swedish, following a 
multistep procedure and in collaboration with the developers using their conceptual 
framework of items to ensure conceptual/semantic equivalence.11–13 Online supplement 
1 provides details on all the 11 steps of the translational procedure. This included an 
external back translation and review by linguistic services of Mapi Language Services 
(Lyon, France).
For each country, the translated version was tested with structured interviews in at least 
five patients (interview questions are shown in the online supplement 2). This was fol-
lowed by harmonization meetings to reconcile issues raised. The resulting final versions 
of the Dutch, French, Italian, and Swedish K-BILD are shown in the online supplements 
3 to 6.
Psychometric validation of the Dutch K-BILD
Patients and measurements
All consecutive patients with ILD visiting the tertiary outpatient clinic of the pulmonary 
department of Erasmus Medical Center, between December 2013 and May 2014, were 
asked to participate. For Sweden, France, and Italy, patients were included between 
August 2015 and April 2016. Patients were excluded if they had sarcoidosis, emphy-
sema (clinician’s judgment, based on lung function and computer tomography scan), 
or if there was a language or intellectual barrier. ILD was classified consistent with 
international guidelines.14,15 Patients willing to participate were asked to complete two 
questionnaires: K-BILD and SGRQ, and two health status measurements: Punum Lad-
ders and Euroqol EQ-5D-5L (EQ5D), at the day of the current visit and after 2 weeks.16,17 
The sequence of completing the questionnaires was: K-BILD, SGRQ, Punum Ladder, 
and EQ5D. Patients were instructed to fill in the questionnaires alone in a quiet place. 
Nonresponders received a phone call to remind them. Patients who did not complete > 
85% of the questions were excluded from the study.
If performed in routine care, the results of pulmonary function tests (total lung capacity 
(TLC), forced vital capacity (FVC), and transfer capacity of the lung for carbon monoxide 
corrected for haemoglobin (TLCOc)) were recorded from the files.18,19
The ethics committee of the Erasmus Medical Center, Rotterdam, the Netherlands, 
decided to exempt this study from review according to national and international 






tals approved of this decision. All patients gave written informed consent or approval by 
voluntarily returning the completed questionnaires.
Validation
For validation, we tested the following five different aspects:
1. Concurrent validity showing correlations between K-BILD scores and SGRQ scores, 
Punum Ladders, EQ5D, and lung function.
2. Internal consistency reflecting the interrelatedness of items comprising the K-BILD.
3. The test–retest reliability (repeatability) was determined by comparing the K-BILD 
scores at baseline and 2 weeks in patients whose condition was considered stable.
4. Discriminative validity, reflecting the ability of an instrument to differentiate between 
groups of patients, was examined by comparing baseline health status scores of 
“known groups”.
5. Effect size (ES) was calculated by determining partial η2 in K-BILD scores between the 
groups.20
Analysis
Data analysis was executed using SPSS version 21. Results are expressed as mean val-
ues ( ± standard deviation) unless otherwise stated. To determine concurrent validity 
between HRQL variables and clinical variables, we used Pearson correlation coefficient 
or Spearman’s rank correlation coefficients. Internal consistency was determined by cal-
culating the Cronbach’s α coefficients for each domain and the total K-BILD. Cronbach’s 
α coefficient > 0.7 is considered a reliable internal validity. The test–retest reliability was 
assessed with intraclass correlation coefficient (ICC) and Bland–Altman plots. An ICC of 
0.7 is considered the minimum standard for reliability.21 Punum Ladders were used as a 
measure to assess if patients felt stable at 2 weeks. To assess discriminative validity and 
ES, students’ t-test or one-way analysis of variance was used.
RESULTS
Permission to translate the K-BILD questionnaire was obtained by the copyright holders. 
Review by the developers of the cognitive interviews, comments, and back translations 
in each country resulted in minor changes to make sure the translated questionnaires 
reflected the intention of the original K-BILD. Demographics, translation comments, and 










A total of 195 patients were recruited for the psychometric validation of the K-BILD. One 
hundred seventy-six patients (90%) completed and returned the questionnaire at week 
zero and 159 patients (82%) at week 2, with 0.2% missing items in the K-BILD question-
naire and 1.9% in the SGRQ. The diagnoses were: IPF (108), collagen vascular disease-
associated ILD (19), chronic hypersensitivity pneumonitis (10), unclassifiable ILD (14), 
idiopathic nonspecific interstitial pneumonia (13), pulmonary alveolar proteinosis (2), 
obliterative bronchiolitis (3), organizing pneumonia (2), Langerhans cell histiocytosis (1), 
lymphangioleiomyomatosis (1), respiratory bronchiolitis-associated ILD (1), asbestosis 
(1), and desquamative interstitial pneumonia (1). Demographic information is shown 
in Table 2.
Lung function data were used when present; of 139 patients TLCOc data were available, 
72 of the 139 patients had a TLCOc below 50% predicted. There were no floor or ceiling 
effects in the K-BILD total or domain scores; less than 15% of the participants achieved, 
respectively, the lowest or highest possible score.21
Concurrent validity of the K-BILD domain and total scores with the validated SGRQ 
domain and total scores was strong for all domains. Correlation coefficients with other 
HRQL measures and lung function variables are shown in Table 3  for the total group 
and in online supplement 8 for the individual countries. The correlations between SGRQ 
total score and lung function parameters were comparable (FVC %predicted: r= −0.38, 
forced expired volume in 1 second %predicted: r = −0.30, TLC %predicted: r = −0.33, and 
TLCOc %predicted: r = −0.39).
Table 1. Characteristics of participants involved in linguistic validation per country.a
Characteristics
 
France Italy the Netherlands Sweden
(n = 6) (n = 5) (n = 11) (n = 8)
Female 2 (33%) 1 (20%) 4 (36%) 3 (38%)
Age (years) 76 (69-89) 66 (57-77) 59 (39-76) 74 (69-81)
FVC, %predicted 70 (58-92) 70 (52-94) 75 (39-97) 65 (51-81)
TLCOc, %predicted 38 (26-49) 50 (30-80) 42 (33-98) 40 (36-63)
Diagnosis
 IPF 6 3 8 7
 NSIP 2 1
 CVD 1
 Other     1 1
FVC: forced vital capacity; TLCOc: transfer capacity of the lung for carbon monoxide, corrected for hemo-
globin concentration; IPF: idiopathic pulmonary fibrosis; NSIP: nonspecific interstitial pneumonia; CVD: col-
lagen vascular disease associated ILD.
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































r 2Internal consistency was good in the chest domain and excellent in the other domain 
and total scores (Table 4). Repeatability was tested in 159 patients; the average length 
of time between baseline and measurement at week 2 was 16 days. ICCs for consistency 
and Bland–Altman plot demonstrated good repeatability and thus reliability of the 
K-BILD (Table 4  and  Figure 1  for the total group and online supplements 9 to 13 for 
the individual countries). Punum Ladders were completed by 156 patients, 99% had no 
change or minimal change in Punum scores quality of life between baseline and week 
2, which confirmed their stable health status. Removing the two patients with major 
changes from test–retest analysis did not alter the results.













Total -0.86 -0.87 -0.72 -0.64
Activity -0.77 -0.84 -0.62 -0.51
Impact -0.83 -0.81 -0.70 -0.62
Symptoms -0.65 -0.59 -0.55 -0.59
EQ-5D-5L
Index Value 0.68 0.69 0.59 0.46
VAS 0.63 0.67 0.56 0.40
Lung Function
FVC %predicted 0.35 0.42 0.29 0.16c
FEV1%predicted 0.28 0.37 0.22 0.15d
TLC %predicted 0.34 0.37 0.33 0.13d






HRQL: health-related quality of life; K-BILD: King’s Brief Interstitial Lung Disease questionnaire; SGRQ: St. 
George’s Respiratory Questionnaire; VAS: Visual Analogue scale; FVC: forced vital capacity; FEV1: forced ex-
pired volume in 1 second; TLC: total lung capacity; TLCOc: transfer capacity of the lung for carbon monox-
ide, corrected for hemoglobin concentration.
aThe correlation coefficients for the corresponding domains are shown in bold.







Figure 2: Bland Altman plot of repeatability of the King’s Brief Interstitial Lung Disease (K-BILD) questionnaire of 
all countries. The solid line shows the mean difference,  the dashed lines represent the 95% limits of agreement. 
 
 
Figure 1. Bland Altman plot of repeatability of the K-BILD questionnaire of all countries. The solid line 
shows the mean difference and the dashed lines represent the 95% limits of agreement. K-BILD: King’s Brief 
Interstitial Lung Disease questionnaire.
Table 4. Internal consistency and reliability K-BILD (total all countries).a
Internal 
reliability ICC 95% CI
K-BILD
 Breathlessness/ activities 0.89 0.90 0.87-0.93
 Psychological 0.91 0.90 0.87-0.93
 Chest symptoms 0.70 0.86 0.81-0.89
 Total 0.93 0.93 0.91-0.95
K-BILD: King’s Brief Interstitial Lung Disease; ICC: intraclass correlation coefficient for K-BILD repeatability; 
95%CI: 95% confidence interval.






Both K-BILD and SGRQ total scores were able to discriminate between patients based on 
severity of their disease (Table 5). The discriminative power of the K-BILD and SGRQ is 
expressed in ES between the known subgroups. The ES is the strongest (0.4) for symp-
tom-based classification of groups and poor for those based on lung function and other 
non-symptom parameters, which is not surprising as they measure a different aspect of 
disease. The magnitude of the ES indicates both questionnaires having good discrimina-
Table 5. K-BILD and SGRQ total scores in known groups.a
Clinical variables  N  K-BILD Total ES SGRQ Total ES
Supplemental oxygen
Yes 59 38.3 (15.3) 0.27 60.8 (15.5) 0.25
No 117 62.6 (20.3) 38.7 (19.7
Perceived health status
Poor/Very poor 28 33.6 (14.1) 0.41 68.5 (11.6) 0.46
Fair 80 55.4 (17.5) 46.5 (16.6)
Very good / Good 40 74.1 (15.1) 26.9 (15.3)
TLC
≤ 60 %predicted 49 48.2 (19.7) 0.14 51.8 (17.9) 0.13
> 60 %predicted 76 64.6 (19.7) 36.6 (20.5)
FVC
≤ 50 %predicted 15 39.8 (12.7) 0.10 63.6 (14.8) 0.14
51-90 %predicted 113 53.4 (22.3) 47.1 (20.1)
>90 %predicted 35 66.0 (20.3) 33.4 (20.9)
TLCOc 
≤ 35 %predicted 27 45.8 (20.1) 0.06 55.6 (16.0) 0.11
36-70 %predicted 90 56.5 (22.9) 44.0 (22.1)
> 70 %predicted 22 64.9 (21.6)*
ILD
IPF 108 51.9 (22.2) 0.02 48.9 (20.9) 0.03
Non-IPF 68 58.6 (21.1) 41.7 (20.8)
Gender
Female 69 54.6 (21.3)* 0.00 45.4 (20.5)* 0.00
Male 107 54.4 (22.5) 46.6 (21.5)
K-BILD: King’s Brief Interstitial Lung Disease questionnaire; SGRQ: St. George’s Respiratory Questionnaire; 
ES: effect size; TLC: total lung capacity; FVC: forced vital capacity; TLCOc: transfer capacity of the lung for 
carbon monoxide, corrected for hemoglobin concentration; ILD: interstitial lung disease; IPF: idiopathic 
pulmonary fibrosis.
a Values represent mean scores (standard deviation). Statistical tests used to determine difference between 
groups was student’s test or one-way analysis of variance. ES are expressed in partial h2 : small effect ≥ 0.01, 
medium effect ≥ 0.06, large effect ≥ 0.14.





tive power. Table 6 shows the concurrent validity, internal reliability, and repeatability of 
the K-BILD questionnaire in patients with IPF when comparable to patients with other 
ILDs (non-IPF).
DISCUSSION
In this study, the K-BILD was translated into an Italian, French, Swedish, and Dutch 
version and psychometrically validated. It is the first health status questionnaire for IPF 
and other ILDs available in these languages. During the cultural adaptation process, 
only minor changes were necessary. The K-BILD was brief with only 15 items easy to 
administer, well-received by patients, and applicable to non-English speaking countries. 
The K-BILD was also validated for the first time in non-English speaking populations and 
showed good concurrent validity, internal consistency, repeatability, and discriminative 
performance, comparable with the original K-BILD. Also a strong correlation of the EQ5D 
index value with K-BILD was found. This had not been assessed before.
Instruments to measure HRQL have become increasingly important in trials and clinical 
care. However, major improvements are needed to develop and validate new or existing 
instruments.23
The K-BILD questionnaire is the first disease-specific questionnaire to examine HRQL in 
patients with IPF and other ILDs. Other questionnaires were not specifically developed 
Table 6. Concurrent validity, internal reliability, and repeatability of K-BILD in IPF in comparison with other 




SGRQ Total -0.82 -0.91
SGRQ Symptoms -0.59 -0.71
SGRQ Activity -0.73 -0.82







K-BILD: King’s Brief Interstitial Lung Disease questionnaire; IPF: idiopathic pulmonary fibrosis; ILD: intersti-
tial lung disease; SGRQ: St. George’s Respiratory Questionnaire.






for ILDs; a-tool-to-assess-quality-of-life-in-IPF (ATAQ-IPF) and an IPF specific version of 
SGRQ-I were only validated in an IPF population.23,24 The University of California San 
Diego Shortness of Breath Questionnaire only measures symptoms and was developed 
in a non-ILD population and tested for content and construct validity in IPF.25–27
In the absence of disease-specific measures for ILDs, clinically relevant patient-reported 
outcome measures for obstructive lung disease such as SGRQ have been used in trial 
assessing, for example, medication treatment in ILD/IPF.28
The current patient population showed reduced HRQL in all domains of K-BILD and 
SGRQ, with the activity domain most impaired. This is in line with a review by Swigris 
of three studies that assessed HRQL in IPF and other ILD patients and also showed that 
HRQL was most impaired in the physical activity domains.2 The mean (SD) K-BILD total 
score was 59 (22) in ILD patients and 52 (22) in IPF patients; in the original development 
study of the K-BILD, these scores were comparable with 59 (25) and 52 (26), respectively.8
Concurrent validity and repeatability were comparable with the results of the original 
version.8 In the current study, correlation of FVC and TLCOc with the breathlessness and 
activity domain was weaker than in the original study; FVC (0.42 vs. 0.51) and TLCOc 
(0.44 vs. 0.52). Correlations of SGRQ total score with FVC and TLCOc yielded comparable 
correlation coefficients to those of the K-BILD. The weak correlation of FVC with the 
HRQL questionnaires confirms that HRQL informs us about aspects of disease severity 
that are relevant to patients but cannot be measured with physiologic measures such 
as lung function. In other validation studies, the same results were found. In a study 
that assessed HRQL in 50 patients with ILD SGRQ total score correlated with FVC %pre-
dicted r = −0.45 and with TLCOc %predicted r = −0.55.7 The SGRQ-I showed in IPF popu-
lation correlations with FVC %predicted r = −0.33.23 The ATAQ-IPF correlations revealed 
comparable results.24
These findings confirm FVC contributes only partly to the impact ILD or IPF has on qual-
ity of life. TLCOc %predicted with a moderate correlation appears to be more related to 
quality of life in both our study and others.7,23,24
It is interesting to note that in the current study, differences in between countries are 
seen in HRQL. In Italy, more impairment in HRQL is found both with the K-BILD and the 
SGRQ, while mean FVC values are comparable to the other countries. Also, correlations 
between FVC and K-BILD differed between countries. This could be due to small num-
bers; however, in Sweden and the Netherlands, correlations are similar to the original 





could be that factors such as climate and diet influence disease burden or disease per-
ception and consequently HRQL, with the Northern countries having more resemblance 
in these factors with the original study population from the United Kingdom and more 
similar outcomes. To the best of our knowledge, no studies have yet been performed in 
ILD looking at influences of diet and climate on disease and HRQL.
The K-BILD was developed for ILDs, including IPF. To assess more specifically its ability 
to measure HRQL in IPF, we compared the construct validity, internal reliability, and 
intraclass correlation between IPF and non-IPF ILD subgroups. These results show that 
the K-BILD is also a reliable and valid tool in IPF patients. Our study confirms HRQL is 
more affected in IPF than in other ILDs as has also been previously noted in studies using 
the generic measure Short Form-36.2
The K-BILD questionnaire detected differences in disease severity. HRQL was more 
impaired in patients using supplemental oxygen (in line with the original study), with 
lower perceived health status and with lower lung function values (this was not tested in 
original study). In the original article of Patel et al., no ES are calculated. In our study, ES 
show that K-BILD discriminates better in the home oxygen and TLC subgroups, and the 
SGRQ discriminates better in the TLCOc and perceived health status subgroups (based 
on one question describing general health status). Both questionnaires had acceptable 
levels of missing items, K-BILD scored better with only 0.2% missing items versus 1.9% 
in SGRQ. The advantage of the K-BILD is that it is much shorter, 15 questions versus 50 
questions.
With the economically challenging climate and new and expensive medications, gov-
ernmental organizations increasingly investigate cost-effectiveness of treatment, with 
the benefit of interventions expressed in quality-adjusted life years (QALYs). A generally 
accepted tool for the calculation of QALYs is the EQ5D, a generic five questions measure 
of health. EQ5D was used in intervention studies in IPF to assess quality of life and to 
calculate cost-effectiveness of new treatment options.29 In our study, K-BILD total score 
correlated well with EQ5D (0.68). The Dutch general population norm for the EQ5D 
index value is 0.91.30 In our study, the mean EQ5D index value was 0.74 for ILD and 0.66 
for the IPF subgroup.
A limitation of this study is that it did not assess responsiveness and minimal clinically 
important difference (MCID). The study of Patel et al. suggests that the K-BILD is a re-
sponsive health status outcome measure in ILD with an MCID of around eight; however, 
as they also state that this was only assessed in a small sample size and only four patients 






rently follow up a patient cohort prospectively, to gain information about responsive-
ness and MCID in a bigger multicultural cohort. Another limitation is that both in the 
original as well as in our study, only small numbers of patients with ultrarare ILDs were 
included. Only larger international collaborative studies will be able to further validate 
the K-BILD in specific disease groups.
In conclusion, the current study developed a Dutch, Italian, French, and Swedish ver-
sion of the K-BILD and demonstrated that the K-BILD is a reliable and valid instrument 
to measure HRQL in an international cohort of patients with ILD, consistent with the 
evidence of the original version. With only 15 items, it is easy to use in daily practice, 
and moreover, its use in different languages could facilitate collaborative international 
research aiming at improving quality of life in these rare diseases. 
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Online supplement 1. Steps in translation procedure K-BILD questionnaire
Online supplement 1. Steps in translation procedure K-BILD questionnaire 
 
Q = Questionnaire in English, T = Translation into target language, R = Report with comments 
Approval from developers to use final version T4
Review of (Q3) by MAPI and by developers
Back translation of T4 into English (Q3)
Review of report (R2 )with developers , harmonisation meeting, final adaptations of T3 (-> T4)
Face-to-face structured patient interviews with the pre-final version (T3)
comments in report R2
Review of report (R1) and back translation (Q2) together with developers
incorporate comments from  T2 -> T3
Back translations of T2 from local language into English  (Q2)
translators fluent in English and native language
Reconciliation in case of any discrepancies and incorporation of remarks in T1 (-> T2)
Review of T1 for conceptual equivalence  by bilingual  professionals (physician, nurse, research assistant)
comments in report R1
Forward translation of Q1 to local language (T1)
by two bilingual translators
Permission obtained from developers  to use questionnaire (Q1)
Identify the conceptual framework together with developers 





Online supplement 2: Questions patient interviews K-BILD questionnaire
1. Was the questionnaire relevant?
2. Did you understand the question? / What does the question mean to you?
3. Could the question mean more than one thing to you? Could you interpret it in another 
way?
4. Was the response scale appropriate?
5. Was the questionnaire easy to complete? If not, please can you explain why not?
6. Did you find the questionnaire comprehensive?
7. Did you miss anything in the questionnaire?
8. Do you have suggestions to improve it?
9. Any other comments?
Online supplement 3 1  
King's korte vragenlijst over interstitiële longziekte (K-BILD)  King's College Hospital 2011 
 
 




Deze vragenlijst is gemaakt om de invloed van uw longziekte op 
verschillende aspecten van uw leven te beoordelen. Lees elke vraag 
zorgvuldig en geef antwoord door de respons die het beste bij u past, te 











Datum:  .................. 
 












1. De laatste 2 weken was ik buiten 
adem bij het trappen klimmen of bij het 
oplopen van een helling of heuvel. 
 
1. Altijd 
2. Bijna altijd 
3. Verschillende keren 
4. Enkele keren 




2. De laatste 2 weken had ik door 
mijn longziekte een beklemmend gevoel 




3. Een groot deel van de tijd 
4. Enkele keren 
5. Weinig 
6. Bijna niet 
7. Nooit 
 
3. Heeft u zich de laatste 2 weken 





3. Een groot deel van de tijd 
4. Enkele keren 
5. Weinig 
6. Bijna niet 
7. Nooit 
 
4. Heeft u de laatste 2 weken 
vermeden dingen te doen die u buiten 




3. Een groot deel van de tijd 
4. Enkele keren 
5. Weinig 
6. Bijna niet 
7. Nooit 
 
5. Had u de laatste 2 weken het 
gevoel dat u grip hebt op uw longziekte? 
 
1. Nooit 
2. Bijna niet 
3. Weinig 
4. Enkele keren 




6. Voelde u zich de laatste 2 weken 





3. Een groot deel van de tijd 
4. Enkele keren 
5. Weinig 
6. Bijna niet 
7. Nooit 
 
7. De laatste 2 weken had ik een 
gevoel van drang om adem te halen, ook 




3. Een groot deel van de tijd 
4. Enkele keren 
5. Weinig 
6. Bijna niet 
7. Nooit 
 
8. De laatste 2 weken maakte ik me 




3. Een groot deel van de tijd 
4. Enkele keren 
5. Weinig 
6. Bijna niet 
7. Nooit 











9. Hoe vaak hoorde u de laatste 2 





3. Een groot deel van de tijd 
4. Enkele keren 
5. Weinig 
6. Bijna niet 
7. Nooit 
 
10. Hoe vaak had u de laatste 2 





3. Een groot deel van de tijd 
4. Enkele keren 
5. Weinig 
6. Bijna niet 
7. Nooit 
 
11. Heeft uw longziekte de laatste 2 
weken invloed gehad op uw werk of 




3. Een groot deel van de tijd 
4. Enkele keren 
5. Weinig 
6. Bijna niet 
7. Nooit 
 
12. Verwachtte u de laatste 2 weken 





3. Een groot deel van de tijd 
4. Enkele keren 
5. Weinig 
6. Bijna niet 
7. Nooit 
 
13. In hoeverre heeft uw longziekte u 
de laatste 2 weken beperkt in het dragen 





3. Een groot deel van de tijd 
4. Enkele keren 
5. Weinig 
6. Bijna niet 
7. Nooit 
 
14. Heeft u door uw longziekte de 





3. Een groot deel van de tijd 
4. Enkele keren 
5. Weinig 
6. Bijna niet 
7. Nooit 
 
15. Bent u financieel slechter af door 
uw longziekte? 
 
1. Een enorm bedrag 
2. Een groot bedrag 
3. Een aanzienlijk bedrag 
4. Een redelijk bedrag 
5. Een klein bedrag  
6. Bijna niet 






Hartelijk bedankt voor het invullen van 
deze vragenlijst! 
 






Online supplement 8. Correlation coefficients between K-BILD scores and other HRQL 
scores and clinical variables for the individual countries.
The Netherlands
Outcome scales K-BILD Total K-BILD Breath/Activ K-BILD Psych K-BILD Chest
SGRQ
 Total -0.89 -0.85 -0.79 -0.65
 Activity -0.81 -0.83 -0.70 -0.55
 Impact -0.84 -0.80 -0.76 -0.59
 Symptoms -0.71 -0.60 -0.63 -0.71
EQ-5D-5L
 Index Value 0.71 0.68 0.66 0.48
 VAS 0.66 0.61 0.62 0.45
Lung Function
 FVC %predicted 0.38 0.45 0.30 0.26a
 FEV1%predicted 0.28a 0.36 0.22a 0.19b
 TLC %predicted 0.33 0.36 0.32 0.17b











Outcome scales K-BILD Total K-BILD Breath/Activ K-BILD Psych K-BILD Chest
SGRQ
 Total -0.87 -0.93 -0.67 -0.64
 Activity -0.72 -0.88 -0.51 -0.44a
 Impact -0.85 -0.85 -0.67 -0.68
 Symptoms -0.76 -0.76 -0.61 -0.64
EQ-5D-5L
 Index Value 0.76 0.77 0.55 0.66
 VAS 0.69 0.74 0.56 0.47
Lung Function
 FVC %predicted 0.51 0.53 0.49 0.21b
 FEV1%predicted 0.44 0.53 0.37a 0.13b
 TLC %predicted 0.54 0.54 0.51 0.29b












Outcome scales K-BILD Total K-BILD Breath/Activ K-BILD Psych K-BILD Chest
SGRQ
 Total -0.65 -0.84 -0.33b -0.20b
 Activity -0.46 -0.79 -0.14b -0.05b
 Impact -0.66 -0.83 -0.33b -0.29b
 Symptoms -0.52a -0.36b -0.44a -0.29b
EQ-5D-5L
 Index Value 0.66 0.87 0.32‡ 0.02b
 VAS 0.65 0.78 0.33‡ 0.12b
Lung Function
 FVC %predicted 0.29b 0.38b 0.21b -0.20b
 FEV1%predicted 0.23b 0.34b 0.13b -0.14b
 TLC %predicted 0.41b 0.33b 0.40b -0.13b











Outcome scales K-BILD Total K-BILD Breath/Activ K-BILD Psych K-BILD Chest
SGRQ
 Total -0.81 -0.81 -0.72 -0.68
 Activity -0.77 -0.79 -0.70 -0.56
 Impact -0.77 -0.76 -0.69 -0.68
 Symptoms -0.53 -0.57 -0.41a -0.47a
EQ-5D-5L
 Index Value 0.76 0.71 0.73 0.66
 VAS 0.63 0.69 0.59 0.42a
Lung Function
 FVC %predicted 0.24b 0.26b 0.22b 0.10b
 FEV1%predicted 0.18b 0.22b 0.22b 0.14b
 TLC %predicted - - - -





 Chest symptoms  -0.44a
Values shown represent Pearson’s correlation coefficients, all p < 0.01 unless otherwise stated (a p < 0.05, bp 
> 0.05). Correlation coefficients for the corresponding domains are shown in bold.
Abbreviations: HRQL = health-related quality of life, K-BILD = King’s brief interstitial lung disease question-
naire, SGRQ = St. George’s respiratory questionnaire, VAS = visual analogue scale, FVC = forced vital capac-
ity, FEV1 = forced expired volume in 1 second, TLC = total lung capacity, TLCOc = transfer capacity of the 






Online supplement 9. Internal consistency and reliability K-BILD for the individual 
countries.a
The Netherlands
Internal reliability ICC 95% CI
K-BILD
 Breathlessness/ Activities 0.89 0.88 0.82-0.92
 Psychological 0.91 0.89 0.84-0.93
 Chest symptoms 0.74 0.84 0.77-0.89
 Total 0.93 0.92 0.88-0.95
Sweden
Internal reliability ICC 95% CI
K-BILD
 Breathlessness/ Activities 0.92 0.97 0.93-0.98
 Psychological 0.92 0.86 0.73-0.93
 Chest symptoms 0.67 0.73 0.52-0.86
 Total 0.94 0.93 0.86-0.97
France
Internal reliability ICC 95% CI
K-BILD
 Breathlessness/ Activities 0.83 0.76 0.46-0.91
 Psychological 0.88 0.86 0.65-0.95
 Chest symptoms 0.44 0.69 0.32-0.88
 Total 0.85 0.87 0.68-0.95
Italy
Internal reliability ICC 95% CI
K-BILD
 Breathlessness/ Activities 0.88 0.95 0.89-0.98
 Psychological 0.95 0.98 0.95-0.99
 Chest symptoms 0.69 0.97 0.94-0.99
 Total 0.95 0.99 0.97-0.99
K-BILD: King’s brief interstitial lung disease questionnaire; ICC = intra class coefficient for K-BILD repeatabil-
ity, 95%CI = 95% confidence interval







Bland Altman plot of repeatability of the K-BILD questionnaire for the Netherlands. The solid line shows the 




Bland Altman plot of repeatability of the K-BILD questionnaire for Sweden. The solid line shows the mean 








 Bland Altman plot of repeatability of the K-BILD questionnaire for France. The solid line shows the mean 
difference and the dashed lines represent the 95% limits of agreement. K-BILD: King’s Brief Interstitial Lung 
Disease questionnaire.
ONLINE SUPPLEMENT 13
 Bland Altman plot of repeatability of the K-BILD questionnaire for Italy. The solid line shows the mean dif-
ference and the dashed lines represent the 95% limits of agreement. K-BILD: King’s Brief Interstitial Lung 
Disease questionnaire.
“the King’s Sarcoidosis Questionnaire (KSQ) now 
available in Dutch to assess patient perspectives  
in care and research.”
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ABSTRACT
Background
The King’s Sarcoidosis Questionnaire (KSQ) is a brief questionnaire assessing health 
status using five modules (General Health Status, Lung, Medication, Skin and Eyes) in 
patients with sarcoidosis. The KSQ was only validated in one English sarcoidosis cohort.
Objective
The aim of this study was to validate the KSQ in a Dutch sarcoidosis population.
Methods
The KSQ was translated according to international guidelines and tested in interviews 
with patients. Consecutive outpatients completed multiple questionnaires twice, two 
weeks apart. Construct validity, internal consistency and repeatability were determined.
Results
Of the 98 patients included 85 had lung, 22 skin and 24 eye disease. There was good 
construct validity of the KSQ General Health Status module against the World Health 
Organization Quality of Life-BREF questionnaire. The Medication module correlated 
weak to moderate with most questionnaires. The correlations with organ-specific ques-
tionnaires varied from strong for Eyes (r=0.75), Skin (r=-0.62) to moderate for Lung (r=-
0.45 with MRC breathlessness scale). Internal consistency was good for all KSQ modules 
(Cronbach’s α 0.72-0.93). Intraclass correlation coefficients (0.70-0.90) and Bland-Altman 
plots showed good repeatability of the KSQ.
Conclusion








Sarcoidosis is a heterogeneous multisystem disease with different clinical phenotypes. 
Sarcoidosis manifests most commonly in the lungs, but can affect skin, eyes, lymphatic 
nodes and other organs as well.1 Health status is impaired in the majority of patients 
with sarcoidosis due to symptoms such as dyspnea, persistent cough, peripheral pain, 
fatigue and cognitive dysfunction, leading to limitations in activities, social isolation and 
depression.1-3 Therapy for sarcoidosis often leads to side effects impacting health sta-
tus.4,5 In recent years patient related outcome measures (PROMs) have gained increasing 
importance in clinical trials and health status is now a standard outcome measure.6 
Most studies evaluating health status used generic questionnaires such as the World 
Health Organization Quality of Life-BREF (WHOQOL-BREF) or the MOS 36-item Short 
Form Health Survey (SF-36), both non-disease specific questionnaires.7-12 Currently, no 
sarcoidosis specific instruments measuring health status in patients with sarcoidosis are 
available in Dutch. In 2012 the King’s Sarcoidosis Questionnaire (KSQ) was developed.13 
This self-administered measure for sarcoidosis covers different domains of health status; 
General Health Status (GHS), Lung (L), Medication (M), Skin (S) and Eyes (E). The aim of 
this study was to validate the KSQ in a Dutch sarcoidosis population.
METHODS
Translation validation
The KSQ was translated from English to Dutch according to a multi-step forward-back-
ward procedure, following international guidelines 14-16, and was reviewed by sarcoidosis 
experts and the developers (online supplement 1). The relevance and applicability of 
the translated KSQ was tested using ten structured patient interviews.
Psychometric validation
Subjects
In July 2014 consecutive sarcoidosis outpatients of the pulmonary department of the 
Erasmus Medical Center were asked to participate. During the same period sarcoidosis 
outpatients of the ild care team, Hospital Gelderse Vallei were approached by email. 
Patients were excluded from the study if they were unable to understand questionnaires 
due to intellectual impairment or language barrier, when comorbidities that severely 
impact health status existed (such as malignancies, collagen vascular diseases and 
cardiac failure other than due to sarcoidosis) or when they had unstable disease as 





naire they were withdrawn from the study. Formal consultation with the Medical Ethical 
Committee of the Erasmus Medical Center learnt that, under the Dutch act for medical 
research involving human subjects (Wet Medisch Onderzoek), approval of this study by 
the Medical Ethical Committee is not required.
Study procedure
All patients were asked to complete up to seven questionnaires (depending on organ 
involvement) in addition to the KSQ: WHOQOL-BREF, 7 Fatigue Assessment Scale (FAS), 
17 Small Fiber Neuropathy Screening List (SFNSL) 18, Medical Research Council dyspnea 
scale (MRC dyspnea scale), 19 Dermatology Life Quality Index (DLQI), 20 National Eye 
Institute Visual Function Questionnaire (NEI-VFQ25) 21 and Euroqol-5D-5 level (EQ-5D-
5L). 22 Online supplement 2 shows the organ specific questionnaires and corresponding 
KSQ modules. Patients also completed two general health status measurements: Punum 
Ladders 23 and Global Rating of Change-Quality of Life (GRC-QoL).24 Patients were asked 
to self-complete the questionnaires at home, two weeks apart.
Results of routinely measured pulmonary function outcomes were gathered from the 
medical records. The diagnosis of sarcoidosis was established when there was compat-
ible clinical behaviour and pathological or BAL confirmation, according to international 
guidelines 25. Patients were asked about their organ involvement during a short face to 
face interview or interview by telephone.
Statistical analysis
Data are presented as mean values (± standard deviation). KSQ scores were calculated 
on a logit scale as this scale is more linear and has the potential to perform better at 
the extreme ends of health related QoL.26 The validity of the KSQ remains unchanged 
from the original format.27 Construct validity between the general and organ specific 
domains of KSQ and the corresponding questionnaires were determined using Pear-
son’s correlation coefficients. A correlation coefficient of < 0.30 is considered weak, 0.30 
– 0.50 moderate and > 0.50 strong.16 Cronbach’s α coefficient was used to determine the 
internal consistency of the reliability of the KSQ. A minimum of 0.70 is considered a good 
internal consistency. Bland-Altman plots and intraclass correlation coefficients were 
used to evaluate the repeatability at baseline and at two weeks, in patients with stable 
disease. To assess stable disease we used Punum ladders.23 Patients with ≥ 4 differences 
in Punum score were excluded in the repeatability analyses. The limits of agreement 
were calculated as mean ± 1.96 X SD of within-subject differences. Values of p < 0.05 








A Dutch version of the KSQ, achieved after forward and backward translation, was ap-
proved by the KSQ developers. Following this approval, ten patient interviews with the 
Dutch version of the KSQ took place (step T3 online supplement 1). Discussion of these 
interview results with the KSQ developers did not necessitate any further adaptations of 
the translation and resulted in the final Dutch KSQ-version (online supplement 3).
Psychometric validation
One hundred and four consecutive outpatients in the Erasmus Medical Center were 
evaluated for participation, 89 were interested and 54 participated in this study. At the 
same time 117 patients of the ild care team, Hospital Gelderse Vallei were approached 
by email, 60 patients responded and 44 were recruited. Reasons for exclusion were: 
clinical instability (15), comorbidity that severely impacted quality of life (14), no PA/
BAL confirmation (9), not able to read or write Dutch (5) or other reasons (8) (not willing 
to participate, not reachable by telephone or by email, participating in another study). 
Thus in total 98 patients were included. Eighty-eight (90%) of them completed week 
zero and 83 (85%) week two (Figure 1).
Consecutive outpatients 
asked to participate 
Erasmus Medical Center 
104 
Consecutive outpatients 
approached by email  













Not able to read or write Dutch    5 
54 
Clinical instable   15 
Comorbidity that severly impact QoL  14 
Sarcoidosis not PA/BAL confirmed    9 











Lost to  
follow-up 
5 






Table 1 shows the demographics of the patients included. Patients with two or more 
organs involved showed a significantly worse health status than patients with single-or-
gan disease: mean (SEM) KSQ GHS score 53(1.6) versus 68(3.7); mean difference 15; 95% 
Confidence Interval (CI) 7-23; p = 0.001. No significant difference was found between 
the KSQ GHS score for females compared with males: mean (SEM) 54(2.5) versus 60(2.3); 
mean difference 5; 95% CI 1-12, p = 0.115. Patients with more complaints of fatigue (FAS 
score ≥ 22) have a significantly worse health status (mean (SEM) KSQ GHS 52(1.5)), than 
those with lower FAS scores (mean (SEM) 76(3.2); mean difference KSQ GHS -24; 95% CI 
-30 to -17, p = 0.000).
Construct validity
The correlations between the KSQ GHS domain and all generic questionnaires (WHO-
QOL-BREF and EQ-5D-5L) were strong (r= 0.50 – 0.84). KSQ organ modules combined 
with the GHS module all showed a moderate to strong correlation with the WHOQOL-





Number 88 85 22 24
Age, years, mean (SD) 52 (11) 51 (11) 52 (11) 52 (13)
Women, n (%) 36 (41) 35 (41) 10 (46) 11 (46)
Ethnicity, n (%)
Caucasian 70 (80) 67 (79) 17 (77) 16 (67)
Afro-American 2 (2) 2 (2) - -
Surinamese-Hindi 13 (15) 13 (15) 4 (18) 5 (21)
Morrocan 2 (2) 2 (2) 1 (5) 2 (8)
Unknown 1 (1) 1 (1) - 1 (4)
Smoking status, n (%)
Current 3 (3) 3 (4) - 1 (4)
Ex 15 (17) 15 (18) 5 (23) 8 (33)
Never 64 (73) 61 (72) 15 (68) 12 (50)
Unknown 6 (7) 6 (7) 2 (9) 3 (13)
Time since diagnosis, years, mean (SD) 8.0 (8.8) 8.1 (8.9) 7.4 (10.5) 8.4 (11.2)




Small nerve fibers 26 (30)
FVC % predicted, mean (SD), [n] 92 (20) [84] 91 (20) [81]
FEV1/FVC ratio % predicted, mean, [n] 76 (13) [74] 76 (13) [72]
TLCOc % predicted, mean (SD) , [n] 81 (21) [73] 81 (21) [70]
TLC % predicted, mean (SD) , [n] 86 (18) [57] 86 (18) [56]
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; TLCO, diffusing capacity of the lung for 






BREF and EQ-5D-5L (r= 0.44 – 0.85). The Medication module showed a weak to moderate 
correlation with the generic questionnaires (r= 0.26 – 0.47) (Table 2).
All KSQ modules correlated moderately to strongly with the FAS. The relationship 
between the KSQ organ-specifi c modules and their corresponding organ-specifi c ques-
tionnaires was also moderate to strong. The Lung module was weakly correlated with 
the FVC% predicted (r= 0.24) (Table 2).
Reliability
All domains of the KSQ had good internal consistency, Cronbach α; 0.90 (GHS), 0.91 
(Lung), 0.72 (Medication), 0.84 (Skin), and 0.93 (Eyes). With regard to the repeatability 
(test-retest) 83 patients (lung n= 80, skin n= 20 and eyes n= 22) completed the KSQ 
twice. The following intraclass correlations were found: GHS 0.85, Lung 0.74, Medication 
0.70, Skin 0.77, Eyes 0.90, suggesting a good reliability. Twelve patients in the GHS and 
13 patients in the Lung module groups were excluded from the analysis for repeatability, 
because they did not show stability in their Punum scores. The Bland-Altman plots in 
fi gure 2 and 3 show the repeatability of the KSQ GHS and Lung module, respectively. 



































Figure 2. Bland Altman plot of repeatability of King’s Sarcoidosis Questionnaire General Health Status module. 





































































































































































































































































































































































































































































































































































































































































































































































































Both plots have a few outliers (outside the 95% of limits of agreement). We found a mean 
diff erence between the fi rst and second measurement of 2.20 in the KSQ GHS module 
and 2.45 in the Lung module.
DISCUSSION
The Dutch KSQ is the fi rst health status questionnaire for sarcoidosis in the Netherlands. 
It is also the fi rst non-English validation of the questionnaire. The KSQ is simple to ad-
minister, adaptable to individual organ involvement and shown to be a valid and reliable 
health status measurement in Dutch patients with sarcoidosis.
PROMs are becoming more important in clinical trials and daily care.6 Health status 
is nowadays a standard outcome measure. Most sarcoidosis studies use non-disease 
specifi c questionnaires such as the WHOQOL-BREF and the SF-36.10-12 The KSQ is a 
self-administered sarcoidosis specifi c instrument. The KSQ questionnaire was originally 
developed in the UK and was not available in languages other than English. The availabil-




































Figure 3. Bland Altman plot of repeatability of King’s Sarcoidosis Questionnaire Lung module. 





ity of the KSQ in other languages could facilitate international collaboration aiming at 
measuring, comparing and improving health status in patients with sarcoidosis, which is 
often severely affected. During translation in Dutch and the patient interviews no major 
cultural difference was noted and the questionnaire was considered comprehensible 
and relevant by Dutch patients.
The patient demographics of the current Dutch study population were in line with the 
original study, though there were slightly more Caucasians in our study and lung func-
tion was less severely affected.13 Quality of life was worse in females similar to Patel et al. 
but in contrast did not reach statistical significance.13,28
The following domains of health status are covered in the KSQ: General Health Status, 
Lung, Medication, Skin and Eyes. Construct validity of the organ-specific questionnaires 
with their corresponding modules is similar to the development paper.13 The KSQ Lung 
module showed a weaker correlation with the MRC. In the original article from Patel et 
al. the MRC dyspnea scale as well as the St. George Respiratory Questionnaire (SGRQ) 
was used. They found a Pearson’s correlation of -0.58 for the MRC dyspnea scale and 
-0.85 for the SGRQ. It therefore seems that the MRC dyspnea scale is a less reliable tool 
to assess construct validity in this population. We did not include the SGRQ, because 
of the high number of questionnaires patients had to complete for validation and we 
feared this would lead to ‘questionnaire fatigue’. Moreover, the SGRQ is a disease-specific 
questionnaire developed for chronic obstructive pulmonary disease, with 50 items and 
no questions about skin or eye involvement.
We found a difference in study population between Patel et al. and ours; our population 
had less patients with a severe impairment of the lungs, which is shown in the differ-
ence in TLCOc% predicted (63 vs. 81 in our group)13 This could also explain the weaker 
correlation found between the Lung module and FVC% predicted (r= 0.24). To date, this 
lack of correlation between health status questionnaires and lung function has often 
been reported in other pulmonary diseases as well. 29 This underlines the idea that 
health status questionnaires measure different aspects of disease severity and therefore 
are very important additional outcome measures. When combined with the KSQ GHS 
module all organ-specific KSQ modules showed a better correlation with the generic 
questionnaires. This supports the use of organ-specific modules in combination with 
the GHS module.
Fatigue is a major problem in patients with sarcoidosis with an important impact on 
health status.30 This was reflected by a strong correlation between the FAS and GHS. This 






results are in line with other studies showing the major effect of fatigue on the wellbeing 
of patients.30
Small fiber neuropathy related symptoms, which are disabling and difficult to control, 
can also significantly reduce health status.31 We chose to include the SFNSL question-
naire to evaluate if the KSQ also captures this problem as this had not been evaluated 
before. Strong correlations with the SFNSL were found by combining the KSQ GHS and 
the organ-specific KSQ modules. This suggests that the KSQ captures the small fiber 
neuropathy related influences on health status.
In line with Patel et al. findings, weak to moderate correlations were found between 
the optional Medication module and almost all questionnaires.13 Therapy for sarcoidosis, 
as for instance corticosteroids, often causes burdensome side effects. It is tempting to 
speculate that these side effects may have affected health status more than the symp-
toms of sarcoidosis. In both Patel et al. and the present study the Medication module 
does not contribute much. Longitudinal studies are needed with changes in medication 
to see if the KSQ captures influences of medication on health status.
According to the study of Patel and colleagues, we found that the KSQ has a good inter-
nal consistency.13 Reliability was also assessed with Bland-Altman plots showing good 
repeatability (test-retest) in measurements.
At the time of this study, the Sarcoidosis Health Status Questionnaire (SHQ) was the only 
alternative sarcoidosis health status questionnaire.32 In our view this 29-item instrument, 
developed in 2001, has some important limitations. It contains only few organ-specific 
questions, has not been validated for eye and skin disease and can, therefore, not be 
tailored to individual clinical phenotypes. Furthermore, the SHQ is mostly longer than 
the KSQ, because most patients do not have to fill in all the organ-specific KSQ modules.
Recently, Judson et al. validated a new patient reported outcome measure, the Sarcoid-
osis Assessment Tool (SAT).31,33 The SAT was constructed in a similar way as the KSQ and 
also consists of organ-specific modules. With 51 questions it is considerably longer than 
the KSQ. The SAT was validated in an interventional study giving the advantage that 
the MCID has been calculated.5 However, to our knowledge repeatability has not yet 
fully been assessed making it difficult to conclude if a difference in scores indicates a 
low repeatability or a true change in health status. It would be valuable to compare the 





In sarcoidosis any organ can be involved and it remains unclear if the KSQ will also cap-
ture the impact of more rare forms of sarcoidosis on health status. Another limitation of 
our study is the lack of follow-up after two weeks. Responsiveness of the questionnaire 
can thereby not be assessed. Further research, through longitudinal studies in larger 
patient cohorts, is warranted to determine the responsiveness, the influence of rarer 
disease forms and the value of the Medication module.
In conclusion, the Dutch KSQ is the first translation of the English KSQ, validated in a 
Dutch sarcoidosis population.
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Dutch King’s sarcoidosis health status questionnaire (D-KSQ) : T3 
Patient interviews  
• 10 patiënts (Dutch native speakers)  
• Different ages, sexes, stages of severity and level of education 
• Evaluate (face to face) T3 with a structured questionnaire 
Dutch King’s sarcoidosis health status questionnaire (D-KSQ) : T4 
Discuss results patient interviews with KSQ 
developers and experts 
King’s sarcoidosis questionnaire (KSQ) : BT12 
T4 (D-KSQ) validated 
King’s sarcoidosis questionnaire (KSQ) 
Forward translation by a translational agency 
and a Dutch native speaker 
Dutch King’s sarcoidosis health status questionnaires (D-KSQ’s) : T1 + T2 
Evaluation by pneumonologists 
Dutch King’s sarcoidosis health status questionnaire (D-KSQ) : T12 
Backward translation by native speakers 
King’s sarcoidosis questionnaires (KSQ’s) : BT1 + BT2 
Evaluation and approval KSQ developers 





Online Supplement 2. Depending on their organs affected patients will be asked to complete specific 
questionnaires
Questionnaire KSQ (GHS + M) KSQ (L) KSQ (S) KSQ (E) MRC DLQI NEI-VFQ25
Organ(s) affected
Lung X X X
Skin X X X
Eyes X X X
Lung, Skin X X X X X
Lung, Eyes X X X X X
Skin, Eyes X X X X X
Lung, Skin, Eyes X X X X X X X
KSQ, King’s Sarcoidosis Questionnaire; GHS, General Health Status; M, Medication; L, Lung; E, Eyes; MRC, 







Online supplement 3. The Dutch King’s Sarcoidosis Questionnaire
The KSQ is protected by copyright, King's College Hospital, U.K 
Online Supplement 3 - The Dutch King's Sarcoidosi  Questionnaire 
King’s Sarcoïdose Vragenlijst (KSQ) 
Invuldatum: ………………………………………………….. 
Het doel van deze vragenlijst is het bepalen van de invloed van sarcoïdose op 
verschillende aspecten van uw leven. Lees elke vraag zorgvuldig door en 
omcirkel het antwoord dat het meest op u van toepassing is. Beantwoord ALLE 
vragen zo eerlijk mogelijk. Deze vragenlijst is vertrouwelijk. Alle vragen hebben 
betrekking op de manier waarop SARCOIDOSE uw gezondheid heeft beïnvloed. 
ALGEMENE GEZONDHEIDSTOESTAND 
In de laatste 2 weken … De hele 
tijd 
Het grootste 
deel van de 
tijd 
Een flink 












1 Heb ik me gefrustreerd gevoeld 1 2 3 4 5 6 7 
2 Heb ik moeite gehad me te 
concentreren 
1 2 3 4 5 6 7 
3 Heb ik onvoldoende motivatie 
gehad 
1 2 3 4 5 6 7 
4 Heb ik me moe gevoeld 1 2 3 4 5 6 7 
5 Heb ik me zorgen gemaakt 1 2 3 4 5 6 7 
6 Heb ik last of pijn in mijn 
spieren/gewrichten gehad 
1 2 3 4 5 6 7 
7 Heb ik me geschaamd 1 2 3 4 5 6 7 
8 Heb ik me zorgen gemaakt over 
mijn gewicht 
1 2 3 4 5 6 7 
9 Heb ik me zorgen gemaakt over 1 2 3 4 5 6 7 
mijn sarcoïdose 




Matig sterk Enigszins Weinig Zeer 
weinig 
Niet 
10 Heeft vermoeidheid mij 1 2 3 4 5 6 7 
gehinderd bij mijn normale 
sociale activiteiten, zoals 
uitgaan met vrienden of familie 
Zie volgende pagina 











 In de laatste 2 weken … De hele 
tijd 
Het grootste 















11 Heb ik pijn/ongemak gehad 
door het hoesten 
1 2 3 4 5 6 7 
12 Ben ik buiten adem geraakt 
als ik de trap op klom of een 
flauwe helling op liep 
1 2 3 4 5 6 7 
13 Heb ik diep moeten 
ademhalen, ook bekend als 
“snakken naar adem” 
1 2 3 4 5 6 7 
14 Heb ik me benauwd op de 
borst gevoeld 
1 2 3 4 5 6 7 
15 Heb ik perioden van 
benauwdheid gehad 
1 2 3 4 5 6 7 
16 Heb ik last gehad van pijn op 
de borst 









Gebruikt u medicatie voor uw sarcoïdose? 
 
JA O                           NEE O (ga naar het volgende onderdeel) 
 
 






Enigszins Weinig Zeer 
weinig 
Niet 
17 Heb ik me zorgen gemaakt 
over bijwerkingen van mijn 
medicijnen 
1 2 3 4 5 6 7 
18 Heb ik me slechter gevoeld 
door mijn medicijnen voor 
sarcoïdose 
1 2 3 4 5 6 7 
19 Ben ik aangekomen door mijn 
medicijnen voor sarcoïdose 










Zie volgende pagina 


















Enigszins Weinig Zeer 
weinig 
Niet 
20 Heb ik last gehad van mijn 
huidproblemen 
1 2 3 4 5 6 7 
21 Heb ik me zorgen gemaakt 1 2 3 4 5 6 7 
 over veranderingen in de 
kleur van mijn 
huidafwijkingen 
       
In de laatste 2 weken … De hele 
tijd 
Het grootste 















22 Heb ik mij geschaamd 1 2 3 4 5 6 7 










 In de laatste 2 weken … De hele 
tijd 
Het grootste 















23 Heb ik droge ogen gehad 1 2 3 4 5 6 7 
24 Heb ik problemen gehad met 
fel licht 
1 2 3 4 5 6 7 
25 Zijn mijn ogen rood geweest 1 2 3 4 5 6 7 
26 Heb ik pijn in of rond mijn 
ogen gehad 
1 2 3 4 5 6 7 
27 Heb ik moeite gehad met 1 2 3 4 5 6 7 
 lezen        






Enigszins Weinig Zeer 
weinig 
Niet 
28 Heb ik last gehad van wazig 
zien 
1 2 3 4 5 6 7 
29 Heb ik me zorgen gemaakt 
over mijn gezichtsvermogen 





The KSQ is protected by copyright, King’s College Hospital, U.K.
“the Dutch version of the CaMphOr is a reliable and 
valid questionnaire to measure quality of life and health 
status in patients with pah and Cteph.”
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ABSTRACT
Background
The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is the first 
disease-specific instrument for pulmonary arterial hypertension (PAH) to assess patient-
perceived symptoms, activity limitations and quality of life. To be able to use this 
questionnaire in the Netherlands, the aim of the study was to translate and validate this 
instrument for the Dutch-speaking population.
Methods
First the CAMPHOR was translated into Dutch (by means of a bilingual and a lay panel) 
and field-tested by means of cognitive debriefing interviews with ten PAH patients. For 
psychometric evaluation, 80 patients with PAH or chronic thromboembolic pulmonary 
hypertension (CTEPH) were asked to complete the CAMPHOR twice over a two-week 
period. To test for construct validity, participants also completed the Nottingham Health 
Profile (NHP).
Results
The Dutch version of the CAMPHOR showed high internal consistency for all scales 
(Cronbach’s alpha 0.89–0.91) and excellent reproducibility over two weeks (reliability 
coefficients 0.87–0.91). Concurrent validity showed that the CAMPHOR scales correlated 
as expected with the NHP scales. The CAMPHOR was able to distinguish between pa-
tient groups based on self-reported general health status, disease severity and NYHA 
classification demonstrating evidence of known group validity. The CAMPHOR activity 
limitations scale correlated moderately with the distance walked during the 6-minute 
walk test (r = –0.47, p < 0.01) and the symptoms scale with the Borg dyspnoea score (r = 
0.51, p < 0.01).
Conclusion
The Dutch version of the CAMPHOR is a reliable and valid measure of quality of life and 








Pulmonary arterial hypertension (PAH) is a progressive disease of the pulmonary vascu-
lature, leading to increased pulmonary vascular resistance ultimately resulting in right 
heart failure and premature death.1 PAH can affect persons of all ages, and females are 
more affected than males.1,2 Symptoms include breathlessness, fatigue, chest pain, palpi-
tations, ankle oedema and syncope.1 Unfortunately, it is not possible to cure the disease 
with the currently available treatments. The aim of therapy is to lengthen survival time, 
to ameliorate symptoms, to improve quality of life and to reduce the number of hospi-
talisations.3 Chronic thromboembolic hypertension (CTEPH) is a form of precapillary PH. 
Patients with non-operable CTEPH suffer from the same symptoms as patients with PAH 
and despite treatment with specific PAH medication have a poor life expectancy.4,5
In spite of the current treatment options, health-related quality of life (HRQL) is impaired 
in most patients suffering from PAH.6-9 HRQL should be measured with an appropriate 
questionnaire.10 Generic HRQL measures employed in PAH populations are of limited 
value in the assessment of PAH, since these do not take into account all aspects of 
the disease and its treatment.11-14 Therefore, a  disease-specific outcome measure for 
patients with PAH has been developed, the Cambridge Pulmonary Hypertension Out-
come Review (CAMPHOR).15 The questionnaire comprises three scales that assess overall 
symptoms (25  items), activity limitations (15  items) and quality of life (25  items). This 
tool is designed for use in clinical practice as well as clinical trials. This questionnaire has 
been used as an outcome parameter in studies concerning PAH over the last years.16-18 
The CAMPHOR health questionnaire has been translated and validated in several lan-
guages for several countries.19-23 This paper describes the adaptation and the validation 
of CAMPHOR for Dutch-speaking population in the Netherlands.
METHODS
The adaptation of the CAMPHOR questionnaire was conducted in two PH centres in the 
Netherlands, the Erasmus University Medical Center in Rotterdam and the VU University 
Medical Center in Amsterdam. The process consisted of three stages: translation (by 
means of a  bilingual and a  lay panel), cognitive debriefing interviews with ten PAH 
patients and validation by means of a postal validation study. The study was approved 






A professional translation panel of six individuals who were fluent in both English and 
Dutch, led by the local investigator’s representative and a research scientist from Galen 
Research, produced the first translation. A separate lay panel consisting of five individu-
als of average educational level (3 men and 2 women aged between 21 and 67 years) 
discussed the proposed wording of the items and decided whether these were accept-
able or required adjustments to improve the clarity and to make the sentences sound 
more natural. The local investigator evaluated and discussed the changes made with the 
scientist from Galen Research.
Cognitive debriefing interviews
The draft version of the instrument was tested with ten patients, via one-to-one semi-
structured interviews. A  representative selection of PAH patients was made based on 
gender, age, severity of PAH and social background. The respondents were asked to 
complete the questionnaire in the presence of an interviewer who observed whether 
any problems were experienced. Respondents were required to provide feedback on 
their comprehension of the measure and the relevance of the items.
Postal validation survey
During a  consecutive three-month period from September  2014 to December 2014, 
80 Dutch-speaking patients (who were able to read the Dutch language), suffering from 
pre-capillary PAH (WHO group 1) or CTEPH (WHO group 4), were asked to complete the 
new language version of the CAMPHOR and the Nottingham Health Profile (NHP) on the 
day of their clinic visit and the CAMPHOR questionnaire again after two weeks.
The NHP is a generic measure of perceived distress consisting of 38 items divided into 
six sections (energy level, pain, emotional reactions, sleep, social isolation and physical 
ability).24,25 In both questionnaires higher scores indicate worse health status.
Baseline characteristics were obtained (sex, age, employment status) and illness 
information (duration of PH, perceived general health, self-perceived disease severity, 
oxygen use) was also collected. The NYHA functional class was determined, a six-minute 
walk test (6MWT) was performed and the NT-pro BNP level was measured.
Patients were asked to complete the questionnaires at home and to return the ques-
tionnaires by post in pre-addressed, stamped envelopes. After two weeks, they received 
a phone call to remind them to fill in the second CAMPHOR questionnaire and to inquire 







Patients who did not complete more than 85 % of a questionnaire were withdrawn from 
the analysis. For the test-retest reliability, patients were excluded if they were not clini-
cally stable.
Data analysis
Continuous variables are expressed as mean ± SD. Internal consistency of the CAMPHOR 
adaptation was evaluated by determining Cronbach’s alpha coefficient. An alpha coeffi-
cient >0.7 is considered to be the minimum value required to indicate sufficient internal 
consistency.
Test re-test reliability (patient-specific agreement between two repeated administra-
tions) was examined using Spearman’s rank correlations. Correlation coefficients above 
0.85 indicate good reproducibility.26 Convergent validity was assessed with the NHP as 
the comparator instrument using Spearman’s rank correlations. Known group valid-
ity was tested by Mann-Whitney U test. Correlation between CAMPHOR scores, demo-
graphic factors, the results of the 6MWT (including Borg scores) and NT-pro BNP levels 




The group reached consensus on the appropriate wording for most items. A few phrases 
could not be translated literally. For example, one item from the symptoms scale; ‘My 
stamina levels are low’ was translated as ‘Mijn lichamelijke conditie is slecht’ (literally: 
‘My physical condition is weak’). For a few items consensus could not be reached and 
alternative versions of these items were taken forward for consideration by the lay 
translation panel.
Lay panel
Some expressions were altered from the original translation into more commonly used 
Dutch. For example, for item 9 of the symptoms scale: ‘I soon run out of energy’. This sen-
tence was translated as; ‘Mijn energie is snel op’. The panel felt that this translation was 






Ten patients were interviewed (6 females, 4 males, mean age 49.1, range 20–77 years, 
PH symptoms ranged from mild to quite severe). Average time for completion was 
12.6 minutes (range 6–24 minutes, median 11.5 minutes). Overall patients thought the 
questionnaire was appropriate and applicable. Some patients found it hard to choose 
between the ‘Yes’ or the ‘No’ response format, and would have liked the option of ‘Some-
times’. For the activity limitations scale, the response option ‘Doing it on your own with 
problems’ was changed into ‘With difficulties doing it on your own’. In the quality of life 
section item  17; ‘I feel that I’m losing my role in life’, translated as; ‘Ik voel dat ik mijn 
rol(len) [verantwoordelijkheden] in het leven verlies’ was considered to be a  difficult 
question by the majority of the patients.
Postal validation survey
From the 80  patients who were asked to participate, 76  completed and returned the 
questionnaires. Of these only 0.14 % of the items were missing. Missing items from the 
CAMPHOR as well as the NHP questionnaire were handled according to the manuals. 
Demographic and disease characteristics of the respondents are listed in Table 1. The 
cohort consisted of 59 females and 17 males, which is consistent with the gender ratio 
in a PAH population. Disease information is listed in Table 2. The descriptive statistics 
for the questionnaires at both time points are shown in Table 3. High floor effects (high 
number of patients scoring the minimum) were observed in the NHP subscales, but not 
in the CAMPHOR scales.




Sex Male 17 22.3
Female 59 77.7
Age in years Mean 56
Median 59.5
Range 20–79
Diagnosis in years Mean 7.1
Median 4.2
Range 0–50
Aetiology IPAH 26 34.2
HPAH 4 5.3
Congenital heart disease 5 6.6
Connective tissue disease 11 14.5
HIV 3 3.9







For all three CAMPHOR scales, Cronbach’s alpha coefficients were above 0.8, indicating 
high internal consistency (detailed in Table 4).
Test-retest reliability
Test-retest reliability was excellent for all three scales, (0.87 for symptoms, 0.91 for activ-
ity and 0.87 for quality of life), which demonstrates low levels of random measurement 
error.











Treatment ERA monotherapy 13 17.1
PDE-5 inhibitor monotherapy 7 9.2
Riociguat 2 2.6
Duo therapy: ERA and PDE-5 inhibitor 30 39.5
Prostacyclin monotherapy 6 7.9
Prostacyclin and PDE-5 inhibitor 2 2.6
Prostacyclin and ERA 1 1.3















NT-pro BNP in pmol/ml Mean 53.4
Median 24.8
Range 3.9–439.2
IPAH  idiopathic pulmonary arterial hypertension,  HPAP  heritable pulmonary arterial hyperten-
sion,  PVOD  pulmonary veno-occlusive disease,  CTEPH  chronic thromboembolic pulmonary hyperten-





Table 2. Disease information at time 1 (n = 76)





Very good 6 7.9
Self-reported severity of disease
No symptoms 8 10.7
Mild 28 37.3
Moderate 35 46.7
Quite severe 3 4.0




Table 3. Questionnaire descriptive statistics





CAMPHOR symptoms 76 4.0 (2.0–8.0) 5.3 (4.6) 0.0–25.0 13.2 0.0
CAMPHOR activities 76 4.0 (2.0–9.0) 5.6 (4.9) 0.0–30.0 14.5 0.0
CAMPHOR QoL 76 4.0 (1.0–8.0) 5.1 (4.9) 0.0–25.0 14.5 0.0
NHP
Energy scale 74 0.0 (0.0–33.3) 19.8 (32.6) 0.0–100.0 66.2 9.5
Pain scale 75 0.0 (0.0–0.0) 7.0 (18.4) 0.0–100.0 78.7 0.0
Emotional Reactions 75 0.0 (0.0–11.1) 10.8 (18.7) 0.0–100.0 58.7 1.3
Sleep scale 75 20.0 (0.0–40.0) 25.3 (30.2) 0.0–100.0 46.7 2.7
Social isolation 74 0.0 (0.0–0.0) 5.1 (13.7) 0.0–100.0 85.1 0.0
Physical mobility 74 12.5 (0.0–25.0) 15.4 (19.0) 0.0–100.0 47.3 0.0
NHP–D 73 2.0 (0.0–4.0) 2.9 (3.9) 0.0–24.0 32.9 0.0
Time 2
CAMPHOR Symptoms 74 6.0 (1.8–9.0) 5.9 (5.0) 0.0–25.0 16.2 0.0
CAMPHOR Activities 75 4.0 (2.0–9.0) 5.9 (5.1) 0.0–30.0 17.3 0.0






Table 4. Cronbach’s alpha coefficients
Time 1 Time 2
CAMPHOR symptoms 0.89 0.89
CAMPHOR activities 0.91 0.90
CAMPHOR QoL 0.89 0.91
Neth Heart J (2018) 24:1–1
Fig. 1 Median CAMPHOR scales scores for self-reported general
health tested with Mann Whitney U. Interquartile ranges (IQR) for the
Camphor scales scores for very good/good and fair/poor, respectively,
are: Symptoms 0.8–4.3 and 4.0–11.0; Activities 1.0–5.0 and 3.0–10.0;
Qol 1.0–5.0 and 1.8–10.0
Fig. 2 Median CAMPHOR scales scores for self-reported disease
severity tested with the Mann-Whitney U test. Interquartile ranges
(IQR) for the Camphor scales scores for no symptoms/mild and mod-
erate/severe, respectively, are: Symptoms 0.0–3.0 and 5.0–11.0; Activ-
ities 0.3–5.8 and 3.0–10.0; Qol 0.0–5.0 and 3.0–10.0
NYHA class 2 and four patients in NYHA class 3), tested
by the Mann-Whitney U test: CAMPHOR symptoms p =
0.59, CAMPHOR activities p = 0.92 and CAMPHOR qual-
ity of life p = 0.94.
Discussion
This study demonstrates that the new adaptation of the
CAMPHOR for Dutch-speaking participants in the Nether-
lands is valid and reliable. The objective of adapting the
questionnaire is to ensure that items are understood in the
same way in different countries and that conceptual equiv-
alence rather than linguistic equivalence is achieved in the
translated items. Moreover, it is vital that translated items
are expressed in common (everyday) language. No major
problems were encountered during the translation process.
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Figure 2. Median CAMPHOR scales scores for self-reported disease severity tested with the Mann-Whitney 
U test. Interquartile ranges (IQR) for the Camphor scales scores for no symptoms/mild and moderate/severe, 






The CAMPHOR symptoms scale correlated strongly with the energy and physical mobil-
ity scales of the NHP, showing the importance of these factors on PAH symptomatology. 
It also correlated moderately with Borg dyspnoea scores. There were significant correla-
tions between the CAMPHOR QoL scale and the NHP energy scale, physical mobility 
and NHP-D (summation of sub-set of NHP items scores) indicating that multiple factors 
influence QoL. As expected, the activity limitations scale showed the strongest correla-
tion with the NHP physical mobility and 6MWT. The correlation coefficients between 
CAMPHOR scales and the NHP are listed in Table 5.
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Figure 4. Group validity of six-minute walk distance ≥ 466 m and < 466 m and median CAMPHOR scales 
scores using the Mann-Whitney U test. Interquartile ranges (IQR) for the Camphor scales scores for ≥466 m 







No significant correlations were demonstrated between the CAMPHOR scales and the 
NT-pro BNP (Table 5).
Association of CAMPHOR scores and demographic factors
No significant differences in the CAMPHOR scores were found between patients 
grouped by age. However, significant differences were shown in the scores of symptoms 
and QoL scales between males and females. Females scored higher on these two scales 
compared with males. A chi-square test of independence was performed to assess the 
relation between gender and self-reported severity of disease. No significant association 
was found between these variables (χ2 (1, n = 75) = 0.08, p = 0.93). Similarly, no signifi-
cant relationship was found between gender and NYHA class (χ2  (1, n = 76) = 1.1, p = 
0.74). The relation between gender and cause of PH was also investigated, but again no 
significant association was found (χ2 (7, n = 76) = 8.5, p = 0.29).
Known group validity
CAMPHOR scales scores were able to discriminate between patients based on perceived 
general health (‘very good/good’ versus ‘fair/poor’) and severity of disease (‘no symp-
toms/mild’ versus ‘moderate/severe’). Patients with worse perceived general health 
(Figure 1) and more severe PAH (Figure 2) had higher scores for all three scales of the 
CAMPHOR.
Table 5. Correlation coefficients between CAMPHOR scales and NHP, 6MWT and NT-proBNP
Symptoms Activities QoL
NHP
Energy scale 0.71* 0.65* 0.66*
Pain scale 0.38* 0.38* 0.42*
Emotional reactions 0.43* 0.24** 0.37*
Sleep scale 0.32* 0.22 0.38*
Social isolation 0.23 0.34* 0.39*
Physical mobility 0.67* 0.76* 0.61*
NHP-D 0.58* 0.49* 0.63*
6MWT
Distance walked(m) −0.34* −0.47* −0.42*
Borg dyspnoea score 0.51* 0.49* 0.32*
NT-proBNP −0.08 −0.08 0.10






Patients in NYHA class 3 showed significantly higher scores on all three CAMPHOR scales 
compared with patients in NYHA class 2 (Figure 3).
Patients grouped based on the distance walked during 6MWT (below and above the 
mean value of 466 metres) showed significant differences in all CAMPHOR scales (Fig-
ure 4).
No differences were observed in the CAMPHOR subscales between PAH and CTEPH 
patients (16 patients in NYHA class 2 and four patients in NYHA class 3), tested by the 
Mann-Whitney U test: CAMPHOR symptoms p = 0.59, CAMPHOR activities p = 0.92 and 
CAMPHOR quality of life p = 0.94.
DISCUSSION
This study demonstrates that the new adaptation of the CAMPHOR for Dutch-speaking 
participants in the Netherlands is valid and reliable. The objective of adapting the ques-
tionnaire is to ensure that items are understood in the same way in different countries 
and that conceptual equivalence rather than linguistic equivalence is achieved in the 
translated items. Moreover, it is vital that translated items are expressed in common (ev-
eryday) language. No major problems were encountered during the translation process.
Descriptive statistics showed the CAMPHOR had low floor effects and no ceiling effects, 
which indicates the CAMPHOR is well targeted to the PAH population. Consequently, 
the measure should be sensitive and responsive in clinical studies (e. g. in longitudinal 
studies). In contrast, the NHP showed very high floor effects indicating patients with the 
lowest possible score cannot be distinguished from each other, which reduces sensitiv-
ity.
Cronbach’s alpha coefficients were above 0.8 for the three CAMPHOR scales, indicating 
that the items were related adequately to form scales. Test-retest reliability was excellent 
for all three scales showing the scales have low levels of random measurement error.
The CAMPHOR scales showed different levels of association with the scales of the NHP, 
demonstrating evidence of convergent validity. As expected, CAMPHOR activities cor-
related most strongly with the NHP physical mobility scale and 6MWT as was also shown 






Patients with worse perceived general health and more severe PAH had higher scores 
for all three scales of the CAMPHOR scores showing that the scales could distinguish 
appropriately between groups of known importance.
Females scored higher on the scales of symptoms and QoL compared with males. Further 
analyses were performed to investigate this difference. The relation between gender 
and self-reported severity of disease as well as gender and NYHA class and gender and 
cause of PAH was assessed. No significant association was found between gender and 
the investigated variables. Based on these findings it was unclear what contributed to 
the differences between gender groups. However, due to the relatively small sample of 
males the results could be spurious.
The sample of patients included in this study seemed to have less severe disease than 
the sample included in the original paper describing the development of the CAMPHOR 
questionnaire. One explanation may be that with the currently available treatment, in-
cluding triple therapy, less patients are now in NYHA class 4. Another explanation might 
be that only patients who visited the outpatient clinic were asked to participate in the 
study. In this way the very severe patients, who were hospitalised during this period (for 
example those waiting for lung transplantation), were not included.
However, the CAMPHOR scores were able to clearly distinguish between patients in 
NYHA class 2 and NYHA class 3. Moreover, the results of the 6MWT correlate well with 
the CAMPHOR scale scores.
CONCLUSIONS
The new Dutch language version of the CAMPHOR is a valid and reliable instrument for 
assessment of health-related quality of life in PAH and CTEPH patients and is recom-
mended for use in clinical practice. Moreover the CAMPHOR provides a  valid tool for 
a single-point measurement in cross-sectional studies.
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Development of patient-recorded outcome 
measures
“Daily home spirometry detected that the major
 treatment effect of prednisone on FVC and symptoms  
is reached within 2 to 3 weeks in newly treated  
sarcoidosis patients.”
Chapter 5
Daily home spirometry to detect early 
steroid treatment effects in newly treated 
pulmonary sarcoidosis
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Prednisone is the mainstay of sarcoidosis treatment. However, prednisone treatment 
optimisation is warranted, since prolonged high-dose prednisone therapy is associated 
with burdensome and harmful side-effects.1,2 Early prednisone dose tapering has the 
potential to reduce side-effects. Gaining insight in the early treatment response can 
help to determine when tapering could be initiated. To date, there are no prospective 
studies that look at early treatment response to prednisone in sarcoidosis by monitoring 
clinical symptoms and daily patient-administered lung function. Therefore, we initiated 
a multicentre, prospective and observational study with daily home spirometry to detect 
early steroid treatment effects in newly treated pulmonary sarcoidosis (Dutch National 
Trial Register NTR4328; www.trialregister.nl/trialreg).
Treatment-naïve sarcoidosis patients in whom prednisone therapy was about to be initi-
ated for a pulmonary indication were eligible. Patients were intended to be treated with 
the following prednisone regimen: 4 weeks 40 mg·day−1, 2 weeks 30 mg·day−1, 2 weeks 
20 mg·day−1, 2 weeks 15 mg·day−1, 2 weeks 10 mg·day−1 (unless the treating physi-
cian decided that the clinical situation demanded deviation). During these 3 months, 
daily home monitoring of forced vital capacity (FVC) was performed by the patient on 
a calibrated hand-held spirometer (Micro Diary; Carefusion, Hoechberg, Germany). Ad-
ditionally, patients were asked to fill out a Medical Research Council (MRC) dyspnoea 
and Fatigue Assessment Scale (FAS) score at the end of each week in a diary. Data are 
presented as mean±SD unless stated otherwise. More details on the study design can be 
found in the trial register online.
The study group consisted of 21 patients (13 male and eight female; age 43±11 years). 
The majority of the patients (76%) were diagnosed with Scadding stage II sarcoidosis. 
Routine in-hospital lung function monitoring showed a significant FVC increase fol-
lowing treatment from 69.7±13.9 to 81.5±13.7 % predicted at month 1 (mean change 
11.8±9.2, p<0.001) (figure 1a). A smaller FVC improvement was observed between 
month 1 (81.5±13.7) and month 3 (84.8±13.2) (mean change 3.3±6.4, p=0.039) (figure 
1a). The estimated mean FVC change obtained using daily home spirometry over time 
was calculated using a fixed effect model, meaning that the regression lines of all 21 in-
dividual patients were incorporated (figure 1c). A maximal mean increase of 9.7 (95% CI 
8.4–10.9) % pred FVC was estimated after treatment initiation. Interestingly, a plateau of 
FVC increase was observed at 24 days (95% CI 14–33) and 90% of the total FVC increase 
was already reached by day 18 (95% CI 10–28).
Together, these data show that most of the improvement in FVC occurs within 2–3 weeks 

























































































FIGURE 1. a) In-hospital clinical monitoring of forced vital capacity (FVC; n=19) and b) diffusing capacity 
of the lung for carbon monoxide (DLCO) (corrected for haemoglobin levels; n=17) values at baseline, month 
1 and month 3 during prednisone treatment of patients with data available at all three time-points. Lines 
represent paired results from one patient. Significance was determined using a two-tailed paired t-test. c) 
Daily best FVC measurements recorded on the home spirometer (Micro Diary; Carefusion) per individual 
patient over time (in days) as % predicted, including regression lines of all 21 individual patients. Daily FVC 
measured during home monitoring was used as the outcome in a fixed effect model (fixed effect nonlinear 
least squares model). Regression line of all d) weekly Medical Research Council (MRC) dyspnoea scores 
and e) Fatigue Assessment Scale (FAS) scores filled out in a home diary per individual patient over time (in 






Our results are in line with other studies that have suggested that the major increase 
in FVC during prednisone treatment in sarcoidosis occurs within 1 month.3,4 However, 
these studies were either performed retrospectively in patients experiencing an exac-
erbation who previously were shown to be responsive to prednisone and/or evaluated 
changes on in-hospital lung function equipment at pre-determined time-points, pos-
sibly missing early and daily changes in FVC.3,4
No single clinical test has been found to accurately assess disease burden in pulmonary 
sarcoidosis.5 Therefore, it is important to evaluate whether other outcomes improve as 
well. Multilevel analyses of the weekly filled out MRC scores showed that dyspnoea symp-
toms decreased significantly with 0.3 (95% CI 0.2–0.4) MRC points per week (p<0.001), 
stabilising after 1 month (figure 1d). Similarly, FAS scores decreased significantly with 
1.8 (95% CI 1.5–2.2) FAS points per week (p<0.001), stabilising after 1 month (figure 1e). 
Importantly, this is the first study to evaluate early therapy effects on dyspnoea (MRC) 
and fatigue (FAS)6, and the early improvements observed strengthen our home spirom-
etry data.
In a sub-cohort of patients, participating at a select number of study sites, diffusing 
capacity of the lung for carbon monoxide (DLCO) (corrected for haemoglobin level) was 
measured. A significant increase in DLCO % pred was observed within 1 month from 
60.4±20.6 to 72.5±19.7 (mean change: 12.0±8.5, p<0.001). However, DLCO decreased 
somewhat again between month 1 and 3 to 67.5±15.6 (mean change −5.0±8.5, p=0.028) 
(figure 1b). These data may indicate subclinical worsening of the disease during predni-
sone tapering, as DLCO measurements may reflect earlier interstitial changes in sarcoid-
osis.7 However, we cannot be certain that this is a relevant change, as reproducibility 
of DLCO measurements is well known to be lower than FVC measurements, and only 
a major change (>15%) in DLCO has been suggested to reliably exclude confounding 
by measurement variation.5 Furthermore, daily home spirometry and weekly dyspnoea 
and fatigue scores showed that the initial improvement was retained in the majority of 
patients up to 3 months while prednisone dose was tapered. In addition, inflammatory 
markers that are thought to reflect disease activity in sarcoidosis, such as angiotensin-
converting enzyme and soluble interleukin-2 receptor5,8, decreased significantly within 
1 month, also remaining stable up to 3 months (data not shown). However, it remains to 
be investigated whether these outcomes remain stable in the long term.
Quality of life was also captured in this study during hospital visits at baseline, month 
1 and month 3.  The St George’s Respiratory Questionnaire improved significantly at 
1 month, exceeding the reported minimal clinically important difference (table 1).9,10 





the Short-Form Health Survey and King’s Sarcoidosis Questionnaire general health sta-
tus, showed either no or less pronounced changes during prednisone treatment in our 
study group than scores purely including physical symptoms such as the MRC, FAS and 
King’s Sarcoidosis Questionnaire lung scores (table 1). This may have been caused by 
concurrent side-effects that occur during prednisone treatment, counterbalancing the 
positive outcomes of prednisone treatment. Indeed, in our study a number of adverse 
events were reported that are associated with prednisone treatment, including weight 
gain. Weight significantly increased within the first 3 months of treatment (mean in-
crease 5.2±4.1 kg, p<0.001). These data confirm that it remains relevant to continuously 
evaluate benefit–risk ratio of prednisone treatment in consultation with the individual 
patient.2,11,12
This study is the first to perform daily home spirometry in pulmonary sarcoidosis. Daily 
home spirometry could facilitate a personalised approach to treatment for each patient, 
aiming at achieving the maximum effect of lung function and symptom improvement 
with the lowest possible dose of prednisone, in order to minimise side-effects. This study 
shows that reliability of daily measured home spirometry in sarcoidosis patients is high; 
Table 1. Symptoms and quality of life (QoL) assessed during prednisone treatment
Symptom and/or QoL-related 
questionnaire
Patients Baseline Month 1 Month 3#
MRC score 18 2.44±1.04 1.33±0.91* 1.39±0.92*
FAS score 18 27.4±10.8 21.0±6.6* 20.7±7.6*
SGRQ
 Symptoms 17 45.0±21.1 29.7±22.4* 27.5±25.1*
 Activity 17 55.9±24.9 38.8±27.0* 36.8±28.4*
 Impact 17 28.4±23.5 18.5±15.7 18.2±15.1*
 Total 17 40.2±21.8 26.5±18.1* 25.4±19.1*
SF-36
 PCS 15 39.0±6.9 40.2±6.9 37.4±6.9
 MCS 15 33.5±6.3 36.2±7.0 39.2±8.0*
KSQ
 GHS 11 61.9±14.5 72.0±18.2* 67.0±15.0¶
 Lung 10 59.0±13.5 70.4±23.1 70.1±20.2*
Data are presented as n or mean±sd. MRC: Medical Research Council; FAS: Fatigue Assessment Scale; SGRQ: 
St George’s Respiratory Questionnaire; SF-36: Short-Form health survey; PCS: physical component score; 
MCS: mental component score; KSQ: King’s Sarcoidosis Questionnaire; GHS: general health status. #: none 
of the values are statistically significant at month 3 compared with values at month 1; ¶: p=0.055; *: p<0.05 






Pearson correlation between FVC measurements on the home spirometer and the in-
hospital lung function equipment was 0.98 (p<0.001).
Together, our data argue that monitoring FVC changes at approximately 2–3 weeks after 
initiation of therapy, either at home or in clinic, can help physicians to better evaluate 
response to therapy in newly treated sarcoidosis patients. Consequently, physicians 
might decide on earlier dose tapering and/or the need for initiation of second-line 
steroid-sparing therapies than is now advised.13,14 Future studies are needed to evalu-
ate whether home monitoring of prednisone treatment (including FVC and symptom 
scores) and personalised dose titration15 will allow for a non-inferior treatment effect 
compared to current clinical practice, while reducing side-effects and increasing the 
quality of life for patients with pulmonary sarcoidosis.
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“a home monitoring program including wireless home 
spirometry, is highly feasible and appreciated  
by patients with IpF, and enables real-time  
detection of change in FVC and symptoms,  
facilitating personalized care.”
Chapter 6
a home monitoring program including 
real-time wireless home spirometry in 
idiopathic pulmonary fibrosis: a pilot study 
on experiences and barriers
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ABstrAct
In idiopathic pulmonary fibrosis (IPF), home monitoring experiences are limited, not yet 
real-time available nor implemented in daily care. We evaluated feasibility and potential 
barriers of a new home monitoring program with real-time wireless home spirometry in 
IPF. Ten patients with IPF were asked to test this home monitoring program, including 
daily home spirometry, for four weeks. Measurements of home and hospital spirometry 
showed good agreement. All patients considered real-time wireless spirometry useful 
and highly feasible. Both patients and researchers suggested relatively easy solutions for 







Idiopathic pulmonary fibrosis (IPF) is a progressive, devastating disease with a poor 
prognosis.1 Symptoms as increasing shortness of breath and immobility make regular 
hospital visits a challenge for many patients. New eHealth technologies hold great po-
tential for research and care by facilitating real-time, frequent data collection at home. 
In IPF, home monitoring experiences are limited and not yet implemented in daily care. 
Few studies using daily handheld spirometry have been performed in patients with IPF. 
2,3 These studies showed that home spirometry in IPF is feasible, may allow for better 
disease prediction and decrease sample size for future trials.2,3 However, earlier studies 
using home spirometry in interstitial lung diseases used paper-based collection or cen-
tral read-out of Forced Vital Capacity (FVC) results. 2-4 This limits possibilities to control 
quality of measurements, or respond directly to FVC decline or non-adherence.
We assessed feasibility of a pre-developed home monitoring program in IPF 5, integrated 
with real-time, wireless home spirometry. Furthermore, we evaluated potential barriers 
and solutions for implementation of wireless home spirometry in this mostly elderly 
patient population.
methods
This was a prospective pilot study at the Erasmus Medical Center in 2017. Consecutive 
outpatients with IPF were invited to participate. Approval of the Medical ethics com-
mittee was obtained, and participants provided written informed consent. Patients 
were asked to test the home monitoring program “IPF-online” (www.ipfonline.nl) for 
four weeks on a tablet. IPF-online is a secured online personal platform, following 
European safety regulations. The program consists of daily home spirometry, online 
patient-reported outcomes (PROs) at baseline and after four weeks, weekly reporting of 
side-effects and symptoms on visual analogue scales, an information library, medication 
coach and eConsultations. The bluetooth-enabled spirometer (MIR Spirobank Smart, 
Italy) transmits data real-time via a secure encrypted connection, enabling patients 
and healthcare providers to access data directly (Figure 1). The system generates email 
alerts when patients report bothersome side-effects or FVC declines >10% for three 
consecutive days. If patients fail to perform spirometry or record symptoms, they receive 
a reminder. Incorporated PROMs are King’s Brief Interstitial Lung Disease health status 
questionnaire, Hospital Anxiety and Depression Scale, Euroqol 5D-5L and an evaluation 
questionnaire.6-8 At start, patients received standardized instructions about the correct 





considered trained when they were able to perform three good, reproducible FVC 
measurements, with less than 150 ml difference in the two highest FVCs. Before start 
of the study, potential barriers of the system were identified based on literature and 
own experiences. At baseline, potential barriers were discussed with patients. After 
four weeks, their experiences and suggestions were evaluated. Furthermore, patients 
performed hospital spirometry at baseline and after four weeks.
Pearson correlation and Bland-Altman plots were used to compare home with hospital 
spirometry, Wilcoxon signed ranked test was used to compare baseline with follow-up 
scores. Data are presented as mean (SD) or median (range).FVC declines > 10% for three consecutive days. If patients
fail to perform spirometry or record symptoms, they
receive a reminder. Incorporated PROMs are King’s Brief
Interstitial Lung Disease health status questionnaire,
Hospital Anxiety and Depression Scale, Euroqol 5D-5 L
and an evaluation questionnaire [6–8]. At start, patients
received standardized instructions about the correct
use of home spirometry and the different components
of the online tool. Patients were considered trained
when they were able to perform three good, reprodu-
cible FVC measurements, with less than 150 ml dif-
ference in the two highest FVCs. Before start of the
study, potential barriers of the system were identified
based on literature and own experiences. At baseline,
potential barriers were discussed with patients. After
four weeks, their experiences and suggestions were
evaluated. Furthermore, patients performed hospital
spirometry at baseline and after four weeks.
Pearson correlation and Bland-Altman plots were used
to compare home with hospital spirometry, Wilcoxon
signed ranked test was used to compare baseline with
follow-up scores. Data are presented as mean (SD) or
median (range).
Results
Of 12 patients invited to participate, 10 patients were
included (9 men), with a mean age of 71 years (5). All
patients were on disease-modifying medication (60%
nintedanib, 40% pirfenidone). The mean FVC was 3.28 L
(1.04) or 79% of predicted (16).
Reliability of home spirometry
Measurements of home and hospital spirometry for FVC
(r = 0.94 (p < 0.001)) and FEV1 (r = 0.97 (p < 0.001)) were
highly correlated, and a Bland-Altman plot showed good
agreement (Fig. 2). Median difference between hospital
and home spirometry was 0.22 L (0.01-0.69 L) with over-
all lower readings for home spirometry. To evaluate
within-subject reproducibility, the median SD for 28
measurements was calculated (0.13 L (0.05 -0.39 L)).
The median coefficient of variation was 3.76% (3-12%).
Feasibility and potential barriers of home spirometry in
patients with IPF
The vast majority of patients considered daily spirometry
easy (80%) and not burdensome at all (90%), the other
patients were neutral. The mean adherence to home
Fig. 1 a Daily FVC in % predicted of one patient during two weeks. A star on top of the bar corresponds with a forced expiration > 6 s, and is
intended as extra motivation for patients. b Two examples of flow volume loops including daily remarks/advices
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Figure 1a. Daily FVC in % predicted of one patient during two weeks. A star on top of the bar corresponds 
with a forced expiration > 6 s, and is intended as extra motivation for patients. b. Two examples of flow 







Of 12 patients invited to participate, 10 patients were included (9 men), with a mean age 
of 71 years (5). All patients were on disease-modifying medication (60% nintedanib, 40% 
pirfenidone). The mean FVC was 3.28L (1.04) or 79% of predicted (16).
Reliability of home spirometry
Measurements of home and hospital spirometry for FVC (r=0.94 (p<0.001)) and FEV1 
(r=0.97 (p<0.001)) were highly correlated, and a Bland-Altman plot showed good agree-
ment (Figure 2). Median difference between hospital and home spirometry was 0.22L 
(0.01-0.69L) with overall lower readings for home spirometry. To evaluate within-subject 
reproducibility, the median SD for 28 measurements was calculated (0.13L (0.05 -0.39L)). 
The median coefficient of variation was 3.76% (3-12%).
Feasibility and potential barriers of home spirometry in patients with IPF
The vast majority of patients considered daily spirometry easy (80%) and not burden-
some at all (90%), the other patients were neutral. The mean adherence to home spirom-
etry was 98.8% (2.5). Most patients (80%) found it pleasant to see their FVC results, 20% 
spirometry was 98.8% (2.5). Most patients (80%) found it
pleasant to see their FVC results, 20% was neutral. All
patients considered real-time spirometry useful and
would recommend it o others, 90% wished to continue
home monitoring after the pilot: “It helps me feel more
in control”, “I like to monitor my own disease and be
monitored” and “I hope this program can replace out-
patient clinic visits in the future”. Daily home monitor-
ing did not lead to higher anxiety levels (HADS anxiety
score at baseline 4.5, score after 4 weeks 4.3, p = 0.57),
and quality of life remained stable (K-BILD total score at
baseline 59.2, score after 4 weeks 60.3, p = 0.65). Table 1
provides a comprehensive overview of potential barriers,
experiences and solutions for use of the home monitor-
ing system.
Discussion
This pilot study shows that a home monitoring program
integrated with real-time wireless home spirometry is
feasible in patients with IPF. In line with other
studies, home-based measurements were slightly lower
than hospital-based FVC, which may partly be
equipment-related, but also effort-related [2, 4]. We
tried to minimize the risk for ‘underperforming’ at
home by motivating patients through graphically
displaying their personal target value and prior
results, a six seconds countdown and advices to tech-
nically improve the measurements. However, home
and hospital readings are highly correlated and the
relative variability of home-based FVC is low, indicat-
ing that home spirometry is a reliable tool to monitor
patients at a distance. In a patient population with
progr ssive breathlessness and decreasing mobility
this enables close monitoring, while lowering the
burden of hospital visits, especially in countries with
long distances to the hospital. Moreover, real-time
uploading of results and automated email alerts not
only allow quality review of measurements, it also
enables real-time detection of FVC decline. For ex-
ample, we already observed a decrease in FVC two
days before a patient reported symptoms of a respira-
tory tract infection. Early detection may potentially
improve efficiency and quality of care for patients.
Besides spirometry, patients also recorded symptoms
and validated questionnaires online, which could be
important additional features for future studies.
All patients in our study supported the usefulness
of home monitoring, and appreciated being actively
involved in monitoring their disease. One patient
experienced technical problems with spirometry,
highlighting the importance of good instruction. No
effects on anxiety or quality of life were observed,
however, we believe that the duration of the study is
too short to draw definite conclusions on this. We
found no major barriers regarding use of real-time
wireless home spirometry; relatively easy solutions
were suggested by patients and investigators for po-
tential issues.
Fig. 2 Bland-Altman plot comparing hospital and home spirometry. The value for hospital FVC is the mean of the hospital-based FVC at baseline
and after four weeks. The value for home spirometry is the mean of 28 home FVC readings. The solid line represents the mean difference and
the dashed lines 95% limits of agreement (− 0.61 to 0.90 L).* This patient did not use the mouthpiece correctly leading to more variable and
higher readings compared to hospital spirometry
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Figure 2: Bland-Altman plot comparing hospital and home spirometry. The value for hospital FVC is the 
mean of the hospital-based FVC at baseline and after four weeks. The value for home spirometry is the 
mean of 28 home FVC readings. The solid line represents the mean difference and the dashed lines 95% 
limits of agreement (-0.61 to 0.90L).* This patient did not use the mouthpiece correctly leading to more 





was neutral. All patients considered real-time spirometry useful and would recommend 
it to others, 90% wished to continue home monitoring after the pilot: “It helps me feel 
more in control”, “I like to monitor my own disease and be monitored” and “I hope this 
program can replace outpatient clinic visits in the future”. Daily home monitoring did 
not lead to higher anxiety levels (HADS anxiety score at baseline 4.5, score after 4 weeks 
4.3, p=0.57), and quality of life remained stable (K-BILD total score at baseline 59.2, score 
after 4 weeks 60.3, p = 0.65). Table 1 provides a comprehensive overview of potential 
barriers, experiences and solutions for use of the home monitoring system.
Table 1. A comprehensive overview of the identified potential barriers for use of the home monitoring 
system (wireless and real-time), experiences from the pilot study, and possible solutions as suggested by 
patients and staff.
Potential barriers for the use of 
real-time home spirometry
Findings in our pilot 
experiment
  Possible solutions
No internet access Patient who never used 
internet before had no 
problems using the tablet and 
perform spirometry because of 
the simple design.
-  Provide patients with a 
smartphone or tablet with 4G SIM 
card during study to guarantee 
internet access
-  Use a simple application without 
too much information
Quality of measurements is 
difficult to control
All patients performed mostly 
good quality flow volume 
loops, which could be checked 
real-time.
-  New wireless spirometers have 
automated quality control and 
provide advice to patients
-  Use a device that shows a flow 
volume loop accessible to patient 
and researchers to review quality
A handheld spirometer may be 
difficult to use
A few patients had to get used 
to handheld spirometry the 
first days.
Only one patient had variable 
results, due to technical 
difficulties with the standard 
mouthpiece. After providing 
an additional mouthpiece the 
readings were comparable to 
hospital readings.
-  Provide a clear instruction manual 
and good training at start of 
the study. Patients should be 
able to perform 3 good quality 
measurements with ≤ 150 ml 
difference in the 2 highest FVC’s.
-  Assess individual patients’ needs
-  Consider using an extra/other 
mouthpiece
-  Use a video consultation or clinic 
visit for refreshment training
Motivation A 6 seconds countdown and 
FVC target value is always 
shown during a forced 
expiration. This motivated 
patients to blow as good and 
long as possible.
-  Do not use an FVC of 100% 
predicted as target value as this 
might demotivate patients
-  Provide an individual target value 
for each patient and adjust target 







This pilot study shows that a home monitoring program integrated with real-time 
wireless home spirometry is feasible in patients with IPF. In line with other studies, 
home-based measurements were slightly lower than hospital-based FVC, which may 
partly be equipment-related, but also effort-related 2,4. We tried to minimize the risk for 
‘underperforming’ at home by motivating patients through graphically displaying their 
personal target value and prior results, a six seconds countdown and advices to tech-
nically improve the measurements. However, home and hospital readings are highly 
correlated and the relative variability of home-based FVC is low, indicating that home 
spirometry is a reliable tool to monitor patients at a distance. In a patient population 
with progressive breathlessness and decreasing mobility this enables close monitoring, 
while lowering the burden of hospital visits, especially in countries with long distances 
to the hospital. Moreover, real-time uploading of results and automated email alerts 
not only allow quality review of measurements, it also enables real-time detection of 
Table 1. A comprehensive overview of the identified potential barriers for use of the home monitoring 
system (wireless and real-time), experiences from the pilot study, and possible solutions as suggested by 
patients and staff. (continued)
Potential barriers for the use of 
real-time home spirometry
Findings in our pilot 
experiment
  Possible solutions
Home spirometry might induce 
coughing
Some patients mentioned 
more urge to cough compared 
to hospital spirometry, but one 
measurement a day was not a 
problem at all.
-  Advise patients to perform 
spirometry after a period of rest
-  Advise patients to try again later 
that day when a measurement 
failed because of coughing
Patients might get worried 
seeing their own results
Anxiety and depression scores 
were not higher after this 
short pilot. Almost all patients 
considered it pleasant to see 
their daily results.
-  Incorporate automated email 
alerts to the researchers and 
explain to patients that they will 
be contacted if FVC declines 
significantly
-  Provide an extra option that 
blinds patients from their results
Daily home spirometry can be 
bothersome to patients
None of the patients in the 
pilot considered once daily 
spirometry bothersome, 
because it was not time 
consuming and became part of 
their routine.
-  Advise patients to perform 
spirometry at almost the same 
time every day to create a routine
-  Explain that the whole process 
takes less than two minutes
Compliance Patients got motivated by 
keeping track of their own 
results and almost all patients 
continued home spirometry 
after the pilot.
-  Send patients email reminders 
when they do not perform 






FVC decline. For example, we already observed a decrease in FVC two days before a 
patient reported symptoms of a respiratory tract infection. Early detection may poten-
tially improve efficiency and quality of care for patients. Besides spirometry, patients 
also recorded symptoms and validated questionnaires online, which could be important 
additional features for future studies.
All patients in our study supported the usefulness of home monitoring, and appreciated 
being actively involved in monitoring their disease. One patient experienced technical 
problems with spirometry, highlighting the importance of good instruction. No effects 
on anxiety or quality of life were observed, however, we believe that the duration of 
the study is too short to draw definite conclusions on this. We found no major barriers 
regarding use of real-time wireless home spirometry; relatively easy solutions were sug-
gested by patients and investigators for potential issues.
A limitation of this study is that it is a single center study, with 10 out of 12 consecu-
tive patients willing to participate. In the Netherlands, use of internet amongst elderly 
people is rather high, however, also in other countries internet use among people over 
the age of 65 is steadily growing. 9 With worldwide increasing internet use and techno-
logical advances, we envision that relatively simple and low-cost systems like this, will 
facilitate access to care and research for a wider group of patients, also in remote areas 
and lower socio-economic settings. Further limitations of this pilot are the small sample 
size and short duration. Although this was sufficient to evaluate reliability and potential 
barriers of a home monitoring program with real-time wireless home spirometry, larger 
studies are required to assess whether it improves care, allows for earlier detection of 
exacerbations, and enhances data collection in clinical trials.
coNcLusioN
A home monitoring program including wireless home spirometry, is highly feasible and 
appreciated by patients with IPF, and enables real-time detection of change in FVC and 
PROs facilitating personalized care.
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“adopting the new Global Lung Function Initiative tLCO 
reference values may positively impact clinical trial 
eligibility for IpF patients.”
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We read the paper by Derom et al.1 with great interest. This paper describes the nation-
wide introduction and implementation of the new Global Lung Function Initiative (GLI) 
reference equations for spirometry and transfer factor of the lung for carbon monoxide 
(TLCO) in Belgium.2,3 Convinced of the advantages of using these all-age and globally 
most accurate reference value set available4, the Belgium Thoracic Society applied a 
stepwise approach to launching them. The aimed nationwide collective transition is cur-
rently ongoing, involving pulmonologists, lung function technologists and equipment 
manufacturers.
Although one could comment that this approach delayed the implementation of the GLI 
2012 spirometry equations in Belgium compared to other countries, we fully endorse 
the importance of a nationwide implementation based on our findings in a study de-
scribed below. In daily practice, there are many reference value sets implemented and 
it is acknowledged that use of different sets may lead to interpretation differences of 
equal measured TLCO values within an individual patient. For example, this may happen 
when a patient is referred from one hospital to another. Uniformity in reference sets will 
not only avoid potential erroneous effects on treatment decisions; it will also provide 
clarity to patients and investigators for research purposes, especially when looking at 
eligibility for trial participation. Below, we describe the impact of the new GLI TLCO 
reference values on trial inclusion for patients with idiopathic pulmonary fibrosis (IPF).
IPF is a progressive and life-threatening interstitial lung disease. Scarring of the lung 
tissue leads to a restrictive lung function pattern and impaired gas exchange, caus-
ing dyspnoea and desaturation on exertion.5 The TLCO, indicator of the gas exchange 
function of the lungs, is almost always decreased in patients with IPF.6,7 There is no 
cure for IPF, except lung transplantation in a select group of patients. Two anti- fibrotic 
drugs slow-down disease progression but do not stop or reverse the fibrosis.8 Multiple 
clinical trials in IPF are ongoing in search for better treatment. IPF patients are often 
keen to participate in these clinical trials that may give them a chance to improve their 
disease outcome.9 Inclusion criteria for these trials usually include a threshold for the 
TLCO %predicted. Screen-failures are frequently based on TLCO below lower limits, and 
are disappointing to patients. Many lung function laboratories still use older reference 
values of the European Community for Steel and Coal (“ECSC”, 1993)10, Crapo and Morris 
(“Crapo”, 1981)11, Miller and co-workers (“Miller”, 1983)12 or Neas and Schwartz (National 
Health and Nutrition Examination Survey 1971-1975; “NHANES-1”, 1996 ).13 Therefore, 






In a retrospective cohort study, we collected lung function data of consecutive IPF 
patients, routinely measured in 2017. The TLCO %predicted was calculated using the 
older prediction equations and the new GLI (2017) equations. Predicted values were 
extrapolated if the age of the patient was beyond the data range of the reference 
population (ECSC, Miller). Only NHANES-1 has different TLCO reference equations for 
adults with African-American and Caucasian background.13 We compared the number of 
patients eligible for clinical trials that use a threshold of TLCO ≥30% predicted. SPSS 24 
was used for statistical analysis. The ethics committee of our center exempted this study 
from review because of the noninterventional design (MEC-2018-1383).
We included data of 145 patients, 118 (81%) male, mean±SD age 72±8 years, 11 (8%) 
non-Caucasian. The mean forced vital capacity (FVC) was 75±16% predicted, Z-score 
−1.6±1.0, using GLI 2012 spirometry equations. Calculated with the different equations, 
the median % predicted values and Z-scores for the TLCO, the transfer coefficient (KCO) 
and the alveolar volume (VA) are shown in Table 1.
With an inclusion threshold of TLCO ≥30 %predicted, the number of patients eligible 
using GLI equations was significantly higher than using the older equations, except for 
those derived by Miller (McNemar’s Test); GLI 104/145 (72%) patients, ECSC 96/145; (66%; 
p= 0.008), Crapo 73/145 (50%; p<0.001), Miller 102/145 (70%; p=0.69), NHANES-1 81/145 
(56%; p<0.001). Figure 1 shows that for all individual patients, GLI TLCO %predicted val-
ues are consistently higher than TLCO %predicted values using older equations, except 
for those of Miller. Using GLI, eligibility status would have changed positively in 2-31 of 
patients (depending on reference set).
Table 1. Values for transfer factor of the lung for carbon monoxide (TLCO), transfer coefficient (KCO) and 
alveolar volume (VA) as calculated using the different reference equations
TLCO % pred# Z-score KCO % pred Z-score VA % pred Z-score
GLI3 37% (29–46) −5.0 64% (52–73) −2.5 60% (53–69) −3.5
ECSC10 35% (28–44) −3.9 66% (55–78) −1.8 55% (48–64) −4.1
Crapo11 30% (24–38) −4.4 55% (46–64) −2.5 54% (47–62) −4.0
Miller12 36% (29–45) −3.3 65% (54–75) −1.9 55% (48–63) −3.5
NHANES-113 33% (26–41)
Data are presented as median % predicted values with interquartile ranges. The Z-score represents the 
difference between the measured value and the reference population mean in standard deviation units. 
For example; a Z-score of −3 means that the measured value is far below the 2.5th percentile in a healthy 
population. #: TLCO % predicted values from all older equations were significantly lower than the Global 
Lung Function Initiative (GLI) TLCO % predicted (p<0.001, Wilcoxon signed ranks test). ¶: Z-scores, KCO % 
predicted and VA % predicted could not be calculated. ECSC: European Community for Steel and Coal; 






Our results show that switching to the new GLI TLCO reference equations may a have 
significant positive effect on trial inclusion for IPF patients. This difference in eligibility 
may have large implications for the individual patient on clinical trial participation. Not 
only physicians should be aware of this impact of the choice of reference equations, but 
also sponsors of clinical trials when writing the study protocol.
Systematic differences between the several predicted values have been explained 
from differences in sample size, population characteristics and distribution of the ages, 
equipment and setting, measurement techniques and applied statistical methods.3,14 In 
our study the Miller TLCO % predicted values and number of eligible patients were clos-
est to the GLI. This is remarkable considering that 57% of our patients were >70 years of 
age, outside the age range of Miller’s reference population, and reference values were 
extrapolated. The largest shift in trial eligibility occurred when changing from Crapo to 
GLI. The higher Crapo predicted values may be explained by physiologic adaptations of 
the reference subjects due to altitude (1400 m).12
Our study shows that urgent adoption of the globally derived and applicable GLI refer-
ence set is needed to reduce variability in trial eligibility between laboratories. Currently 
GLI TLCO equations are only available for Caucasians, which limits their validity. Collect-
ing data to expand the equations are ongoing. However, being derived from the largest 

























TLCO %predicted values for all individual patients calculated by the different reference equations; TLCO: Transfer factor of the 
lung for carbon monoxide, ECSC: European Community for Steel and Coal reference values 1993, NHANES1: National Health and 
Nutrition Examination Survey 1971-1975, GLI:  Global Lung Function Initiative reference value 2017. 
Figure 1. Transfer factor of the lung for carbon monoxide (TLCO) % predicted values for all individual pa-
tients
calculated by the different reference equations. ECSC: European Community for Steel and Coal; NHANES-1:





not prevent adoption of the GLI equations in their current form. The implementation 
strategy as described by Derom et al.1 should hopefully encourage other national 
societies to follow this path as well, as in the end patients, healthcare providers and 
researchers will benefit.
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Interventions aimed at  
improving quality of life for patients
“a home-based pilot study showed that individual IpF 
patients may benefit from a walk-bike, as it improved 
action radius and tended to improve QOL. No effect on 
exercise capacity was observed. a larger study seems not 
feasible due to practical barriers.”
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a Feasibility Study.
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ABSTRACT
Purpose: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of 
pulmonary function and exercise capacity, leading to loss of quality of life and often 
social isolation. A new walking aid, the walk-bike, showed an improvement in exercise 
performance in COPD patients. Aims of this pilot study were to evaluate the feasibility of 
a homebased walk-bike intervention study in IPF patients and to explore the effect of the 
walk-bike on quality of life (QoL) and exercise capacity.
Methods: We conducted a randomized multicenter, crossover study in patients with 
IPF with 8 weeks of standard care and 8 weeks of walk-bike use at home. Feasibility 
outcomes and patients’ satisfaction and experience with the walk-bike were collected. 
Health-related QoL (St. George’s Respiratory Questionnaire - SGRQ, King’s Brief Interstitial 
Lung Disease questionnaire - K-BILD) and 6-minute walk test (6MWT) were recorded. An 
additional 6MWT was performed to compare the distance covered with and without the 
walk-bike. 
Results: Ten patients completed both periods. Potential barriers for feasibility of the study 
included reluctance to participate and external factors (e.g. weather and road conditions) 
that hampered adherence to the protocol. Patients’ satisfaction and experience with the 
walk-bike varied greatly. After training with the walk-bike, SGRQ and K-BILD question-
naire scores demonstrated a tendency towards improvement, exercise capacity did not. 
A clinically important difference was found between the 6MWT with the walk-bike and 
the standard test; median (range) respectively 602 m (358-684) and 486 m (382-510). 
Conclusions: A larger study on walk-bike training-effects in IPF patients does not seem 
feasible. Patient experience and satisfaction with the bike greatly varied, which seems 
to limit its use to a small minority of patients. The walk-bike improved action radius and 








Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive and life-threatening disease 
of unknown cause.1 As the disease progresses, worsening of lung function and gas 
exchange impairment cause hypoxemia during physical activity, resulting in a down-
ward spiral; dyspnea, cough and fatigue lead to a reduction of daily physical activities, 
exercise tolerance, muscle strength and quality of life. Problems reported by IPF patients 
are social isolation, increased level of dependency and immobility.1-5
Pharmacologic treatment options are limited.5 There are two drugs that reduce pul-
monary function decline in patients with IPF, however their effect on quality of life is 
not convincingly established.6-8 In a selected, limited group of patients with IPF, lung 
transplantation can be an option. Non-pharmacologic treatments that could improve 
quality of life are increasingly investigated.4,9-11 Pulmonary rehabilitation programs are 
recommended by expert opinion for the majority of IPF patients to improve QoL and 
exercise tolerance.1,5,12 Cochrane reviews on physical training in patients with different 
interstitial lung diseases (ILD), including IPF, indicate pulmonary rehabilitation has a 
beneficial effect on quality of life and functional exercise capacity in IPF patients.3,13,14 
Another problem is that the long-term effects of PR are debated.15-18 Furthermore, 
pulmonary rehabilitation programs are offered in outpatient clinics and specialized 
rehabilitation centers with a duration of usually 6 -12 weeks.16,19-21 Due to the limited life 
expectancy of IPF patients and practical problems with decreased mobility and trans-
port, patients are often hesitant to participate in these external programs. Therefore, in 
recent years homebased (supervised) training has become increasingly investigated.22 
An earlier study has demonstrated that a new-walking aid, the walk-bike or modern 
draisine, improved exercise performance in Chronic Obstructive Pulmonary Disease 
(COPD) patients due to the more efficient way of moving without excessive metabolic 
demand.23 To our knowledge no (large) randomized controlled trials in IPF patients have 
been performed with homebased supervised training, nor for the walk-bike interven-
tion. To assess whether a study using this new method for homebased training is feasible 
and of benefit for IPF patients, we designed a crossover pilot study. We hypothesized 
that use of this walk-bike in daily life extends the range and everyday mobility of IPF 
patients, thereby decreasing the level of dependency and social isolation and improving 
quality of life. If daily activities of IPF patients increase, exercise capacity might improve 
too. The objectives of this pilot study were (1) to evaluate the feasibility of a homebased 
walk-bike intervention study in IPF patients, and (2) to explore the effect of the walk-bike 







Patients were eligible to participate in this study if they were diagnosed with IPF accord-
ing to American Thoracic Society (ATS) / European Respiratory Society (ERS) criteria, had 
a diffusing capacity of the lung for carbon monoxide (TLCO) ≥ 25 % predicted, a Forced 
Vital Capacity (FVC) ≥ 50 % predicted, a 6-minute walk distance (6MWD) ≥ 150 meters 
and were clinically stable without a decline in TLCO and FVC of 10% or more in the past 
six months.1,5 If TLCO could not be measured because of cough or other reasons, FVC 
should be ≥ 50% and no history of known pulmonary hypertension should be present 
to include patients in the study.
Patients were excluded if they participated in an official rehabilitation program < 4 
months before the start of the study, if they suffered from musculoskeletal disorders, 
severe cardiac diseases (an ejection fraction < 30%, daily angina, or otherwise specified 
by treating cardiologist), if they were unable to understand informed consent or if there 
were other conditions that could hamper the use of a walk-bike. Patients were recruited 
at the outpatient clinics of three respiratory medicine departments in the Netherlands, 
Denmark and Spain. The study was approved by ethic committees of all participating 
sites and all patients gave written informed consent to participate (MEC-2014-047, 
Erasmus University Medical Center). The study was registered in the Dutch Trial Register, 
NTR number 5334 (www.trialregister.nl).
Study design
This prospective multicenter pilot study followed a 2-period crossover design with an 
intervention period and a control period of each 8 weeks. The intervention was a home-
based training program using a walk-bike in daily life during 8 weeks, with the aim of 
a minimum of 1 hour per day. Patients were asked to record the time of real use of the 
walk-bike in a diary. At baseline, instructions and training under supervision were given. 
During the control period patients received standard treatment only. The walk-bike is 
an ambulation aid, a form of a bicycle but without pedals (Figure 1). By sitting on the 
seat the load on the muscles of ambulation is reduced which results in a lower cost of 
transport (oxygen uptake in mL/min per meter distance).23
Study procedure
Prior to randomization clinical stability was assessed by the physician. Pulmonary func-
tion and exercise performance were tested by spirometry, TLCO and 6MWT. Patients were 
randomly allocated to start with the intervention- or control period by an independent 






Block randomization was used to ensure that the numbers of participants assigned to 
each group were equally distributed during the different seasons. After 8 weeks of inter-
vention- or control period, patients were asked to cross over. Outcome variables were 
measured at baseline, after 9 weeks and at the end of the study at 18 weeks. Pulmonary 
function tests including FVC and TLCO were done as part of the routine medical follow 
up of treatment. 
Feasibility outcomes
Outcomes of feasibility comprise the number of patients assessed for eligibility, the 
proportion of patients that were randomized, the number of patients that finished both 
periods of the crossover study and adherence with the intervention (1 hour use of the 
walk-bike per day). Throughout the study, comments and suggestions for improvement 
from patients and the medical team were collected to explore potential barriers of this 
study for future research. After the study, patients were asked about their experience 
and satisfaction with the use of the walk-bike. Feasibility outcomes of all patients that 
signed informed consent were used. 
Patient-reported outcomes
The primary outcome was change in total score in health-related QoL measured with 
the St. George’s Respiratory Questionnaire (SGRQ) after 8 weeks of standard of care and 
after 8 weeks of walk-bike use at home. Although designed for patients with obstruc-
tive disease, the SGRQ has been found to be a valid measure of health-related QoL in 
patients with restrictive disease including IP.24,25 The SGRQ is a self-administered ques-
tionnaire with 50 items comprising the three domains symptoms, activity and impact, 
each scored from 0-100, with higher scores corresponding to worse health-related QoL. 






important difference (MID) for IPF patients.26 Secondary outcome was change in total 
score of the disease-specific King’s Brief Interstitial Lung disease health status question-
naire (K-BILD). The K-BILD questionnaire comprises of 15 items and has three domains; 
psychological, breathlessness & activities and chest symptoms.27 The K-BILD domain and 
total score ranges are 0-100, with higher scores indicating better health-related QoL. The 
MID range in ILD for the total score is 6-10 units.28 Other secondary outcomes are change 
in SGRQ and K-BILD domain scores, and in scores measured with the General Anxiety 
Disorder Screener (GAD-7). The GAD-7 measures the presence and severity of general 
anxiety disorder and contains 7 self-rated items, total score range is 0–21 with higher 
scores indicating more anxiety.29
Exercise capacity
Additional secondary outcomes were change in functional exercise capacity, deter-
mined by the 6MWD after 8 weeks of standard of care or 8 weeks of walk-bike use at 
home, and change in the number of steps per day as a proxy for daily physical activities, 
measured with a pedometer. To compare exercise performance with or without the 
walk-bike, patients were asked to perform an additional 6MWT using the walk-bike, 
after the regular 6MWT. This was done at the visit after the intervention period (in week 
9 or week 18 depending on allocation). The 6MWT was administered according to ATS 
criteria.30 The assessor that measured the regular 6MWT at 9 and 18 weeks was blinded 
for the allocation and patients were instructed not to inform the care provider. Patients 
were asked to wear a pedometer (Yamax Digiwalker SW-200) for a week at baseline, at 
the crossover moment and after the study. This small device worn on the belt detects 
the steps taken by vertical accelerations of the hip during gait cycles and gives an indica-
tion of the volume of physical activity.31
Pulmonary function tests 
PFT’s were performed according to ATS/ERS 2005 criteria.32,33 FVC and TLCO were re-
corded and expressed as percentage of the predicted value (%pred).
Analysis
Due to the explorative nature of this pilot study, no sample size calculations were done 
and results are given in a descriptive way. As it concerns a small group of patients, results 








One hundred and twenty five outpatients with IPF were assessed for eligibility for the 
study, 23 (18%) were interested in participating, signed informed consent, and were 
randomized. Twelve patients were allocated to start in the intervention group and 11 
patients to the control group. Sixteen patients finished the first phase of 8 weeks of the 
study and after crossover, 10 patients also completed the second phase. Two patients 
who started in the intervention group did not crossover because they wanted to con-
tinue using the walk-bike. Other reasons for not completing the full protocol are shown 
in Figure 2.
Patients assessed for eligibility (n=125)
Randomized (n=23)
Allocated to control group (n=11)
(n=1) discontinued
- acute exacerbation IPF
(n=10) completed first phase
Allocated to walk-bike group (n=12)
(n=3) did not start intervention
- side effects pirfenidone
- too much hassle with O2 transport
- did not start training
(n=3) discontinued intervention
- too cold and uncomfortable with bike
- hard to bike off-road
- stopped to use the bike without reason
(n=6)  completed first phase
Crossover to control group (n=2)
(n= 2) completed this phase
Crossover to walk-bike group (n=10)
(n=1) did not start intervention
- airway infection
(n=1) discontinued intervention
- after 2 weeks; too slippery, fell with bike
(n= 8) completed this phase
(n=10)  completed both phases, analyzed
(n=4)  did not crossover
- 2  patients continued use of 
walk-bike 
- 1  exacerbation/detoriation IPF
- 1  withdrew consent
Excluded (n=102)
- not meeting inclusion criteria (n = 33)
- not want a walking-aid (n = 20)
- declined to participate (n=46)
- other reasons (n=3)





Table 1. Overview of detected potential barriers for homebased use of the walk-bike for research as de-
tected by patients and the medical team.
Potential barriers Findings in this study Possible solutions
Weather conditions Patients frequently recorded not using 
the bike due to rain, storm, snow, 
slipperiness, heat and humidity.
Additionally offering a homebased 
indoor trainings program
Transport of oxygen 
device
(a small bottle of 
oxygen can be 
attached with Velcro 
to the rear of the 
frame below the 
saddle).
One patient stopped 1 week after the 
start because he experienced attaching 
the oxygen to the bike was too much 
hassle. Another patient solved her 
problem with transportation of the 
oxygen bottle by transporting a smaller 
oxygen device in a back pack.
Ask the vendor to add a larger 
basket at the rear of the bike to 
facilitate oxygen transport or 
providing the option of a back pack.
Hills and unpaved 
roads
A patient recorded that even a minor 
hill makes using the walk-bike heavier 
than regular walking. Another patient 
mentioned the walk bike is most useful 
when the road is smooth or goes 
downhill and uphill, it is useful as a 
support object, like a walker.
Another patient living in the countryside 
stopped using the bike because it was 
too heavy to use on unpaved roads.
The walk-bike seems more fit for 
paved roads and flat countries. 
The option of electrical support to 




Some patients were very compliant 
and recorded they used the bike every 
day for at least 60 minutes, others 
were hampered by external factors or 
symptoms and didn’t use the bike for 
days.
Using accelerometers and new 
e-health technologies may help the 
medical team to detect barriers in 
use of the walk-bike at an earlier 
stage enabling them to contact 
and coach or support the patient in 
finding solutions.
Fear of stigmatization Some patients didn’t want to participate 
as they (or their spouse) where being 
afraid to be stigmatized for using an 
assistive device.
For some patients the potential 
benefit of the walk-bike will not 
outweigh the impact of making 
their disease visible by using an 
assistive device. Similar findings 
have been reported for ambulatory 
oxygen and careful discussion may 
help but in the end it is the patient 
who decides.
Saddle pain Some patients were bothered by saddle 
pain or felt the saddle was uncomfortable
Provide silicone gel saddles
Limitations to use the 
walk bike in public 
places and public 
transport
None of the patients mentioned these 
problems
Patients were provided with a card 
that the walk-bike is an assistive 







Ten of the 14 patients that completed the walk-bike period, recorded the actual use of 
the walk-bike in a diary; the median (min-max) use of the walk-bike was 5.3 (2.0- 6.9) 
days a week and 43.9 (11.3-60.6) minutes per actual usage day. An overview of potential 
barriers and solutions as reported by patients and medical staff during this study is 
provided in Table 1.
Patient satisfaction and experience with the walk-bike are shown in Table 2. Comments 
differed from very satisfied with continuation of using the walk-bike after the study, 
to not satisfied because using the walk-bike was too heavy or because of feelings of 
embarrassment. 
One patient reported two fall-incidents due to wet and slippery roads, without any 
physical complaints, and decided to stop with the study. 
Baseline characteristics (Table 3) demonstrate that patients were predominantly male 
with a decreased FVC, TLCO, exercise tolerance and health-related QoL. The patients 
who dropped out during the study showed on average worse scores in diffusing capac-
ity, exercise measures and health status. The results of the 10 patients that followed the 
complete protocol are given in Table 4.
Table 2. Comments on the walk-bike
Positive comments
Bike is really good for training; feel fit after 8 weeks of training
Although not comfortable with the bike because of shoulder pain, would like to continue using it
Able to walk further with less dyspnea
Enables me to leave the house and e.g. go to the bakery without being dependent of my spouse
Easier and nicer to walk
Able to walk further; it is more comfortable and gives possibility to rest
The walk bike has been a good means of contact with other people, it has the interest of news.
Negative comments
Too heavy in combination with oxygen; difficult to use with oxygen bottle
Difficult way of making steps
Able to walk further because of better stability but feel embarrassed when using walk bike
Uncomfortable with bike, roads are too slippery





Figure 3. Individual changes in SGRQ- and K-BILD total scores during control and intervention period. A 
negative change in SGRQ score indicates an improvement in quality of life, a positive change in K-BILD 
score indicates an improvement in quality of life.
Table 3. Baseline characteristics of the study patients
Randomized (N=23) Completed study (N=10) Drop outs (N=13)
Male 18 (78%) 8 (80%) 10 (77%)
Age (years) 71 (54-88) 71 (60-88) 72 (54-88)
Pulmonary function
FVC (%pred) 69 (48-97) 69 (53-87) 72 (48-97)
TLCO (%pred) 43 (26-67)a 51 (26-62) 40 (26-67)g
Exercise measures
6MWD (m) 443 (278-593)a 481 (360-540) 433 (278-593)g
Nadir SpO2 (%) 87 (78-96)a 89 (81-95) 85 (78-96)g
Average steps/day 3521 (478-9869)b 4016 (707-9636)e 3185 (478-9869)h
Health status scores
SGRQ total [0-100]j 50 (16-62)c 44 (32-52)f 55 (16-62)i
K-BILD total [0-100]k 63 (30-83)a 66 (56-78) 58 (30-83)g
Perceived health status [1-5]l 3 (2-4)d 3 (3-4) 3 (2-3)i
GAD-7 [0 –21]m 2 (0-11)a 2 (0-8) 5 (0-11)g
Data are presented as absolute number (%) or median (min-max). FVC: forced vital capacity (% predict-
ed), TLCO: diffusing capacity of the lung for carbon monoxide (%predicted), 6MWD: distance walked in a 
6-minute walk test (meters), SpO2: oxygen saturation from pulse oximetry measured during 6MWT, SGRQ: 
St George’s Respiratory Questionnaire, K-BILD: King’s Brief quality of life questionnaire for Interstitial Lung 
Diseases, GAD-7: Generalized Anxiety Disorder 7-item scale. a: n=22, b: n=17, c: n=19, d: n=21, e: n=7, f: n=8, 
g: n=12, h: n=10, i: n=11, j: SGRQ lower scores indicate better health-related QoL, k: K-BILD lower scores in-






SGRQ- and K-BILD total score, as well as the domain scores, tended to improve after 
training with the bike (Figure 3), with the most striking improvement in SGRQ symp-
toms- and K-BILD chest scores.
No change after training was observed in exercise capacity measured with the 6MWD. 
Training with the walk-bike did not change the anxiety score or perceived health status 
(Table 4). 
A meaningful difference in distance covered was found between the 6MWT performed 
with the walk-bike and the unaided 6MWT with a median (min-max) 6MWD of 602 
meters (358-684) vs. 486 meters (382-510); (Figure 4). The lowest oxygen saturation dur-
ing the 6MWT with the walk-bike and unaided did not differ with a nadir SpO2 of 86% 
(80-91) vs. 87% (78-90). 
Table 4. Change in health status and exercise measures of patients that completed both phases (N=10)
ΔControl period ΔWalk-bike period
SGRQ a
Total (n = 8) 1.2 (-12.3 - 8.3) -7.1 (-17.8 - 5.9)
Symptoms (n = 9) 6.7 (-22.7 - 38.9) -7.9 (-42.6 - 16.0)
Activity (n = 9) 0.0 (-18.1 - 6.3) -5.2 (-14.2 - 1)
Impact (n = 8) 0.3 (-12.3 - 8.9) -7.4 (-22.3 - 9.9)
K-BILD b
Total (n = 8) 1.8 (-14.7 - 15.3) 6.5 (-10.0 - 29.4)
Chest (n = 8) 0.0 (-25.0 - 25.0) 12.5 (0.0 - 37.5)
Breathlessness & activity (n = 9) 0.0 (-29.8 - 14.9) 0.0 (-21.8 - 46.8)
Psychological (n = 8) 0.0 (-11.1 - 23.5) 6.2 (-16.1 - 18.5)
Other
GAD-7 (n = 9) 0 (-2 - 6) 0 (-2 - 0)
Perceived health status (n = 9) c 0 (-2 - 0) 0 (-2 - 2)
Exercise measures
6MWD (m) (n=7) -4 (-25 - 28) -3 (-34 - 23)
Nadir SpO2 (%) (n =7) -1 (-3 - 6) -3 (-7 - 2)
Average steps/day (n =6) 132 (-903 - 3056) -461 (-4335 - 1063)
Data are presented as median (min-max) [n]; FVC: Forced vital capacity (%predicted), TLCO: transfer capac-
ity of the lung for carbon monoxide (%predicted), 6MWD: distance walked during 6-minute walk test, SpO2: 
oxygen saturation from pulse oximetry, SGRQ: St George’s Respiratory Questionnaire (MID for total score is 
7 points) , K-BILD: King’s Brief quality of life questionnaire for Interstitial Lung Diseases (MID range for total 
score is 6-10 points), GAD-7: Generalized Anxiety Disorder 7-item scale. a: A negative change in SGRQ score 
indicates an improvement in health-related QoL, b: A positive change in K-BILD score indicates an improve-





During the study, the lung volume remained stable with a median (min-max) FVC at 
baseline of 69 %pred (53-87) vs. 70 %pred (57-86) in week 18. Gas exchange parameters 
showed a tendency toward decline with a TLCO at baseline of 50 %pred (26-62) vs. 45 
%pred (25-59) in week 18.
We also analyzed the data including the four patients that did not cross over; no changes 
in results were found.
DISCUSSION
In this crossover pilot study, we explored the feasibility of a homebased walk-bike in-
tervention study in IPF patients, and evaluated its effects on quality of life and exercise 
capacity.
The feasibility outcomes demonstrate that a homebased walk-bike intervention study 
in its current design is difficult to accomplish. Potential barriers for feasibility of the 
study include reluctance to participate in the study, but also external factors such as 
weather and road conditions that may hampered adherence to the protocol. Patients 
satisfaction with the bike greatly varied. Despite the moderate usage intensity of the 
walk-bike, we found a tendency towards improvement in quality of life after the 8-week 
homebased training program with the walk-bike. Functional exercise capacity did not 
change. Mobility increased with an average of 116 meters in distance covered when 
using the walk-bike during the 6MWT, compared to an unaided regular 6MWT. Use of 
the walk-bike proved to be safe.
A larger future RCT to detect clear walk-bike training-effects on quality of life and ex-
ercise capacity does not seem feasible unless potential barriers detected in our study 






are being solved. We chose a crossover design as it holds the advantage over a parallel 
study that the patient is its own control, thereby reducing the influence of confounding 
variables and sample size. However, this crossover design warrants a longer duration 
of study for the individual patient (16-18 weeks). Despite the block randomization to 
account for seasonal changes, weather changes during the study period turned out 
to affect the use of the walk-bike. A study incorporating both walk-bike use as well as 
a homebased indoor training alternative, maybe be a better design for a homebased 
training program. As table 1 shows, another potential barrier is the collection of correct 
information of the intensity of training. In our pilot study patients recorded the time of 
walk-bike use in a diary. However, this patient-recorded time may have included time 
spent waiting and resting on the bike without movement. Accelerometers are devices 
that if worn by the patient, can record intensity duration and frequency of activities and 
makes assessments of the potential effects of the walk-bike more accurate. 
Patient satisfaction with the walk-bike varied greatly from positive to negative. Patients 
positively evaluated the walk-bike because it enabled them to walk further with less 
dyspnea, or made it possible to leave the house again. The feeling of an increased level 
of independence and social participation are both important aspects of IPF patients’ 
quality of life.9,34 Negative comments related to being afraid to be stigmatized when us-
ing the walk-bike. Swigris et al. investigated how IPF affects quality of life from patients’ 
perspective and noted many patients feel the need to try to hide the fact that they have 
a chronic illness when they are in public.34 This aspect, together with unfamiliarity with 
this new walking-aid, may also have played a role in the difficult inclusion of patients in 
our study. Other patients noted that the walk-bike was too heavy when used outdoors 
e.g. on hilly roads. It might well be that when the road includes obstacles or hills, use of 
the walk-bike is more complicated, which was also observed in another study.35
In this pilot study, the use of the walk-bike led to improvement of the SGRQ total equal 
to the MID of 7 points, with a median difference in change of 8.3 points between the 
intervention period and control period. This improvement in SGRQ scores is comparable 
with the effects reported in a recently published systematic review on pulmonary reha-
bilitation in IPF.36 Meta-analysis on the results of three studies demonstrated a weighted 
mean difference SGRQ total score of -8.34 (95% CI, -11.30 - -5.39; n = 82) between 
intervention - and control groups, favoring pulmonary rehabilitation. In our study, we 
also assessed quality of life with the ILD specific K-BILD questionnaire and found similar 
results in magnitude and direction of changes compared to the SGRQ. The K-BILD holds 





We found no effect in exercise capacity (6MWD). In studies that assessed the effect of ex-
ercise training or pulmonary rehabilitation programs in patients with IPF, 6MWD usually 
improved. 14 The previous mentioned review of Gomes-Neto et al.36 showed a weighted 
mean difference in 6MWD of 44 meters (95% CI, 5.3-82.8; n = 113) favoring pulmonary 
rehabilitation. Most pulmonary rehabilitation- or physical training programs contain su-
pervised exercise protocols with a combination of endurance and resistance training.37 
In our walk-bike intervention, the primary aim was to increase quality of life. Participants 
were encouraged to use the walk-bike for at least one hour daily, and it was up to the 
discretion of the patients whether to use it continuously or in intervals. Practical factors 
such as weather conditions and day to day changes in wellbeing turned out to limit 
participants from using the walk-bike stringently and may have minimized the effect on 
exercise capacity. In patients with severe COPD it was shown that interval training at low 
burden could still have a positive effect on exercise capacity.38 We hypothesized that by 
increasing daily activities, patients would also exercise more at low burden which may 
eventually result in improving or maintaining exercise capacity and improving Qol. 
The advantage of a home-based physical exercise program is increasingly recognized. It 
remains to be evaluated if a more structured and supervised use of the walk-bike could 
play a role in such programs. We found a meaningful improvement of 116 meters in 
distance covered during a 6MWT with use of the walk-bike, compared to an unaided 
test. This is in line with the improvement found by Vaes et al. who assessed the effects 
of the walk-bike on exercise performance in COPD patients.23 Improvement of mobility 
by using the walk-bike could potentially lead to a higher level of independence and 
social participation. These factors may have been the main contributing factors to the 
tendency toward improvement in quality of life in our study, even though exercise 
capacity did not improve. 
One of the limitations of our study is the small sample size. We aimed to include 22 
patients, enrolled 23 patients but after randomization, a part of the patients did not start 
or discontinued. Only 10 patients completed both phases which underlines the difficul-
ties encountered when trying to set up an interventional study for such a vulnerable 
patient group. If patients still had a reasonably well-preserved exercise tolerance, they 
did not wish to use a walk-bike. On the other side, when patients were more impaired 
and wished to use the walk-bike, risk of dropout increased, leaving a small subgroup that 
potentially benefits from this intervention. A potential limitation of the study design 
could be a carry-over effect. However, we believe this can be neglected as 8 patients 
were allocated to the control period in the first phase and trained with the walk-bike 
in the second phase, only 2 patient participated in the reverse order. Moreover, with 






fect might have led to underestimation of the effect of the walk-bike. Furthermore, 2 
patients that started with the walk-bike decided to continue with the walk-bike instead 
of crossing over to the control arm.
In conclusion, this pilot study showed that a larger RCT may not be feasible unless most 
of the potential barriers are being solved. Despite the small group studied we found that 
the use of a walk-bike led to a meaningful improvement in quality of life for patients with 
IPF after an 8-weeks homebased training program. Use of the walk-bike also increased 
mobility for patients but did not result in an improvement in exercise capacity. Patient 
satisfaction varied greatly and the use of the walk-bike seems only beneficial for a small 
selected group of patients with IPF.
Acknowledgements
The authors would like to thank all the patients who participated in this pilot study. We 
would also like to thank R.J.H. Koppers and B.G. Bannink for technical support on the 
walk-bikes and C.J. Lammering, F.W. Mertens and F. Muskens for their assistance in this 
study.
Funding
The Pender Foundation of the Dutch pulmonary fibrosis patient association (Longfi-
brose patiëntenvereniging http://longfibrose.netrex.nl/ ) funded this study but had no 







 1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary 
fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 
2011;183(6):788-824.
 2. Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: 
Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. 
Am J Respir Crit Care Med. 2015;192(2):e3-19.
 3. Holland A, Hill C. Physical training for interstitial lung disease. Cochrane Database Syst Rev. 
2008(4):CD006322.
 4. Swigris JJ, Gould MK, Wilson SR. Health-related quality of life among patients with idiopathic 
pulmonary fibrosis. Chest. 2005;127(1):284-294.
 5. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International 
consensus statement. American Thoracic Society (ATS), and the European Respiratory Society 
(ERS). Am J Respir Crit Care Med. 2000;161(2 Pt 1):646-664.
 6. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis 
(CAPACITY): two randomised trials. The Lancet.377(9779):1760-1769.
 7. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary 
fibrosis. N Engl J Med. 2014;370(22):2071-2082.
 8. Behr J, Gunther A, Bonella F, et al. German Guideline for Idiopathic Pulmonary Fibrosis - Update 
on Pharmacological Therapies 2017 S2k-Leitlinie Idiopathische Lungenfibrose - Update zur medi-
kamentosen Therapie 2017. Pneumologie. 2018;72(2):155-168.
 9. Vries JD, Kessels BLJ, Drent M. Quality of life of idiopathic pulmonary fibrosis patients. European 
Respiratory Journal. 2001;17(5):954-961.
 10. Verma G, Marras T, Chowdhury N, Singer L. Health-related quality of life and 6 min walk distance 
in patients with idiopathic pulmonary fibrosis. Canadian Respiratory Journal. 2011;18(5):283-287.
 11. Bajwah S, Ross JR, Peacock JL, et al. Interventions to improve symptoms and quality of life of 
patients with fibrotic interstitial lung disease: a systematic review of the literature. Thorax. 
2013;68(9):867-879.
 12. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory 
Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care 
Med. 2013;188(8):e13-64.
 13. Kenn K, Gloeckl R, Behr J. Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis-
-a review. Respiration. 2013;86(2):89-99.
 14. Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane 
Database Syst Rev. 2014(10):CD006322.
 15. Vainshelboim B. Exercise training in idiopathic pulmonary fibrosis: is it of benefit? Breathe (Sheff ). 
2016;12(2):130-138.
 16. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capac-
ity and symptoms following exercise training in interstitial lung disease. Thorax. 2008;63(6):549-
554.
 17. Cheng L, Tan B, Yin Y, et al. Short- and long-term effects of pulmonary rehabilitation for idiopathic 
pulmonary fibrosis: a systematic review and meta-analysis. Clin Rehabil. 2018;32(10):1299-1307.
 18. Wallaert B, Duthoit L, Drumez E, et al. Long-term evaluation of home-based pulmonary rehabilita-






 19. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idio-
pathic pulmonary fibrosis. Respirology. 2008;13(3):394-399.
 20. Jastrzȩbski D, Kozielski J, Zebrowska A. Pulmonary rehabilitation in patients with idio-
pathic pulmonary fibrosis with inspiratory muscle training. Pneumonologia i Alergologia Polska. 
2008;76(3):131-141.
 21. Huppmann P, Sczepanski B, Boensch M, et al. Effects of inpatient pulmonary rehabilitation in 
patients with interstitial lung disease. Eur Respir J. 2013;42(2):444-453.
 22. Rammaert B, Leroy S, Cavestri B, Wallaert B, Grosbois JM. Home-based pulmonary rehabilitation 
in idiopathic pulmonary fibrosis. Rev Mal Respir. 2011;28(7):e52-57.
 23. Vaes AW, Annegarn J, Meijer K, et al. The effects of a “new” walking aid on exercise performance in 
patients with COPD: a randomized crossover trial. Chest. 2012;141(5):1224-1232.
 24. Swigris JJ, Esser D, Wilson H, et al. Psychometric properties of the St George’s Respiratory Ques-
tionnaire in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2017;49(1).
 25. Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory Questionnaire. Respir Med. 
1991;85 Suppl B:25-31; discussion 33-27.
 26. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum impor-
tant differences in IPF. Respir Med. 2010;104(2):296-304.
 27. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King’s Brief Interstitial 
Lung Disease (K-BILD) health status questionnaire. Thorax. 2012;67(9):804-810.
 28. Patel AS, Siegert RJ, Keir GJ, et al. The minimal important difference of the King’s Brief Interstitial 
Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease. Respir 
Med. 2013;107(9):1438-1443.
 29. Donker T, van Straten A, Marks I, Cuijpers P. Quick and easy self-rating of Generalized Anxiety Dis-
order: validity of the Dutch web-based GAD-7, GAD-2 and GAD-SI. Psychiatry Res. 2011;188(1):58-
64.
 30. Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit 
Care Med. 2002;166(1):111-117.
 31. de Blok BM, de Greef MH, ten Hacken NH, Sprenger SR, Postema K, Wempe JB. The effects of a 
lifestyle physical activity counseling program with feedback of a pedometer during pulmonary 
rehabilitation in patients with COPD: a pilot study. Patient Educ Couns. 2006;61(1):48-55.
 32. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-
338.
 33. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of 
carbon monoxide uptake in the lung. Eur Respir J. 2005;26(4):720-735.
 34. Swigris JJ, Stewart AL, Gould MK, Wilson SR. Patients’ perspectives on how idiopathic pulmonary 
fibrosis affects the quality of their lives. Health Qual Life Outcomes. 2005;3:61.
 35. Vaes AW, Meijer K, Delbressine JM, et al. Efficacy of walking aids on self-paced outdoor walking in 
individuals with COPD: A randomized cross-over trial. Respirology. 2015;20(6):932-939.
 36. Gomes-Neto M, Silva CM, Ezequiel D, Conceicao CS, Saquetto M, Machado AS. Impact of 
Pulmonary Rehabilitation on Exercise Tolerance and Quality of Life in Patients With Idiopathic 
Pulmonary Fibrosis: A SYSTEMATIC REVIEW AND META-ANALYSIS. J Cardiopulm Rehabil Prev. 
2018;38(5):273-278.
 37. Kenn K GR, Heinzelmann I, Kneidinger N. Nonpharmacological interventions: rehabilitation, 
palliative care and transplantation. In: Costabel U, Crestani B, AU W, eds. Nonpharmacological 
interventions: rehabilitation, palliative care and transplantation. Vol ERS Monograph Idiopathic 





 38. Beauchamp MK, Nonoyama M, Goldstein RS, et al. Interval versus continuous training in individu-
als with chronic obstructive pulmonary disease--a systematic review. Thorax. 2010;65(2):157-164.

“an exclusively outpatient multidisciplinary pulmonary 
rehabilitation program improves exercise capacity, 
muscle strength and quality of life of pulmonary 
hypertension patients.”
Chapter 9
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ABSTRACT
Purpose
Pulmonary arterial hypertension (PAH) is characterized by right ventricular failure, 
leading to exertional dyspnea, skeletal muscle weakness, and poor quality of life (QOL). 
Apart from treatment with PAH-specifi c drugs, guidelines recommend pulmonary re-
habilitation (PR). Clinical PR programs have shown improvement in functional capacity 
and QOL. However, little is known about the effectiveness of an outpatient PR program. 
The aim of our study was to assess effectiveness of a multidisciplinary outpatient PR 
program.
Methods
Patients with PAH or chronic thromboembolic pulmonary hypertension (CTEPH), who 
were in a stable condition on optimized drug therapy, followed a 10-wk outpatient 
program in a rehabilitation center. The PR program was designed to improve exercise 
capacity and health status by means of low load cycling, walking, and muscle training 
twice a week combined with psychological counseling. QOL was measured by the Cam-
bridge Pulmonary Hypertension Outcome Review (CAMPHOR) questionnaire.
Results
Twenty-one patients (13 women) with PAH (n = 16) or CTEPH (n = 5) completed the 
study. All patients were in New York Heart Association (NYHA) functional class III, and 
their mean age was 45 ±16 yr. After PR, the mean cycling endurance time increased by 
4.4 min (P < .001), 6-min walk distance by 12.2 m (P < .05), and maximum inspiratory 
pressure by 5.8 cm H 2O (P = .01). Skeletal muscle function increased significantly. The 
CAMPHOR questionnaire demonstrated significant decrease in symptoms and improve-
ment in QOL. Soluble biomarkers did not show any change before and after PR.
Conclusions
Outpatient PR could be an effective instrument to improve exercise capacity and health 







Pulmonary arterial hypertension (PAH) is a rare and incurable condition of the pulmonary 
vasculature, characterized by increased pulmonary vascular resistance and elevated 
pulmonary arterial pressure leading to progressive right ventricular (RV) failure. Despite 
improvement in specific medical treatment of PAH over the last years, patients with PAH 
still suffer from significant dyspnea, fatigue and skeletal muscle weakness, resulting in 
exercise limitation/intolerance and poor quality of life (QOL).1 Exercise intolerance is 
a key feature in PAH for which the underlying hemodynamic impairment is primarily 
responsible.2 Several studies however demonstrated that beside hemodynamic impair-
ment and ventilatory - perfusion mismatches, respiratory and skeletal muscle dysfunc-
tion plays an important role in exercise limitation in PAH patients3-8 and therefore is an 
important determinant for exercise limitation.9-12
Since muscle impairment limits PAH patients in their daily life activities it has a strong 
negative influence on QOL.4,13,14 Reduction in muscle dysfunction and exercise intoler-
ance are therefore recognized to be important goals in the treatment of PAH patients. 
Exercise programs have been shown to improve muscle function by increasing type 1 
fiber surfaces.6,15 Moreover, previous studies have shown both a shift from type IIx to 
type IIa fibers and a total increase in type II fibers. Furthermore, exercise programs have 
been demonstrated to improve muscle capillarization,6,15 muscle strength and exercise 
capacity in PAH patients.5,16,17 This not only results in a higher physical activity level but 
also results in improvement in health-related QoL measured by the 36- item Short Form 
Survey (SF-36).18-20
Historically, patients with PAH were recommended to restrain from physical activity, 
including pulmonary rehabilitation (PR) because of poor prognosis and risk of sudden 
cardiac death. In 2006, Mereles et al.18 were the first to demonstrate in a small random-
ized controlled trial that exercise training is safe and has beneficial effects on functional 
capacity and QOL.
Little is known so far about the effect of exercise training on RV function. Most studies 
did not show a significant effect, while some showed a minor decrease in systolic RV 
pressure measured by echocardiography.18,20-22 The underlying mechanism has not yet 
been elucidated, although in a rat model it was shown that exercise training may lead 
to less pronounced pulmonary vascular remodeling, and only high intensive training 
lowered RV systolic pressure and RV hypertrophy.23,24 Biomarkers such as N-terminal 
pro B-type natriuretic peptide (NT-pro BNP) and high sensitive troponin-T (HsTnT), are 





patients with Pulmonary Hypertension (PH).1 We therefore investigated these markers in 
our patient group before and after PR program as a marker of RV function.
In recent years, evidence for the beneficial effects of PR is increasing.25-27 The European 
Respiratory Society (ERS) and the European Society of Cardiology (ESC) guidelines for 
the diagnosis and treatment of PH recommend supervised rehabilitation programs 
in expert centers for PAH patients in stable condition on optimized PH specific drug 
therapy.1 However, most programs so far have been carried out in a hospital setting or 
were at least started in a hospital setting. Unfortunately, programs in a hospital setting 
are not always feasible for patients.
We know that PAH as a disease that has great impact on the QOL of these patients.28 This 
has also been shown by a QOL questionnaire specifically designed for patients with PAH, 
the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR).29,30 We therefore 
decided to offer a PR program with a multidisciplinary approach including: educational 
sessions, psychological counseling, advice by an occupational therapist, dietary advice, 
and group sessions with fellow patients.
Since knowledge about the safety and effectiveness of a PR program in an exclusively 
outpatient setting is still lacking, our goal was to develop an achievable multidisciplinary 
outpatient PR program.
We considered withholding PAH patients from a PR program at this stage not to be ethi-
cal. This study has therefore specifically been designed as a prospective cohort study.
The aim of our study was to assess the effectiveness of such an outpatient PR program 
on exercise capacity, muscle strength, soluble biomarkers and QOL.
Methods
Study design
This prospective cohort study was conducted from January 2016 until December 2017 
as a collaboration between the Erasmus University Medical Centre (Rotterdam, The 
Netherlands) and the Revant Rehabilitation Centre (Breda, the Netherlands). Patients 
underwent an evaluation at the rehabilitation center before entering the program. They 
followed an outpatient PR program for 10 wk consisting of 2 sessions per week. Im-








All patients were diagnosed according to the ERS/ESC guidelines.1 Patients in World 
Health Organization (WHO) groups I and IV were eligible for the study. Patients had to be 
in a clinically stable condition under optimized PH drug therapy for ≥3 mo before enter-
ing the study (see Supplemental Digital Content 1, available at: http://links.lww.com/
JCRP/A119). No changes in PH specific medication were made during the PR program. 
Patients were excluded if they had participated in a rehabilitation program previously, 
if they were not able to give informed consent, or if they were younger than 18 y. This 
protocol was approved by the medical ethical committee, Erasmus MC Rotterdam, the 
Netherlands (protocol MEC-2011-392). All participating patients signed an informed 
consent form before commencing the program.
Outcome measures
Patients were evaluated at baseline and week 10, immediately after the PR program. 
Primary outcome measures were changes at week 10 compared to baseline in exercise 
capacity, determined by cycling endurance time (CET), and change in QOL as measured 
by the CAMPHOR.
The PR program was designed to focus on both muscle strength and endurance for cy-
cling and walking. Therefore, we chose the measured CET (min) as primary endpoint to 
investigate the effect of PR on endurance and exercise capacity. The CET was measured 
by a sub-maximal constant work rate exercise test at a constant load 75% of the baseline 
peak workload.
The CAMPHOR is a self-administered PH-specific health status questionnaire with 3 
scales to assess symptoms, activity and quality of life. It also contains three symptom-
subscales for energy, breathlessness and mood. Scores for symptoms and QOL range 
from 0-25, higher scores indicating worse QOL. Activity scores range from 0-30, higher 
scores indicating more physical limitations. Prior research validated the CAMPHOR ques-
tionnaire and the correlation between 6MWD and NYHA classification.30 The CAMPHOR 
questionnaire was taken at baseline and after 10 weeks of PR.
Secondary outcome measures were changes at week 10 compared with baseline in 
6MWD, respiratory muscle strength maximal inspiratory mouth pressure and skeletal 
muscle strength (quadriceps force and biceps force ). The 6-min walking test (6MWT) 
was carried out according the ERS/American Thoracic Society (ATS) technical standards.31 
The maximal inspiratory mouth pressure was measured during a forced inspiratory ef-





force and biceps force were assessed using a handheld dynamometer (MicroFET2) dur-
ing maximal isometric knee extension and elbow flexion, respectively.33
The maximal peak cycling workload was measured during a maximal incremental 
symptom-limited cardiopulmonary exercise test (CPX) carried out in semi-supine posi-
tion. The CPX was performed according to ATS guidelines,34 with 3 min of rest, 3 min of 
unloaded cycling, followed by a progressive increase of the workload (5-25 W/minute). 
Ventilation oxygen-uptake and carbon dioxide output were measured breath-by-breath 
using a Jaeger CPX metabolic cart. Ventilatory efficiency was derived from the measured 
ventilation and carbon dioxide output ).
Pulmonary rehabilitation program
The 10-wk PR program with 2 group training sessions/wk was especially developed for 
PH patients. The program included program endurance training (walking and cycling), 
lower- and upper-limb strength training, individualized psychological counseling, 
dietary advice, advice by an occupational therapist, educational group sessions, and 
interaction sessions with fellow patients. Once a week, the group would go out- doors 
during a physical training session to train activities in a real-life setting, for example, go-
ing to a supermarket or walking. The duration of the different activities of both weekly 
training sessions is shown in Supplemental Digital Content 2 (available at: http://links.
lww.com/JCRP/A120). During educational sessions, information was provided by vari-
ous members of the multidisciplinary team on pathophysiological changes in PH, the 
importance of dietary advice on the intake of proteins and vitamins, acceptance and 
coping of the disease, and how to manage energy distribution (breathing techniques 
etc). Specific PH questions from the patients were collected and answered by the PH 
special- ized pulmonologist and PH specialized nurse.
To individualize the training program and determine the training intensity at the start, 
patients performed exercise tolerance tests during the 2 to 3 d of baseline assessments. 
A symptom-limited maximal incremental CPX was performed to assess the maximal 
workload (Wmax) and two 6MWTs to evaluate distance walked and speed.
The training program contained the following components: bicycle occupational train-
ing by a stepwise schedule. Steps 1 and 2 started with exercise-rest interval training at 
40% of the maximal workload achieved during the incremental CPX at baseline (Wmax). 
Steps 3 to 10 comprised continuous cycling for 15 to 20 min at 40% to 80% of Wmax. 
Training intensity progressed to the next step if perceived exertion during exercise 
remained <5 on the Borg dyspnea scale, if fatigue did not last >24 hr after the previous 






Walking training was performed on a treadmill ac- cording to a protocol with the same 
stepwise approach as mentioned earlier. Steps 1 to 3 comprised interval training at 60% 
to 75% of the speed achieved during the 6MWT at baseline. Steps 4 to 10 comprised 
continuous walking during 10 to15 min at 60%-75% to 75%-100% of the baseline 
6MWT-speed.
Resistance training consisted of training leg-, arm and abdominal muscles on weight 
training equipment (Technogym). During the baseline assessment, the1 repetition 
maximum (1RM) training weight that could correctly be moved with appropriate 
breathing was determined for each exercise. During subsequent sessions, the training 
was intensified by gradually increasing repetitions of movements and weight/load to 
improve muscle strength and endurance respectively, according to ATS/ERS statement 
on PR.25
Once weekly the training sessions included a 60-min outdoor group activity, such as 
walking or cycling. Physiotherapists supervised all training sessions and, if needed, edu-
cated the patients in perceiving their physical limits and optimal breathing technique. 
Symptoms, heart rate and oxygen saturation to exercise, were closely monitored follow-
ing specific PH rehabilitation guidelines.1,25
Blood samples were collected on the first and last days of the PR program. Biomarker 
assessment was performed for C-reactive protein, cystatin C, hemoglobin, red cell 
distribution width, NT-pro BNP, HsTnT, iron, and uric acid. Biomarkers were measured in 
peripheral blood samples within <1 hr after venous puncture at the clinical chemistry 
department at the Erasmus MC (Rotterdam, the Netherlands).
Statistics
Values are reported as mean (standard deviation) unless otherwise indicated. Changes 
in exercise capacity, muscle strength and QOL from baseline to 10 weeks were assessed 
using paired t-test or Wilcoxon signed rank test. P-values <.05 were considered statisti-
cally significant. All statistical analyses were performed using Prism (GraphPad Software, 
La Jolla, CA, USA) or SPSS version 24.
resuLts
In this study, 21 patients were included with either PAH (n = 16) or inoperable chronic 
thromboembolic pulmonary hypertension (CTEPH) (n = 5). The demographics of the 





Table 1. Demographic and Patient Characteristicsa
Patients with pulmonary
Characteristic hypertension (n = 21)
Gender, female 13 (62)
Age, yr 45.1 ± 15.5
Height, cm 166.7 ± 9.4
Weight, kg 79.9 ± 23
BMI, kg/m2 28.5 ± 7.1
WHO functional class III 21 (100)
Cause of pulmonary hypertension
CTEPH 5 (24)
PAH 16 (76)
 IPAH 7 (33)
 CHD 5 (24)
 SLE/SSc 3 (14)
 PVOD 1 (5)
PH-specific drugs






Dual therapy 10 (48)
Triple therapy 7 (33)
Echocardiography (<6 mo prior to PR)
RV pressure, mm Hg 55.8 ± 22.9
RA pressure, mm Hg 5.4 ± 3.3
RVSP, mm Hg 61.2 ± 23.4
6MWT, m 465 ± 98
6MWT, % predicted 84 (73, 79)
6MWT Borg fatigue/dyspnea scores (end of test) 4.4 ± 2.3/ 5.4 ± 2.8
CPX
Peak workload, W 70.8 ± 37.9
Peak V’O2, % of predicted 55.3 ± 18.3
Peak V’O2, mL/kg/min 13.7 ± 3.4
RER 1.13 ± 0.13
V’E,max, L/min 50.2 ± 16.1
HRmax, % of predicted 73.1 ± 12.6
Peak V’E/V’CO2 43.1 ± 10.8
Abbreviations: BMI, body mass index; CHD, congenital heart disease; CPX, cardiopulmonary exercise test; 
CTEPH, chronic thromboembolic pulmonary hypertension; ERA, endothelin receptor antagonist; IPAH, id-
iopathic pulmonary arterial hypertension; PAH, pulmonary arterial hypertension; PVOD, pulmonary veno-
occlusive disease; PDE-5, phosphodiesterase-5 inhibitor; RA, right atrial; RER, respiratory exchange ratio; RV, 
right ventricular; RVSP, right ventricular systolic pressure; 6MWT, 6-min walk test; SLE/SSc, systemic lupus 
erythematosus or systemic sclerosis–associated PH patient; V’CO2, carbon dioxide output; V’E , ventilation; 
V’O2, oxygen uptake; WHO, World Health Organization.






subjects tolerated the exercise testing and training well. No adverse events, defined as 
an increase in symptoms, progression of PH, or need for hospital admission, took place 
during the program.There was no withdrawal or loss to follow-up of patients during the 
PR program.
Mean CET increased significantly by 4.4 min (+92%) after 10 wk of PR (Figure 1, Table 2).
Comparing results of the CAMPHOR questionnaire before and after PR, our study group 
showed an improvement in scores for symptoms and QOL (Figure 2).
 Figure 1.  Change in CET for individual patients at baseline and after a 
10-wk outpatient pulmonary rehabilitation program. CET indicates cy-
cling endurance time. 
 Table 2 
 Test Results at Baseline and After a 10-wk Outpatient Pulmonary Rehabilitation Program a 
 Characteristic  Baseline (N  = 21)  Post-rehabilitation Therapy (N  = 21)  P Value 
CET, min 4.8  ± 2.1 9.2  ± 5.5  < .001 
6MWT, m 465.2  ± 97 477.4  ± 92 .01 
6MWT Borg fatigue score 4.4  ± 2.3 4.8  ± 2.0 .38 
6MWT Borg dyspnea score 5.4  ± 2.8 5.3  ± 2.1 .89 
MIP, cm H 2 O 97.6  ± 17.5 103.40  ± 20.1 .01 
MIP, % of predicted 102.95  ± 17.9 109.45  ± 22.3 .01 
Soluble biomarkers    
 Hemoglobin, mmol/L 8.1  ± 1.3 7.9  ± 1.3 .06 
 RDW, % 15.2  ± 2.9 14.9  ± 2.2 .36 
 Uric acid, mmol/L 0.3  ± 0.1 0.3  ± 0.1 .78 
 Iron, micromol/L 15.2  ± 2.8 14.9  ± 2.2 .36 
 Cystatin C, mg/L 1.2  ± 0.5 1.2  ± 0.3 .98 
 CRP, mg/L 6.1  ± 7.2 5.2  ± 6.7 .43 
 Hs-TnT, ng/L 11.2  ± 9.5 12.1  ± 11.0 .46 
 NT-pro BNP, pmol/L 86.8  ± 173.8 88.7  ± 155.4 .87 
 Abbreviations: CET, cycling endurance time; CRP, C-reactive protein; Hs-TnT, high sensitive troponin-T; MIP, maximal inspiratory pressure; NT-pro BNP, N-terminal pro B-type natriuretic 
peptide; RDW, red cell distribution width; 6MWT, 6-min walk test. 
 a Data are given as mean  ± standard deviation. 6MWT Borg score values were end-of-test scores. 
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10 wk of PR, maximal inspira ry mouth pressure increased 
signifi cantly compared with baseline ( Table 2 ). 
 Soluble biomarker levels were measured in all study sub-
jects at baseline and after the PR program. However, no 
signifi cant changes were seen in the soluble biomarker pro-
fi les ( Table 2 ). 
 DISCUSSION 
 In this study, we demonstrated that our multidisciplinary 
outpatient PR program is safe for PH patients, since no 
adverse events occurred during the 10-wk training period. 
Moreover, there was a positive effect on primary outcome 
parameters, including exercise capacity and endurance mea-
sured by the CET, as well as QOL in 2 of 3 scales measured 
by the CAMPHOR questionnaire. In addition, all second-
ary outcome measures improved, including 6MWD, respi-
ratory muscle strength, and skeletal muscle strength. 
 While several studies have shown effectiveness of PR in 
an inpatient setting, 18 , 19 , 35 our study also shows benefi cial 
effects for PR in an exclusively outpatient setting. The most 
benefi cial effect was found in functional endurance mea-
sured by bicycle endurance (increase in the CET of 288 sec). 
This result can be considered as a clinical meaningful effect 
since in a study by Laviolette et al 36 in patients with chron-
ic obstructive pulmonary disease (COPD), a difference of 
100 to 200 sec in the CET was regarded as a clinical sig-
nifi cant result. A signifi cant, however, small increase in the 
6MWD was demonstrated as well. This relatively limited 
effect compared with the larger effect shown in other re-
habilitation studies 18 , 22 could be due to a “ceiling” effect in 
the 6MWT as shown by Frost et al. 37 The mean 6MWD at 
baseline in our cohort was 465 m. Since all other outcome 
parameters (CET, skeletal muscle function, QOL) changed 
signifi cantly with a larger improvement and considering the 
fi ndings by Frost et al, we assume that a ceiling effect in 
the 6MWT is a more logical explanation of our data than 
different exercise volumes. 
 Since assessment of daily activity may be more clinically 
meaningful to a patient than the 6MWD, 38 accelerometry 
may be an even better indicator of physical activity in dai-
ly life. 39 Therefore, accelerometry could be considered for 
all PR programs as an instrument for quantifying physical 
activity. 
 Consistent with other PR programs, 19 , 21 , 35 we observed no 
changes in soluble biomarker levels before and after the PR 
program. A small decrease in RV systolic pressure has been 
seen in just a few, but not all, studies. More studies investi-
gating the effects of exercise training on pulmonary vascular 
remodeling, RV function, and RV remodeling are needed, 
as well as studies assessing possible underlying mechanisms. 
 QOL, as measured by the CAMPHOR questionnaire, 
also improved signifi cantly in our study group for the 
categories “symptoms” and “quality of life.” The “activi-
ty” category, however, did not show a signifi cant change. 
Individual patient evaluations on the contrary showed an 
increased capacity for activity. This observed difference by 
the CAMPHOR questionnaire might be due to a lack of 
discriminative power in a relatively small patient group. 
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Figure 1. Change in CET for individual patients at baseline and after a 10-wk outpatient pulmonary reha-
bilitation program. CET indicates cycling endurance time.
 Figure 2.  Health-related quality-of-life scores (CAMPHOR) at baseline 
(white bars) and after a 10-wk outpatient pulmonary rehabilitation pro-
gram (black bars). Values are mean  ± standard error of mean. CAM-
PHOR indicates Cambridge Pulmonary Hypertension Outcome Review. 
 Figure 3.  Skeletal muscle function of quadriceps/biceps (dominant and nondominant) at baseline (white bars) and after a 10-wk outpatient pulmonary 
rehabilitation program (black bars). Values are shown as mean percentage of predicted  ± standard error of mean . [AQ07]
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 In a PR study by Chan and colleagues, 40 the “function-
ing” category from the CAMPHOR questionnaire did not 
show a signifi cant improvement either. This study group, 
however, was even smaller. 
 At the end of this PR program, all patients received a 
personalized training program to continue physical training 
under supervision of a fi rst-li e physiotherapist to enhance 
the duration of the benefi cial effect. Future studies are need-
ed to evaluate the duration and clinical implications of our 
PR program. 
 Our study, however, also has several limitations. First, 
the study group consisted of PAH patients WHO class 1 
with different underlying causes and WHO class 4 CTEPH 
patients. 
 Analysis of the data of solely PAH/WHO group I showed 
similar results. The study unfortunately lacks power to 
draw conclusions for specifi c PAH subgroups. Second, only 
NYHA class III patients were included, which was not our 
initial intention. However, NYHA class III patients are un-
doubtedly clinically impaired in their functioning in daily 
life, more so than NYHA class I and II patients. They might 
therefore be more motivated to participate in an extensive 
PR program. Moreover, NYHA class III patients are still 
able to participate in an intensive outpatient PR program, 
which might not be possible in the case of NYHA class 
IV patients. This possible explanation was also shown by 
Hayton et al 41 in a study where COPD patients showed de-
creased PR attendance when either their disease was too 
mild or COPD too severe to benefi t from PR. 
 Finally, in an article by Spruit and colleagues, 25 training 
3 times/wk was regarded to be even more effective. Howev-
er, our aim was to maximize training effi ciency and to mini-
mize the impact of the PR program on daily life activities of 
the participating PH patients. 
 CONCLUSION 
 This study demonstrates that a 10-wk multidisciplinary PR 
program has considerable benefi cial effects on functional 
capacity, functional endurance, skeletal muscle function, 
and health-related QOL. While many studies have shown 
effectiveness for inpatient rehabilitation programs for PH 
patients, our study demonstrated that an exclusively out-
patient PR program for PH patients is effective and safe. 
Long-term durability of these improvements and implica-
tions must be further evaluated in future studies. 
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Figure 2. Health-related quality-of-life scores (CAMPHOR) at baseline (white bars) and after a 10-wk outpa-
tient pulmonary rehabilitation program (black bars). Values are mean ± standard error of mean. CAMPHOR






After 10 wk of PR, the 6MWD increased by 3% (12.2 ±20.4 m; Table 2 ). After PR therapy, 
mean muscle function of the dominant quadriceps side increased by 78 N (+ 23%). In 
the nondominant quadriceps, mean muscle function increased by 62 N (+ 18%) after 
PR therapy (Figure 3A ). Similarly, biceps dominant muscle function increased by 11 N 
( + 6%) after PR therapy. In the nondominant biceps, muscle function increased by 16 
N (+ 9%) after PR therapy (Figure 3B). Changes in the percentage of predicted values of 
the muscle function tests are shown in Figure 3. After10 wk of PR, maximal inspiratory 
mouth pressure increased significantly compared with baseline (Table 2).
Soluble biomarker levels were measured in all study subjects at baseline and after the PR 
program. However, no significant changes were seen in the soluble biomarker profiles 
(Table 2).






CET, min 4.8 ± 2.1 9.2 ± 5.5 <.001
6MWT, m 465.2 ± 97 477.4 ± 92 .01
6MWT Borg fatigue score 4.4 ± 2.3 4.8 ± 2.0 .38
6MWT Borg dyspnea score 5.4 ± 2.8 5.3 ± 2.1 .89
MIP, cm H2O 97.6 ± 17.5 103.40 ± 20.1 .01
MIP, % of predicted 102.95 ± 17.9 109.45 ± 22.3 .01
Soluble biomarkers
 Hemoglobin, mmol/L 8.1 ± 1.3 7.9 ± 1.3 .06
 RDW, % 15.2 ± 2.9 14.9 ± 2.2 .36
 Uric acid, mmol/L 0.3 ± 0.1 0.3 ± 0.1 .78
 Iron, micromol/L 15.2 ± 2.8 14.9 ± 2.2 .36
 Cystatin C, mg/L 1.2 ± 0.5 1.2 ± 0.3 .98
 CRP, mg/L 6.1 ± 7.2 5.2 ± 6.7 .43
 Hs-TnT, ng/L 11.2 ± 9.5 12.1 ± 11.0 .46
 NT-pro BNP, pmol/L 86.8 ± 173.8 88.7 ± 155.4 .87
Abbreviations: CET, cycling endurance time; CRP, C-reactive protein; Hs-TnT, high sensitive troponin-T; MIP, 
maximal inspiratory pressure; NT-pro BNP, N-terminal pro B-type natriuretic peptide; RDW, red cell distribu-
tion width; 6MWT, 6-min walk test.







In this study we demonstrated that our multidisciplinary outpatient PR program is safe 
for PH patients, since no adverse events occurred during the 10-wk training period. 
Moreover, there was a positive effect on primary outcome parameters, including exer-
cise capacity and endurance measured by the CET, as well as QOL in 2 out of 3 scales 
measured by the CAMPHOR questionnaire. In addition, all secondary outcome measures 
improved, including 6MWD, respiratory muscle strength and skeletal muscle strength.
While several studies have shown effectiveness of PR in an inpatient setting,18,19,35 our 
study also shows beneficial effects for PR in an exclusively outpatient setting. The most 
beneficial effect was found in functional endurance measured by bicycle endurance 
(increase in the CET of 288 seconds). This result can be considered as a clinical mean-
ingful effect since in a study by Laviolette et al.36 in patients with chronic obstructive 
pulmonary disease (COPD), a difference of 100 to 200 sec in the CET was regarded as a 
clinical significant result. A significant, however small increase in the 6MWD was dem-
onstrated as well. This relatively limited effect compared with the larger effect shown in 
 Figure 2.  Health-related quality-of-life scores (CAMPHOR) at baseline 
(white bars) and after a 10-wk outpatient pulmonary rehabilitation pro-
gram (black bars). Values are mean  ± standard error of mean. CAM-
PHOR indicates Cambridge Pulmonary Hypertension Outcome Review. 
 Figure 3.  Skeletal muscle function of quadriceps/biceps (dominant and nondominant) at baseline (white bars) and after a 10-wk outpatient pulmonary 
rehabilitation program (black bars). Values are shown as mean percentage of predicted  ± standard error of mean . [AQ07]
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 In a PR study by Chan and colleagues, 40 the “function-
ing” category from the CAMPHOR questionnaire did not 
show a signifi cant improvement either. This study group, 
however, was even smaller. 
 At the end of this PR program, all patients received a 
personalized training program to continue physical training 
under supervision of a fi rst-line physiotherapist to enhance 
the duration of the benefi cial effect. Future studies are need-
ed to evaluate the duration and clinical implications of our 
PR program. 
 Our study, however, also has several limitations. First, 
the study group consisted of PAH patients WHO class 1 
with different underlying causes and WHO class 4 CTEPH 
patients. 
 Analysis of the data of solely PAH/WHO group I showed 
similar results. The study unfortunately lacks power to 
draw conclusions for specifi c PAH subgroups. Second, only 
NYHA class III patients were included, which was not our 
initial intention. However, NYHA class III patients are un-
doubtedly clinically impaired in their functioning in daily 
life, more so than NYHA class I and II patients. They might 
therefore be more motivated to participate in an extensive 
PR program. Moreover, NYHA class III patients are still 
able to participate in an intensive outpatient PR program, 
which might not be possible in the case of NYHA class 
IV patients. This possible explanation was also shown by 
Hayton et al 41 in a study where COPD patients showed de-
creased PR attendance when either their disease was too 
mild or COPD too severe to benefi t from PR. 
 Finally, in an article by Spruit and colleagues, 25 training 
3 times/wk was regarded to be even more effective. Howev-
er, our aim was to maximize training effi ciency and to mini-
mize the impact of the PR program on daily life activities of 
the participating PH patients. 
 CONCLUSION 
 This study demonstrates that a 10-wk multidisciplinary PR 
program has considerable benefi cial effects on functional 
capacity, functional endurance, skeletal muscle function, 
and health-related QOL. While many studies have shown 
effectiveness for inpatient rehabilitation programs for PH 
patients, our study demonstrated that an exclusively out-
patient PR program for PH patients is effective and safe. 
Long-term durability of these improvements and implica-
tions must be further evaluated in future studies. 
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Figure 3. Skeletal muscle function of quadriceps (A) and biceps (B) (dominant and nondominant) at base-
line (white bars) and after a 10-wk outpatient pulmonary rehabilitation program (black bars). Values are 





other rehabilitation studies,18,22 could be due to a “ceiling” effect in the 6MWT as shown 
by Frost et a.l37 The mean 6MWD at baseline in our cohort was 465 m. Since all other 
outcome parameters (CET, skeletal muscle function, QOL) changed significantly with a 
larger improvement and considering the findings by Frost et al., we assume that a ceil-
ing effect in the 6MWT is a more logical explanation of our data than different exercise 
volumes.
Since assessment of daily activity may be more clinically meaningful to a patient than 
the 6MWD,38 accelerometry may be an even better indicator of physical activity in daily 
life.39 Therefore, accelerometry could be considered for all PR programs as an instrument 
for quantifying physical activity.
Consistent with other PR programs, 19,21,35 we observed no changes in soluble biomarkers 
levels before and after the PR program. A small decrease in RV systolic pressure has been 
seen in just a few, but not all studies. More studies investigating the effects of exercise 
training on pulmonary vascular remodeling, RV function and RV remodeling are needed, 
as well as studies assessing possible underlying mechanisms.
QOL, as measured by the CAMPHOR questionnaire, also improved significantly in our 
study group for the categories “symptoms” and “quality of life”. The “activity” category, 
however, did not show a significant change. Individual patient evaluations on the 
contrary showed an increased capacity for activity. This observed difference by the 
CAMPHOR questionnaire might be due to a lack of discriminative power in a relatively 
small patient group. In a PR study by Chan and colleagues,40 the “functioning” category 
from the CAMPHOR questionnaire did not show a significant improvement either. This 
study group however, was even smaller .
At the end of this PR program, all patients received a personalized training program to 
continue physical training under supervision of a first line physiotherapist to enhance 
the duration of the beneficial effect. Future studies are needed to evaluate the duration 
and clinical implications of our PR program.
Our study however also has several limitations. First, the study group consisted of PAH 
patients WHO class 1 with different underlying causes and WHO class 4, CTEPH patients. 
Analysis of the data of solely the PAH/WHO group I showed similar results. The study 
unfortunately lacks power to draw conclusions for specific PAH sub-groups. Second, 
only NYHA class III patients were included, which was not our initial intention. However, 
NYHA class III patients are undoubtedly clinically impaired in their functioning in daily 






to participate in an extensive PR program. Moreover, NYHA class III patients are still able 
to participate in an intensive outpatient PR program, which might not be possible in the 
case of NYHA class IV patients. This possible explanation was also shown by Hayton et 
al.41 in a study where COPD patients showed decreased PR attendance when either their 
disease was too mild or the COPD too severe to benefit from PR.
Finally, in a paper by Spruit and colleagues,25 training 3 times/wk was regarded to be 
even more effective. However, our aim was to maximize training efficiency and to mini-
mize the impact of the PR program on daily life activities of the participating PH patients.
CONCLUSION
This study demonstrates that a 10-wk multidisciplinary PR program has considerable 
beneficial effects on functional capacity, functional endurance, skeletal muscle function 
and health-related QOL. While many studies have shown effectiveness for inpatient 
rehabilitation programs for PH patients, our study demonstrated that an exclusively 
outpatient PR programme for PH patients is effective and safe. Long-term durability of 
these improvements and implications must be further evaluated in future studies.
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Supplementary Digital Content 1. Patient characteristics; right heart catheterization values at diagnosis.
Characteristic Patients with pulmonary
hypertension (n = 21)
Right heart catheterization (at diagnosis)
 Mean pulmonary artery pressure, mmHg 46.0 ± 15.6
 Right atrial pressure, mmHg 8.4 ± 4.4
 Pulmonary capillary wedge pressure, mmHg 8.7 ± 4.3
Data reported as mean ± standard deviation
Supplementary Digital Content 2. Group training session schedule.
Group training - Session 1 Group training - Session 2
45 min Treadmill walking
Cycling
Fitness training
45 minutes Treadmill walking
Cycling
Fitness training
15 min Rest 15 minutes Rest
60 min Outdoor walking or cycling 60 minutes PH specific education on health
15 min Rest
45 min Treadmill walking
Cycling
Fitness training
45 minutes Treadmill walking
Cycling
Fitness training












Interstitial Lung Diseases (ILDs) and Pulmonary Hypertension (PH) are two entities of 
chronic lung disorders, that are known to decrease survival and that have a negative 
impact on health-related quality of life of patients. Patients suffer from a wide variety of 
symptoms such as dyspnea, fatigue, cough, reduced exercise tolerance and side effects 
of medication, restricting them to live a normal life.1-7
In the research of this thesis we describe: (1) the translation and validation process of 
instruments that measure patient-reported outcomes in patients with ILD and PH, (2) 
the development of patient-recorded outcome measures in ILD and (3) interventions 
that aimed to improve quality of life of ILD and PH patients.
Validation of ILD and PH patient-reported outcome measures (PROMs)
Traditionally disease progression and effect of treatments are assessed by physiological 
outcomes measured in hospital. However, it is increasingly acknowledged that patient-
reported outcomes (PROs) on symptoms and wellbeing should also be examined, in 
order to quantify the impact of the physical constraints to the patients wellbeing.8-11 In 
clinical trial settings, PROs are mandatory nowadays.12 Patient-reported outcome mea-
sures (PROMs) are formal instruments that, if properly validated, are able to measure and 
quantify these subjective values in a reliable manner. Some PROMs asses a single-item 
e.g. a symptom, other PROMs have multiple outcomes with various domain scores and 
a global score on quality of life. As shown in table 1 of the introduction section there are 
various PROMs available in the ILD and PH field.
What PROM is needed?
For use in routine clinical care, the questionnaire should preferably be short, target suf-
ficient relevant aspects of the disease and be able to detect changes in health status in 
the individual patient. A brief questionnaire facilitates the physician to rapidly monitor 
the disease, identify problems and if necessary, respond to this. Often a physician lacks 
time during a routine consult to interview a patient about how the disease impacts 
his/her life; a PROM may improve communication between the patient and physician. 
Despite these advantages, use of PROMs in clinical practice in ILD and PH is scarce and 
could be improved.
For use in clinical trials the questionnaire should be sensitive enough to detect the effect 
of a treatment at group level within the trial duration and identify clinically relevant 
differences between groups with different disease severities. There must be enough 





population.12,13 Furthermore, the minimal clinically important difference (MCID) is pref-
erably known, to understand what minimal change in PROM score is meaningful for the 
patient.14,15 Ideally, a PROM meets all these conditions and could be used both in clinical 
practice as well as for clinical trials.
How do we get the ideal PROM?
Nowadays, there is a wealth of PROMs and new ones are still being developed. To avoid 
dilution of experience and validation, a balance should be sought between developing 
new and better PROMs and using older, extensively validated ones. If a PROM does not 
exist for the area of interest, a new questionnaire could be developed, ideally from the 
start with a group with broad diversity, consisting of patients and experts. Being a very 
timely and costly process, it may be preferable to look for an existing questionnaire and 
for instance translate a foreign suitable questionnaire. However, when the translation 
process is not performed properly, the meaning of a question or answer can easily be 
lost. To be able to compare scores from questionnaires when they are used cross-cultural 
in global clinical trials or in international collaboration projects, it is crucial that the 
meaning of questions (as intended by the original developer) is preserved throughout 
the translation process. 16 Cross-cultural adaptations of the questionnaire may be nec-
essary. The questions and responses of the translated version should be understood 
similarly by the aimed population as by the population of original development, despite 
potential cultural differences. In chapter 2, 3 and 4 of this thesis, we describe the transla-
tion procedures of respectively the King’s Brief Interstitial Lung Disease (K-BILD) ques-
tionnaire, the King’s Sarcoidosis Questionnaire (KSQ) and the Cambridge Pulmonary 
Hypertension Outcome Review (CAMPHOR). To ensure the aforementioned equivalence 
between the original questionnaires and the translated versions of the K-BILD, KSQ and 
CAMPHOR, we followed a rigorous validation process in three phases: (1) a multistep 
translation procedure (2) cognitive debriefing interviews with patients; and (3) psycho-
metric assessment of the PROM in repeated tests, 2 weeks apart, in the targeted patient 
population.17,18 If there is enough evidence that the PROM performs well in different 
languages and settings, only phase 1 and 2 (linguistic validation) may be sufficient. This 
holds also true for PROMs that have been developed in such a way that they can be 
applied globally, despite known cultural differences.19,20 In this case only translation of 
the questionnaire is needed, which may accelerate its global use. Performing phase 3 of 
the translation procedure, each time the PROM is translated, may hinder its use in global 
clinical trials as it is time consuming to repeat the psychometric assessment in at least 
50 persons of the target population.21,22
Psychometric assessment of a translated PROM, may also yield interesting new insights. 







chometric properties were tested.23 Using exploratory factor analysis and item response 
modeling, the authors found that measurement properties of all domains of the KSQ 
improved when 5 items were removed. This is an interesting finding considering that 
a 24-item instead of 29-item questionnaire takes less time to complete and is therefore 
more convenient for clinical care. However, to adapt this questionnaire for one country 
has disadvantages as it will hamper collaboration and comparison internationally, as 
the longer KSQ version has already been translated in 14 languages.23-25 This is why 
often, even though a better version of the initial questionnaire exists, people tend to 
keep working with the original version. A similar situation occurred with the often used 
SGRQ.26 Even though this questionnaire has been shortened and adapted for idiopathic 
pulmonary fibrosis IPF (SGRQ-I)27, in clinical trials the 50-item originally COPD question-
naire remains used as this allows for comparison with previous studies and has been 
accepted by policy makers as the Food and Drug Administration (FDA) and European 
Medicine Agency.28
In PH, no such example exist. The CAMPHOR was the first disease-specific question-
naire (described in chapter 4). Currently the CAMPHOR questionnaire is available in 
at least 23 languages.29-37 However, since the questionnaire is quite lengthy and not 
freely accessible, its use is limited in a clinical setting. Recently two much shorter PH 
specific questionnaires (Pulmonary Arterial Hypertension-Symptoms and Impact -PAH-
SYMPACT®-questionnaire and EmPHasis-10), have been developed.20,38,39 However, they 
still need further validation. Giving its brevity, especially the EmPHasis-10 may be an 
attractive indicative tool to monitor the impact of PH in clinical care. In an ongoing 
prospective study in PAH and CTEPH patients we incorporate both the CAMPHOR and 
the EmPHasis-10 to examine how they correlate with clinical outcome parameters and 
to compare the outcome of both questionnaires.
As illustrated above, even though better and more practical PROMs may be available, 
this will not automatically lead to incorporation of these PROMs in clinical trials and daily 
practice. Therefore, researchers, pharmaceutical companies and policy makers should 
stimulate the use of newer PROMs in trials as the outcomes they measure are important 
for patients. Even when used as an explorative endpoint, these data may contribute to 
their validation and acceptation.
New technologies to measure PROMs
Also new technologies, may facilitate use of PROMs. An innovative way to assess health 
status with the shortest possible PROM, could be Computer Adaptive Testing (CAT). CAT 
is a type of measure which tailors the questions to the individual patient. The questions 





suring the same construct e.g. fatigue. The questions are ranked in order of difficulty. 
With each response, the computer refines a person’s score and determines what the 
next relevant (most informative) question would be. Irrelevant questions are skipped 
allowing that the number of questions is kept to a minimum (4-10 items), without losing 
precision. Until now there is insufficient experience with the application of this CAT in 
ILD or in PH. Also, its use in clinical trials outside ILD and PH has been limited.40-42
Another way of implementing digital technologies is to administer electronic PROMs. 
Instead of spending valuable time in clinic on completing questionnaires, patients can 
do this at home, online or in the clinic on a computer or handheld device before the 
consultation. Scores and trends are immediately available, which allows the patient 
and the medical team to use these in the consultation and as guidance for manage-
ment decisions. The big advantage of this system is that it allows patients to see the 
results of the PROs, whereas in paper version, these questionnaires are often handed 
in and patients have little insights in their own scores. In the research presented in this 
thesis we describe a pilot study to the feasibility of a home monitoring program in IPF 
patients, which also incorporated PROs collection by the patient at home. The data were 
transmitted real-time to a secured platform, making data immediately accessible for 
the patient and the physician. This allowed the medical team to monitor the patient at 
a distance. For instance, if bothersome symptoms or side-effects of medical treatment 
were reported, the medical team automatically received a notice and could contact the 
patient via the digital tool or by phone. It also allowed patients to self-evaluate the effect 
of changes in management. Patients were very satisfied with the program, felt more in 
control of their disease and wished to continue home monitoring after the pilot study 
stopped. With increasing digitalization, we have to adapt to these developments as 
healthcare providers. Currently, there are many initiatives and apps, but only very little 
research about their effect on patient wellbeing, medical outcomes and implication for 
healthcare consumption, and economical burden. This will need research about the 
optimal use of digital platforms and preferably randomized controlled trials.
Development of patient-recorded outcome measures.
In addition to home monitoring of PROs, also home recording of spirometry and other 
physiological parameters, has the potential to improve medical care and research. In 
patients with IPF, real-time home recordings of FVC, allows for monitoring of disease 
progression and identification of patients with fast deterioration, as shown by Russell et 
al.43 Potentially, it could also play a role in the early detection of acute exacerbations . In 
patients with IPF, this is currently investigated in a national trial in Germany, using the 







Home spirometry to evaluate effects of treatment
In chapter 5 we describe the use of daily home spirometry, to monitor time needed 
for optimal treatment response in patients with sarcoidosis. Daily FVC recordings, 
performed by newly treated patients with sarcoidosis, demonstrated that the greatest 
improvement in FVC occurred within 2-3 weeks after starting steroid treatment. This 
would have been missed with the standard frequency hospital measurements (every 
3-6 months). As prolonged high-dose steroid therapy is associated with negative side-
effects, this finding is important suggesting that physicians could start earlier with dose 
tapering. Future research in patients with sarcoidosis is needed to evaluate if personal-
ized dose titration based on home recorded FVCs and PROMs will lead to a reduction of 
side-effects and improvement of quality of life.
Home monitoring; additional benefits
In chapter 6 we describe the development of a daily home monitoring program with 
real-time wireless spirometry. Though experience with home-based spirometry in ILD 
is currently limited to IPF and sarcoidosis, we have expanded clinical use and research 
to the broader population of patients with ILD. Whether home monitoring of FVC and 
PROs improve quality of life (measured with the K-BILD questionnaire) is currently being 
investigated in a national randomized controlled trial (NCT03420235).
For use in clinical trials, home monitoring of FVC holds additional benefits. Johannson 
et al. have modelled that weekly recording of FVC compared to 6-monthly hospital 
spirometry, importantly reduces the required sample size necessary to demonstrate an 
effect of potential new IPF therapies in clinical trials.44 In our research project to the 
feasibility of a home monitoring program in IPF patients, the median variation coef-
ficient of daily FVC recordings was 3.76%, comparable to the findings of Russell et al. 
who reported 4.96% and better than the 8% variability found by Johannsen in weekly 
recordings.43,45 It remains to be examined if asking the patient to conduct spirometry 
with a lower frequency (e.g. once a week), but then blowing three FVC maneuvers and 
selecting the best measurement, will improve accuracy. Currently home monitoring is 
used in an international observational study to better understand disease behavior in 
patients with a suspected diagnosis of IPF/ILD (NCT03261037). This includes real-time 
recording of FVC and of physical functional capacity through accelerometry. If having 
data on disease behavior during the diagnostic trajectory will facilitate diagnosis, is still 
subject of investigation.
Stimulating uniformity
Another important measure of pulmonary physiology is the transfer factor of the lung 





clinical trials. To manage this variabity and to ensure reliable, useable and reproduc-
ible results, standardization of TLCO and FVC measurements is very important and the 
guidelines on calibration of the equipment and test performance should be followed. 
46,47 TLCO is mostly reduced in IPF patients.48 Often IPF clinical trials use the TLCO as one 
of the inclusion criteria. The lower limit for inclusion varies, but is often 30% of the pre-
dicted value. For calculation of the predicted values , new reference values have been 
developed and published in 2017.49 However, these new Global Lung function Initiative 
(GLI) reference values have not yet been adopted by all lung function laboratories which 
causes interlaboratory variability in trial eligibility.
In chapter 7 we describe how switching to the new GLI reference values may affect the 
number of patients eligible for clinical trials. Especially for severly diseased patients with 
a TLCO near the lower limit, using GLI reference equations may have positive implica-
tions, enabling them to participate in trials. Hopefully our research encourages lung 
function laboratories to adopt the GLI TLCO reference values as soon as possible, and 
sponsors to incorporate them in their study protocol.
Interventions aimed at improving quality of life for patients
The first parts of this thesis describe methods to measure outcomes, however, in the 
end the aim is to improve care and treatments for patients. The third part of this thesis 
describes two intervention studies that aimed to improve the quality of life of IPF and 
PAH/CTEPH patients. Although new pharmacological treatments have been developed 
in the last years, most patients with IPF and PAH/CTEPH still suffer from a progressively 
impaired QOL, limited exercise capacity, and high symptom burden, while their survival 
is still decreased. Therefore, it is important to search for opportunities other than phar-
macological treatment to improve exercise capacity and QOL.
ILD and PH guidelines recommend pulmonary rehabilitation programs as add-on therapy 
to pharmacological treatment.50-52 Reviews have demonstrated that PR programs have 
beneficial effects on exercise capacity, mostly measured with the 6MWD, and health-
related QOL.53-55 However, a major challenge is to maintain these beneficial effects by 
continuing the exercise regime after the program stops. Furthermore, following a PR 
program in an outpatient specialized rehabilitation center with 2-3 visits a week, or to 
stay in clinic away from family, often imposes a high burden to the patients.
Feasibility and efficacy of a home-based training program for IPF patients
To overcome the aforementioned hurdles, we wanted to offer a home-based training 
program with a new training modality, the walk-bike, that if well implemented in daily 







describe a cross over pilot study to the efficacy of a home-based training program in 
IPF patients on QOL and exercise capacity, using this walk-bike. The results showed 
a tendency toward improvement in QOL as measured by SGRQ and K-BILD, and no 
improvement in the 6MWD. We learned that the study design was not ideal for this 
vulnerable patient group. On one hand, patients with reasonably preserved exercise 
capacity didn’t want to participate, while on the other hand, patients with much more 
impaired exercise capacity were too dyspneic to participate or dropped out during the 
study due to disease progression or complications of disease. Another problem with 
inclusion of patients was their fear of being stigmatized. A walk-bike makes the disease 
visible for their surroundings. This is a similar sentiment that has been described by 
patients when facing the decision to start ambulatory oxygen.56 This resulted in a study 
that unfortunately failed, but despite this, we learned that for some individual patients 
the walk-bike contributed to a better quality of life due to a an increased mobility and 
feeling of independency. This emphasizes the importance of personalized care, but also 
the difficulties faced when studying supportive measures for patients with an end-stage 
progressive deadly disease.
Effectiveness of a multidisciplinary outpatient program
In chapter 9 we examined the effects of a multidisciplinary PR program in an entirely 
outpatient setting in PAH/CTEPH patients. After 10 weeks of PR with 2 group training 
sessions per week in a specialized rehabilitation center, significant improvements were 
achieved in exercise capacity (measured by means of cycling endurance time -CET- and 
6MWD), peripheral and respiratory muscle strength, CAMPHOR QOL and symptoms. The 
most beneficial effect was found in functional endurance measured by CET (increase 
of 4.8 minutes or 288 seconds). This result can be considered as a clinical meaningful 
effect since in a study by Laviolette et al. 57 in patients with COPD, a difference of 100-200 
seconds in the CET was regarded as a clinical significant result. Although the improve-
ment in 6MWD was statistically significant, the absolute gain was small compared to 
other studies.54,55 This was most probably caused by a ceiling effect of the 6MWD in the 
patients studied. When patients are already treated with optimized PAH specific drug 
therapy like in our study, the 6MWD may be less able to detect meaningful clinical im-
provements.55,58 Our patient group had, on average, a higher baseline 6MWD compared 
to patients in studies that demonstrated a larger effect in 6MWD. Although the 6MWD 
is currently often used as primary endpoint in PAH clinical trials, one should consider its 
limitations. Recording of daytime activity may be a more reliable and clinically valuable 
tool to assess the effects of a PR program. As demonstrated by Ulrich et al. a reduced 
daytime activity is associated with reduced survival and with severe hemodynamics.59 
Moreover, adoption of a sedentary life by PAH patients as a consequence of not being 





study of our rehabilitation program we included measurement of daily activities by 
means of a move monitor, before and at the end of the PR program.
Improvement of QOL as measured in our study is also the result of the multidisciplinary 
approach of our PR program, including psychological counseling as well as contact with 
peers (reviews of patients, unpublished data). Future studies should be initiated on how 
to maintain daily life activities and QOL after the end of PR program. At this moment we 
advise patients to continue physical training under supervision of a physiotherapist. We 
plan to add an evaluation of daily life activities and QOL six months and one year after 
the end of the PR program.
In conclusion, improving daily life performance and QOL should be ultimate goals of 
add-on therapies like PR programs.
coNcLusioN
The past years, substantial progress has been made in acknowledging the importance 
of patient perspectives, by incorporating the patient’s voice to assess treatment effects 
both in standard care as well as in research. This has taught us important lessons, but 
visualized the challenges of development, validation and implementation of PROMS 
and also the need of new PROMs. With increasing patient participation in research as 
well as in shared decision making in daily practice, we will be forced to further advance 
the field of patient-reported outcomes.61 The importance to not only focus on prolong-
ing survival (or its surrogate endpoint), but also putting emphasis on QOL for patients, 
will enhance our insights in treatments effects from the patient’s perspective and will 
support shared decision making in choosing the best available treatment. Expanding 
digital solutions, new collaborations with different stakeholders (patients, researchers, 
pharmaceutical companies and others) and daring to incorporate new developments, 
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Interstitial Lung Diseases (ILDs) and Pulmonary Hypertension (PH) are umbrella terms to 
describe two groups of chronic and debilitating lung disorders.
Interstitial lung diseases (ILDs) comprise more than 200 different disorders, character-
ized by interstitial inflammation, cellular proliferation, fibrosis or a combination of these 
processes, which damage the lungs. Some ILDs are reversible whereas others show a 
progressive scarring of lung tissue with rapid decline of lung function and ultimately 
death. Two of the most common ILDs are Idiopathic pulmonary fibrosis (IPF) and sar-
coidosis.
IPF is a fatal lung disease of unknown etiology, characterized by an irreversible decline 
of lung volume and gas exchange. Although the clinical course of IPF varies, overall 
prognosis is poor with a median survival of 2-4 year after diagnosis, if patients are not 
being treated. At this moment there is no curative treatment for IPF. Two antifibrotic 
drugs (nintedanib and pirfenidon) which have been demonstrated to slow down dis-
ease progression are currently used as standard medical care. When treatment fails, lung 
transplantation is the only option left, when patients are eligible. The main symptoms 
patients with IPF suffer from are breathlessness, chronic cough, fatigue, anxiety and 
depression, which often severely impair their quality of life (QOL).
Sarcoidosis is a chronic systemic inflammatory disease of unknown cause, characterized 
by formation of granulomas. Although sarcoidosis can affect any organ, particularly the 
lungs, eyes, skin, liver and lymphatic system are involved. Depending on the organs 
involved, patients suffer from symptoms such as dyspnea, cough, fatigue, muscle pain, 
weakness, fever, and lack of appetite having a negative impact on their (QOL). The 
majority of patients recovers from sarcoidosis spontaneously. However, a significant 
minority of the patients develops progressive or chronic disease.
PH is a pathophysiological disorder, characterized by narrowing of the pulmonary ves-
sels, leading to elevated pressures in the pulmonary circulation and in the right ventricle. 
This will lead to progressive right ventricle dysfunction, resulting in right heart failure 
and ultimately death. Patients with PH experience symptoms as breathlessness, fatigue, 
chest pain, dizziness, and syncope. These symptoms start occurring on exertion and 
will eventually also occur at rest. PH is categorized in five groups. The studies described 
in this thesis focuses on two categories: Pulmonary Arterial Hypertension (PAH) and 





PAH is a rare and incurable condition of the pulmonary vasculature, characterized by 
endothelial dysfunction, muscularization of the small arteries and thickening of the 
adventitia. These processes lead to an elevated pulmonary vascular resistance (PVR) and 
increased pulmonary arterial pressures (PAP), which will ultimately lead to progressive 
right ventricular failure. Despite improvements in medical treatment of PAH in the last 2 
decades, patients still have a poor prognosis and an impaired health-related QOL due to 
physical, emotional and social problems (5-years survival approx. 70%).
CTEPH is caused by thromboembolic obstruction of the pulmonary arteries and arteri-
opathy, which increases the PVR and the PAP. Some CTEPH patients can effectively be 
cured by a surgical intervention (pulmonary endarterectomy) or balloon angioplasty. 
For inoperable CTEPH patients, or patients with rest PAH after surgery, specific PAH 
medication is a therapeutic option.
Traditionally disease progression and effect of treatments in ILDs and PH are assessed 
by physiological outcomes measured in hospital, such as lung function and six-minute 
walk test. However, in both disease areas there is an increasing awareness of the impor-
tance to include patient-centered outcomes such as symptoms and quality of life, when 
assessing effects of treatment and other interventions. Patients can play a central role 
in collecting these outcome measures, by using patient-reported outcome measures 
(PROMs) and patient-recorded outcome measures. There is a paucity of patient-centered 
outcome measures and interventions aimed at improving QOL, both for patients with 
ILD and PH. The research described in this thesis aimed to translate and validate PROMs 
for ILDs and PH for Dutch patients (part 1), develop patient-recorded outcome measures 
(part 2) and interventions aimed at improving QOL for patients (part 3).
Part 1: Validation of patient-reported outcomes in patients with ILD and PH
In chapter 2 we present the translation and validation of the King’s Brief Interstitial 
Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch. No disease-
specific instruments existed in Dutch, French, Italian, and Swedish to measure health 
status in idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). 
The K-BILD questionnaire is a 15-item validated questionnaire assessing health status 
in patients with ILD and was originally developed in the United Kingdom (2012). The 
aim of this study was to translate and validate this PROM to make it available for clinical 
trials and clinical care in France, Italy, Sweden and the Netherlands. The French, Italian, 
Swedish, and Dutch versions of the K-BILD questionnaire demonstrated excellent valid-







Chapter 3 describes the translation and validation of the King’s Sarcoidosis Question-
naire (KSQ) into Dutch. The KSQ is a brief questionnaire assessing health status using 
five modules (General Health Status, Lung, Medication, Skin, Eyes) in patients with 
sarcoidosis. The KSQ originates from the UK and was developed in 2012, it contains 29 
items and is adaptable to in dividual organ involvement. The aim of this study was to 
validate the KSQ in a Dutch sarcoidosis population. The Dutch translation showed to be 
a valid and reliable PROM to measure health status in Dutch patients with sarcoidosis.
In chapter 4 we translated and validated The Cambridge Pulmonary Hypertension Out-
come Review (CAMPHOR) into Dutch. The CAMPHOR is the first disease-specific instru-
ments for pulmonary arterial hypertension (PAH) to assess patient-perceived symptoms, 
activity limitations and quality of life. It has been developed in the UK. To be able to use 
this questionnaire in the Netherlands, the aim of the study was to translate and validate 
this instrument for the Dutch-speaking population. The Dutch version of the CAMPHOR 
showed to be a reliable and valid instrument to measure quality of life and health status 
in patients with PAH and CTEPH.
Part 2: Development of patient-recorded outcome measures
In chapter 5 we evaluated early steroid treatment effects in newly treated pulmonary 
sarcoidosis patients using daily patient-recordings of home spirometry. Optimization 
of first-line prednisone therapy for sarcoidosis is urgently needed, since side effects of 
steroid treatment can be severe and long-term benefits are debated. Prospective data 
on the early response of prednisone treatment was still lacking. The aim of the study 
was to evaluate the early lung function response to prednisone treatment and taper-
ing, using daily home spirometry. The results showed that in newly treated sarcoidosis 
patients, the greatest effect on Forced Vital Capacity, fatigue and dyspnea symptoms oc-
curs within 2–3 weeks after initiation of prednisone therapy. These results suggest that 
frequent home monitoring of FVC and symptoms has the potential to help individualize 
prednisone therapy in pulmonary sarcoidosis patients, aiming at early dose tapering, 
resulting in side effect reduction and improvement of quality of life.
Chapter 6 presents our pilot study to evaluate feasibility, experiences and barriers of 
a home monitoring program including real-time wireless home spirometry in IPF pa-
tients. Patients with IPF often experience symptoms such as progressive dyspnea and 
immobility, making regular hospital visits a challenge. New eHealth technologies hold 
great potential for research and care by facilitating real-time, frequent data collection 
from home. Home monitoring experiences in IPF patients are limited, not yet real-time 
available nor implemented in daily care. The results showed that a home monitoring 





by patients with IPF. It enables real-time detection of change in FVC and PROs, and in 
this way could facilitate personalized care. Both patients and researchers suggested 
relatively easy solutions for the identified potential barriers regarding real-time home 
monitoring in IPF, which were used to further optimize the system.
In chapter 7 we assessed the impact of adopting new TLCO reference values on clinical 
trial eligibility for IPF patients. IPF patients are often keen to participate in clinical trials 
that may give them the opportunity to improve their disease outcome. Inclusion criteria 
for these trials include a threshold for the diffusing capacity of the lung for carbon 
monoxide in percentage of the predicted value (TLCO %predicted). Screen failures are 
frequently based on TLCO % predicted below the lower limits permitted in the study. 
In 2017 the Global Lung Function Initiative (GLI) established new reference values for 
the TLCO. Many lung function laboratories still use older reference values. Our study 
aimed to assess the impact of the new TLCO reference values on inclusion in medication 
trials for IPF patients. Our results show that switching to the new GLI TLCO reference 
equations may have a small positive effect on trial inclusion for IPF patients. Physicians 
should be aware that the choice of a reference set can make a difference in trial inclusion 
for the individual patient. Urgent adoption of the globally derived and applicable GLI 
reference set is needed to reduce variability in trial eligibility between laboratories.
Part 3: Interventions aimed at improving quality of life in ILD and PH patients.
Chapter 8 describes a pilot study to explore feasibility and effects of a walk-bike in 
IPF patients. Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of 
pulmonary function and exercise capacity, leading to loss of quality of life and often 
social isolation. A new walking aid, the walk-bike, showed an improvement in exercise 
performance in COPD patients. Aims of this pilot study were to evaluate the feasibility 
of a homebased walk-bike intervention study in IPF patients and to explore the effect of 
the walk-bike on quality of life and exercise capacity.
The study revealed several hurdles and it was concluded that a larger study on walk-
bike training-effects in IPF patients does not seem feasible. Patient experience and 
satisfaction with the bike greatly varied, which seems to limit its use to a small minor-
ity of patients. The walk-bike improved action radius and showed a tendency towards 
improvement in QoL. No effect on exercise capacity was observed.
In chapter 9 we evaluated the effects of a 10-week multidisciplinary pulmonary rehabili-
tation program in PH patients. Pulmonary arterial hypertension (PAH) is characterized 
by increased pulmonary vascular resistance andright ventricular impairment , leading 







treatment with PAH-specific drugs, guidelines recommend pulmonary rehabilitation 
(PR). Clinical PR programs have shown improvement in functional capacity and qual-
ity life. However, little is known about the safety and the effectiveness of an entirely 
outpatient PR program. The aim of our study was to assess safety and effectiveness of 
a multidisciplinary outpatient PR program. This study demonstrated that a 10-wk mul-
tidisciplinary outpatient PR program is safe and has considerable beneficial effects on 
functional capacity, functional endurance, skeletal muscle function, and health-related 









Interstitiële longziekten (ILD) en pulmonale hypertensie (PH) zijn verzamelnamen om 
twee groepen van patiënten te beschrijven met zeldzame, meestal chronische longaan-
doeningen.
ILDs worden gekenmerkt door aantasting van het interstitium (de ruimte tussen long-
bloedvaten en longblaasjes), door ontsteking, littekenweefselvorming (fibrose), of een 
combinatie daarvan. Hierdoor neemt vaak zowel de longcapaciteit als de zuurstofop-
name af. Er zijn meer dan 200 verschillende interstitiële longaandoeningen waarvan 
sommige omkeerbaar zijn, terwijl andere een progressieve littekenvorming van het 
longweefsel laten zien met een snelle afname van de longfunctie en uiteindelijk over-
lijden. De onderzoeken in dit proefschrift richten zich op de twee meest voorkomende 
ILDs: idiopathische pulmonale fibrose (IPF) en sarcoïdose.
IPF is een fatale longziekte van onbekende oorzaak met een progressieve verlitteke-
ning van de longen (fibrose ), met als gevolg achteruitgang van het longvolume en 
toenemende kortademigheid. Hoewel het klinische verloop van IPF varieert, is de alge-
hele prognose slecht met een mediane overleving van 2-4 jaar na de diagnose, zonder 
behandeling. Op dit moment is er geen remedie voor IPF, behalve longtransplantatie. 
Twee anti-fibrotische geneesmiddelen (nintedanib en pirfenidone) die de progressie 
van de ziekte vertragen, zijn momenteel samen met ondersteunende maatregelen, de 
zorgstandaard.
Sarcoïdose is een chronische systeem ziekte van onbekende oorzaak, die gekenmerkt 
wordt door de vorming van granulomen; kleine opeenhopingen van ontstekingscellen. 
Hoewel deze ziekte elk orgaan kan treffen, komt sarcoïdose het meest voor in de longen, 
de ogen, de huid, de lever en het lymfesysteem. De klachten die patiënten ervaren zijn 
afhankelijk van welke organen betrokken zijn, maar kunnen ook aspecifiek zijn, zoals 
bijvoorbeeld moeheid. De meerderheid van de patiënten herstelt spontaan van sarco-
idose, maar bij een significante minderheid wordt de ziekte chronisch en progressief.
Pulmonale hypertensie is een longaandoening waarbij door een vernauwing van de 
longvaten een hoge bloeddruk ontstaat in de longcirculatie. Omdat de rechter harthelft 
steeds harder moet werken om het bloed door de vernauwde longvaten te pompen, 
wordt de spierwand van het hart dikker en de rechter hartkamer groter. Op den duur 
werkt de pompfunctie van het hart onvoldoende en gaat de rechter hartkamer falen. 
Doordat de longen onvoldoende zuurstof op kunnen nemen, krijgen patiënten met 





duizeligheid en flauwvallen. Deze symptomen treden meestal op tijdens inspanning, 
wanneer het hart er niet in slaagt het hartminuutvolume te verhogen.
Oorzaken van pulmonale hypertensie zijn vaak onderliggende aandoeningen zoals 
longziekten en aandoeningen van de linker hartkamer. De Wereldgezondheidsorganisa-
tie (WHO) heeft PH ingedeeld in vijf groepen. Dit proefschrift richt zich op twee daarvan, 
namelijk pulmonale arteriële hypertensie (PAH) en chronische trombo-embolische 
pulmonale hypertensie (CTEPH).
PAH is een zeldzame ongeneeslijke vorm. De vernauwing in de longvaten ontstaat door 
een ziekteproces van de binnenlaag van bloedvaatwand, waaronder beschadiging van 
het oppervlak, een toename van spiervezels in de wand en verdikking van de buitenlaag 
van de bloedvaten. De oorzaak hiervan is niet duidelijk, mogelijk speelt erfelijkheid in 
een aantal gevallen een rol.
Verder is bekend dat bij een aantal auto-immuunziekten PAH vaker optreedt , zoals ook 
bij patienten met bepaalde aangeboren hartafwijkingen. Ondanks verbeteringen in de 
medische behandeling van pulmonale arteriële hypertensie in de laatste twee decen-
nia, hebben deze patiënten met PAH een slechte prognose en een verlaagde kwaliteit 
van leven ten gevolge van fysieke, emotionele en sociale problemen.
CTEPH wordt veroorzaakt door obstructie van longslagaders door het optreden van 
chronische bloedstolsels (longembolieën). Zestig procent van deze patiënten kan te-
genwoordig worden behandeld middels een operatie. Een gedeelte van de patiënten 
kan worden geholpen met een dotter procedure of medicamenteuze therapie.
Traditioneel wordt de ziekteprogressie en de effectiviteit van een behandeling bij 
ILD en PH patiënten beoordeeld aan de hand van fysiologische uitkomstmaten, zoals 
longfunctietesten en de 6-minuten wandeltest. Deze onderzoeken worden uitgevoerd 
in het ziekenhuis. Echter, er is steeds meer erkenning dat uitkomstmaten vanuit patiën-
tperspectief, zoals symptomen en kwaliteit van leven, belangrijk zijn en daarom beter 
moeten worden onderzocht. Patiënten kunnen een centrale rol vervullen bij het verza-
melen van deze gegevens door gebruik te maken van door de patiënt gerapporteerde 
uitkomstmaten (PROMs) en door de patiënt zelf gemeten uitkomstmaten. PROMs zijn 
formele meetinstrumenten (meestal vragenlijsten) die, mits ze goed gevalideerd zijn, 
in staat zijn om subjectieve waarden als symptomen en kwaliteit van leven, op een 







Patiëntgerichte uitkomstmaten én interventies die gericht zijn op het verbeteren van de 
kwaliteit van leven zijn schaars, zowel voor patiënten met ILD als met PH. De onderzoe-
ken beschreven in deel 1 van dit proefschrift zijn gericht op het vertalen en valideren van 
ILD- en PH-specifieke PROMs, om ze beschikbaar te maken voor Nederlandse patiënten. 
In deel 2 van dit proefschrift beschrijven we de ontwikkeling van door de patient zelf 
gemeten uitkomstmaten. Deel 3 van dit proefschrift beschrijft twee interventiestudies 
die gericht zijn op het verbeteren van kwaliteit van leven van ILD- en PH-patiënten.
Deel 1: Validatie van PROMs voor patiënten met ILD en PH
Hoofdstuk 2 In Nederland, Frankrijk , Italië en Zweden was geen PROM beschikbaar 
waarmee de gezondheidstoestand van patiënten met ILD (inclusief IPF) gemeten kon 
worden. In 2012 werd in het Verenigd Koninkrijk de K-BILD vragenlijst ontwikkeld en 
gevalideerd. De K-BILD vragenlijst omvat 15 vragen waarmee de impact van de ziekte op 
drie domeinen (kortademigheid & activiteiten, borstklachten en psychisch) beoordeeld 
kan worden. Het doel van onze studie was deze vragenlijst te vertalen en te valideren 
zodat deze gebruikt kan worden in research en zorg in Nederland, Frankrijk, Italië en 
Zweden. De voor deze landen vertaalde versies van de K-BILD vragenlijst vertoonden 
een uitstekende validiteit, vergelijkbaar met de originele Engelse K-BILD.
In hoofdstuk 3 beschrijven we het vertalings- en validatieproces van de King’s Sarco-
idose Vragenlijst (KSQ), een PROM waarmee de gezondheidstoestand van sarcoïdose 
patiënten gemeten kan worden. In Nederland bestond nog geen ziekte-specifieke vra-
genlijst voor deze patiëntengroep. De KSQ bestaat uit 29 items en 5 modules; Algemene 
gezondheidstoestand, Long, Huid, Ogen en Medicatie. Deze modules kunnen los ge-
bruikt worden of gecombineerd worden, afhankelijk van de individuele orgaanbetrok-
kenheid. We vertaalden en valideerden de KSQ in een Nederlandse sarcoïdose popula-
tie. De Nederlandse versie bleek een valide en betrouwbare PROM te zijn waarmee de 
gezondheidstoestand van Nederlandse patiënten met sarcoïdose gemeten kan worden.
In hoofdstuk 4 presenteren we de vertaling en validering van de Cambridge Pulmonary 
Hypertension Outcome Review (CAMPHOR) in het Nederlands. De in 2006 ontwikkelde 
CAMPHOR is de eerste ziekte-specifieke PROM voor het beoordelen van de door PH 
patiënten waargenomen symptomen, beperkingen in activiteit en kwaliteit van leven. 
Het doel van ons onderzoek was deze PROM voor de Nederlandstalige PAH en CTEPH 
patiënten te vertalen en te valideren. De Nederlandse versie van de CAMPHOR bleek een 
betrouwbare en valide instrument om kwaliteit van leven en de gezondheidstoestand 





Deel 2: Ontwikkeling van door de patiënt gemeten uitkomstmaten.
In hoofdstuk 5 onderzochten we met behulp van thuisspirometrie, hoe snel prednison 
effect heeft op de longfunctie (FVC) en symptomen bij nieuwe behandelde patiënten 
met pulmonale sarcoïdose. Prednison is bij behandeling van pulmonale sarcoïdose het 
geneesmiddel van eerste keuze. Echter, de bijwerkingen van prednison kunnen ernstig 
zijn. We zagen dat in nieuw behandelde sarcoïdose patiënten het grootste deel van de 
verbetering in FVC, vermoeidheid en kortademigheid optreedt binnen 2-3 weken nadat 
de behandeling met prednison is gestart. Deze resultaten suggereren dat het frequent 
thuismonitoren van de FVC en van symptomen, de mogelijkheid biedt bij deze patiën-
tengroep de prednisontherapie te individualiseren, met als doel de dosering eerder af te 
bouwen, bijwerkingen te verminderen en kwaliteit van leven te verbeteren.
Hoofdstuk 6 beschrijft onze pilotstudie naar de haalbaarheid, ervaringen en potentiele 
barrières van een thuismonitoringsprogramma, inclusief real-time draadloze thuisspi-
rometrie bij IPF-patiënten. Patiënten met IPF ervaren vaak symptomen als toenemende 
dyspneu en beperkt inspanningsvermogen, waardoor frequente ziekenhuisbezoeken 
voor de meeste patiënten een grote belasting kunnen zijn. Nieuwe eHealth-technolo-
gieën bieden de mogelijkheid, middels real-time, thuismetingen te doen en frequenter 
gegevens te verzamelen zowel voor zorg als onderzoek, maar ervaringen met eHealth 
bij IPF-patiënten zijn tot nu toe beperkt. Thuisspirometrie bleek betrouwbaar en haal-
baar en werd zeer gewaardeerd door patiënten met IPF. Veranderingen in FVC, symp-
tomen en bijwerkingen worden direct gedetecteerd, waardoor zorg op maat leveren 
gemakkelijker kan worden. Er werden geen grote belemmeringen voor thuismonitoring 
gevonden.
In hoofdstuk 7 onderzochten we de impact van nieuwe longfunctiereferentiewaarden 
op de mogelijkheid voor deelname aan klinische studies voor patiënten met IPF. IPF-
patiënten zijn vaak gemotiveerd om deel te nemen aan klinisch onderzoek dat hen 
een kans biedt hun vooruitzichten te verbeteren. Inclusiecriteria voor deelname aan de 
studie omvatten meestal een drempelwaarde voor het diffunderend vermogen van de 
long voor koolmonoxide, uitgedrukt in percentage van de voorspelde waarde (TLCO 
%voorspeld). Het niet mogen deelnemen aan een studie is vaak gebaseerd op een te 
lage TLCO %voorspeld en is teleurstellend voor patiënten. In 2017 heeft de Global Lung 
Function Initiative (GLI) werkgroep nieuwe referentiewaarden voor de TLCO vastgesteld. 
Veel longfunctielaboratoria gebruiken nog steeds oudere referentiewaarden. Onze 
studie laat zien dat het overschakelen naar de nieuwe GLI TLCO-referentievergelijkingen 
een aanzienlijk positief effect kan hebben voor IPF-patiënten op de mogelijkheid voor 
deelname aan een studie . Dit verschil kan grote gevolgen hebben voor de individuele 







van klinische studies bij het schrijven van het onderzoeksprotocol. Snelle en brede 
implementatie van de nieuwe GLI TLCO-referentiewaarden is nodig om variabiliteit in 
studiedeelname tussen laboratoria te verminderen.
Deel 3: Interventies gericht op het verbeteren van de kwaliteit van leven bij ILD- en PH-
patiënten.
Hoofdstuk 8 beschrijft onze pilotstudie naar de haalbaarheid en effectiviteit van 
training met een loopfiets bij IPF-patienten. IPF wordt gekenmerkt door een progres-
sief verlies van longfunctie en inspanningscapaciteit, leidend tot verlies van kwaliteit 
van leven en vaak sociaal isolement. Een nieuw loophulpmiddel, de loopfiets, liet bij 
COPD-patiënten een verbetering zien in mobiliteit. Het doel van onze pilotstudie was te 
onderzoeken of een interventiestudie met de loopfiets thuis, bij IPF-patiënten haalbaar 
is, en te evalueren wat het effect is van de loopfiets op kwaliteit van leven en inspan-
ningscapaciteit. Onze bevindingen laten zien dat een groter onderzoek naar trainingsef-
fecten van de loopfiets bij IPF-patiënten met het huidige studiedesign niet haalbaar lijkt. 
Ervaringen en tevredenheid van de patiënt met de loopfiets varieerden sterk, wat het 
gebruik ervan lijkt te beperken tot een kleine groep patiënten. Er werd geen effect op de 
inspanningscapaciteit waargenomen, echter de loopfiets verbeterde de actieradius en 
liet aanwijzingen zien voor een verbetering van kwaliteit van leven.
In hoofdstuk 9 onderzochten we de effectiviteit van een poliklinisch en multidiscipli-
naire longrevalidatieprogramma voor PH-patiënten. Van longrevalidatieprogramma’s in 
een klinische setting is bekend dat het de functionele capaciteit en kwaliteit van leven 
van PH-patiënten verbeterd. Er is echter weinig onderzoek gedaan naar de effectiviteit 
van een longrevalidatieprogramma in een poliklinische setting. Onze studie toont aan 
dat een 10-weekse poliklinisch en multidisciplinair longrevalidatieprogramma veilig is 
en zeer gunstige effecten heeft op het uithoudingsvermogen, de skeletspierfunctie en 
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